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CHAPTER 1 - INTRODUCTION
Some of the text in this chapter was reprinted or modified from: Negmeldin, A. T.;
Padige, G.; Bieliauskas, A. V.; Pflum, M. K. H., Structural Requirements of HDAC
Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8
Selectivity, ACS Medicinal Chemistry Letters 2017, 8 (3), 281-286; Bieliauskas, A.
V.; Weerasinghe, S. V. W.; Negmeldin, A. T.; Pflum, M. K. H., Structural
requirements of histone deacetylase inhibitors: SAHA analogs modified on the
hydroxamic acid, Arch. Pharm. (Weinheim, Ger.) 2016, 349, 373-382; and
Negmeldin, A. T. and Pflum, M. K. H., The structural requirements of histone
deacetylase inhibitors: SAHA analogs modified at the C4 position display dual
HDAC6/HDAC8 selectivity, European Journal of Medicinal Chemistry (Submitted)
1.1. Epigenetic mechanism and gene expression
The chromosome is an important X-shaped cellular structure that carry all the
hereditary genetic information of the organism (genome) in the form of genes. In
eukaryotes, the chromosome is a highly condensed structure of long chromatin fiber,
which is a complex that consists of multiple nucleosome units (Figure 1.1). DNA
double strand (blue strand) that carries genetic information is wrapped around
histone proteins forming each nucleosome unit (Figure 1.1).1-2 The compactness of
the nucleosome structure is affected by different epigenetic modifications, which by
its turn affects DNA accessibility.2
Epigenetic modifications play an essential role in regulation of gene
transcription, DNA repair, DNA replication, and cell growth through mechanisms
independent of structure of DNA.3-4 Several epigenetic changes are known to date,
such as DNA methylation and histone tail modifications. Post-translational
modifications of histone proteins are among the major dynamic epigenetic changes
that regulate DNA expression and replication. Several post-translational covalent
modifications of histone proteins are known, such as acetylation, methylation,
phosphorylation, and ubiquitination (Figures 1.1 and

1.2A).4-5 Acetylation is
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controlled by two main classes of enzymes, histone acetyltransferases (writers) and
histone deacetylases (erasers)(Figure 1.1).2

Figure 1.1. Chromosome structure showing the chromatin fiber and the nucleosome
unit with the wrapping of DNA around histone proteins.2 Post-translational
modifications of Histone N-terminal residues are governed by several enzymes
including, histone acetyltransferases and histone methyltransferases (readers),
histone deacetylases and lysine demethylases (erasers). Reused with permission
from nature publishing group (see Appendix E).
1.2. Regulation of transcription by Histone Deacetylase (HDAC) Proteins
Histone Deacetylase (HDAC) proteins play an essential role in the regulation
of transcription in a balanced process with histone acetyl transferases (Figures 1.2A
and 1.2B). DNA double strands are tightly wrapped around histone proteins due to
the electrostatic interaction between the positively charged free amines of lysine side
chains that are abundant in the histone protein N-terminal tails, and the negatively
charged DNA backbone (Figures 1.2A and 1.2C). As a result of the tight interaction,
DNA double strands are inaccessible to transcription factors in this state and
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transcription is repressed (Figure 1.2A). Upon acetylation of the ε-amino group on
the side chains of lysine amino acids with histone acetyl transferases (HATs), the
compact structure will become loosened due to the acetylation of the amine groups
and loss of the electrostatic interaction. In the acetylated state, the nucleosomal
DNA will be accessible to transcription factors and will become transcriptionally
active (Figures 1.2B and 1.2C). Several other key enzymes are involved in activation
of transcription such as, lysine methyltransferases and lysine demethylases (Figure
1.2B). On the other hand, HDAC proteins catalyze deacetylation of acetylated lysine
residues, which will turn off transcription (Figure 1.2A and 1.2C).6 In addition,
deubiquitination, methylation and demethylation of specific lysine amino acid
residues can also lead to repression of transcription (Figure 1.2A). The overall
acetylation levels and the dynamic balance of both acetylation and deacetylation
reactions regulate gene expression as part of several post translational modifications
to histone tails of nucleosome units.4-6

4
A)

B)

C)

Figure
1.2.
Role
of
histone
deacetylase
(HDAC)
proteins
in
regulation of
transcription.
A) The wrapping of
double
stranded
DNA around histone proteins, makes the DNA inaccessible to transcription factors.5
B) Acetylation, methylation, demethylation, or ubiquitination of lysine residues
loosens the histone structure, making the DNA accessible to transcription factors. 5
C) Lysine residue acetylation with histone acetyltransferase and deacetylation with
histone deacetylase (HDAC). Reused from open access article that permits
unrestricted use or reproduction with proper citation (see Appendix E).
1.3. Classification of HDAC proteins
The HDAC family contains 18 different proteins (Figure 1.3), which are
grouped into four classes according to phylogenetic analysis (homology with yeast
HDAC proteins), size, cellular localization, and number of catalytic active sites.7
Eleven of them are metal-dependent, while the rest are NAD+ dependent. The metaldependent HDAC proteins are classified into classes I, II, and IV, while class III are
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NAD+ dependent.7 The eleven metal-dependent HDAC proteins are the focus of this
work.

Figure 1.3. Classification of HDAC proteins into metal dependent and NAD+
dependent, and the classification of the metal dependent into three classes. 8
Reused with permission from Elsevier Ltd. (see Appendix E).
Class I HDAC proteins include HDAC1, HDAC2, HDAC3, and HDAC8 (Figure
1.3), which are relatively smaller proteins (377-488 amino acids) compared to class
II HDACs and are predominantly nuclear enzyme.8-9 Both HDAC3 and HDAC8 can
shuttle between the nucleus and the cytoplasm. HDAC1, 2, 3, and 8 are grouped in
the same class due to homology to yeast RPD3, ubiquitous expression in almost all
cell lines and tissues, and their key role in cell survival and proliferation (Figure 1.3).9
Class II HDAC proteins are relatively large proteins (669-1215 amino acids),
have sequence similarity with yeast HDA1, and maintain the ability to shuttle
between the cytoplasm and nucleus.9-10 Class II HDACs are further divided into two
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subclasses, class IIa and IIb. Class IIa includes HDAC4, HDAC5, HDAC7, and
HDAC9 (Figure 1.3).9 On the other hand, class IIb includes HDAC6 and HDAC10,
which are mainly cytoplasmic and contain two catalytic domains. HDAC11 is a
unique member of the HDAC family with a size of 347 residues and a sequence
similarity to both classes I and II.8-9, 11
1.4. Catalysis mechanism of HDAC proteins
All HDAC enzymes have high sequence similarity in their active sites.12 For
the deacetylation reaction, several essential amino acids are important for catalysis.
For example, based on the HDAC6 crystal structure, the zinc atom, histidine 573
(H573), histidine 574 (H574), and tyrosine 745 (Y745) have a crucial role in the
deacetylation mechanism (Figure 1.4).13-14 The metal ion and the three amino acids
are conserved in most of the HDAC isoforms. The exception is class IIa enzymes, in
which only the metal ion and two histidine amino acids are maintained.

13-23

The

mechanism of deacetylation is believed to be similar among all of the HDAC
isoforms, with differences in catalytic efficiency between them.24-26 The crystal
structure of the HDAC6 catalytic domain 2 (CD2) was recently reported with several
snapshots showing all the key mechanistic steps in catalysis (Figure 1.4).14 First, a
water molecule (red sphere in Figure 1.4a) was chelated (red dashed line) with the
zinc atom (grey sphere) and hydrogen bonded with the two histidine amino acids
residue (black dashed lines with H573 and H574) (Figure 1.4a). In the same
snapshot, an empty space between the chelated water molecule and Y745 is shown
and is proposed to be where a substrate fits in the binding site. In order to study the
binding of the substrate α-tubulin K40 peptide (orange structure in Figure 1.4b),
Y745 was mutated to phenylalanine (Y745F) to prevent catalysis and capture the
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HDAC6-substrate interaction. The second crystallographic snapshot showed the
enzyme substrate-complex with the carbonyl of the ε-acetyl lysine coordinated to the
metal ion without displacing the coordinated water molecule (Figure 1.4b). Next,
H574, which is known to act as a general acid during catalysis, was mutated to
alanine (H574A) in order to capture the enzyme during the transition state (Figure
1.4c). The snapshot showed a tetrahedral intermediate, indicating that H573 acted
as a general base to deprotonate the water molecule. Nucleophilic attack by the
deprotonated water molecule on the substrate carbonyl formed the tetrahedral
intermediate in the active site, which was stabilized by both the zinc atom and Y745
(Figure 1.4c). Finally, the tetrahedral intermediate collapsed and yielded the free εlysine side chain of the substrate (not obtained in the crystal structure), and an
acetate anion that was observed and stabilized by the metal ion, H573, H574, and
Y745 (Figure 1.4d).

8

Figure 1.4. Snapshots of the HDAC6 catalytic domain 2 during catalysis with the
corresponding proposed reaction shown below each snapshot. See text for complete
explanation of images.14 Reused with permission from nature publishing group (see
Appendix E).
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1.5. HDAC proteins and cancers
HDAC proteins regulate the expression of several cancer-related proteins
involved in cell signaling, transcription, and tumor suppression through the
deacetylation of nucleosomal histone proteins.27-30 Mutations of HDAC proteins in
cancer are rare, while aberrant or overexpression of HDAC proteins is common with
many types of cancers.9 Overexpression of HDAC proteins results in unregulated
transcription and aberrant protein activity and function, which is linked to several
diseases, including cancer.28 HDAC proteins are also implicated in several other
diseases, such as asthma and schizophrenia.31-32 The aberrant expression of HDAC
proteins in many cancers leads to poor expression of tumor suppressor proteins that
are normally expressed in normal cells.33
Several reports have shown aberrant expression of individual HDAC isoforms
in different types of cancers. HDAC1 was overexpressed in lung,34 ovarian,35
gastric,36 prostate,37 breast,38 and colon cancers.39 HDAC2 was overexpressed in
colorectal and gastric cancers.40 HDAC8 was highly expressed in neuroblastoma
patients, leading to cancer progression and poor survival rates. 41 In addition, HDAC8
inhibition showed promising results in T-cell lymphoma and leukemia.42 Class II
HDAC6 was overexpressed in oral squamous cell carcinoma and ovarian cancer. 4344

In addition, HDAC6 is implicated in several non-epigenetic cancer-related

intracellular functions.45-46 Overexpression of both HDAC6 and HDAC8 was linked to
breast cancer metastasis and invasion.47
1.6. Anti-tumor activity of HDAC inhibitors
Due to their key role in cancer, HDAC proteins have emerged as interesting
targets for cancer treatment, and several anti-cancer agents targeting HDAC
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proteins have been developed.6, 48-52 HDAC inhibitors, such as SAHA were found to
decrease the sizes of lung, stomach, pancreas, mouth, ovaries, breast, and prostate
tumors in mouse models.31,

53-54

The effect of HDAC inhibitors on the acetylation

states of both histone and non-histone substrates can lead to cell signaling
dysregulation, transcription and expression changes, and protein degradation.
Through these effects on tumor cells, HDAC inhibitors can reduce proliferation,
migration, and angiogenesis, enhance differentiation and immunogenicity, and
promote apoptosis (Figure 1.5).50,

55-56

More specifically, HDAC inhibitors exhibited

the ability to cause cancer cells differentiation, inhibition of the cell cycle, and
induction of apoptosis.55, 57-60 Several studies showed that treatment of cancer cells
with HDAC inhibitors induced cell cycle arrest in the G1 or G2 phases (Figure 1.5a
and 1.5b). Subsequent cancer cell differentiation might be observed after cell cycle
arrest in G1 phase (Figure 1.5b).61-62 Another crucial antitumor mechanism of HDAC
inhibitors is based on apoptosis, where cancer cells that pass by the G1 cycle arrest
can duplicate their DNA and get arrested at the G2 phase, where accumulated DNA
and hyperacetylated histones lead to apoptosis (Figure 1.5a).61-62 Several known
HDAC inhibitors cause cancer cell apoptosis.58, 63-66 HDAC inhibitors have the same
effect on acetylation levels in both normal and cancer cells, but unlike cancer cells,
normal cells can undergo a G2 checkpoint after the cell cycle arrest and survive after
treatment (Figure 1.5). 61, 63, 65-66
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A

C

B

Figure 1.5. Effect of HDAC inhibitors on cancer and normal cells.55 A)HDAC inhibitor
induced G2 cell cycle arrest, and subsequent apoptosis. B) HDAC inhibitor induced
G1 cell cycle arrest and cancer cell differentiation. C) HDAC inhibitor effect on
enhancement of immunogenicity of cancer cells and reduction of angiogenesis.
Reused with permission from nature publishing group (see Appendix E).
In addition to the main two mechanisms mentioned above, HDAC inhibitors
have other indirect secondary effects on cancer cells. HDAC inhibitors can enhance
cancer cells immunogenicity by induction of transcription of several extracellular
proteins, receptors, and complexes (Figure 1.5c). Among these extracellular proteins
are major histocompatibility complex (MHC) proteins, activation molecules (CD40,
CD80, and CD86), and intercellular adhesion molecule (ICAM1). The increased
expression of these proteins and receptors can augment the recognition and activity
of the immune system against cancer cells (Figure 1.5c).67-70
1.7. FDA approved HDAC inhibitors
Several HDAC inhibitors have been approved by the FDA for treatment of
cancer.50 SAHA (suberoylamide hydroxamic acid, Vorinostat, Zolinza™) was
approved in 2006 for treatment of cutaneous T-cell lymphoma (Figure 1.6).49,

71-72

Romidepsin (FK-228, Istodax™) was approved in 2009 for treatment of cutaneous
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T-cell lymphoma and in 2011 for treatment of peripheral T-cell lymphoma.48, 73 In the
last three years, two more HDAC inhibitors gained FDA approval for cancer
treatment. Belinostat (PXD101, Belodaq™) was FDA-approved in 2014 for treatment
of relapsed or refractory peripheral T-cell lymphoma (Figure 1.6).51, 74 More recently
Panobinostat (LBH-589, Farydak™) was approved in 2015 for treatment of multiple
myeloma (Figure 1.6).52,

75

Several other HDAC inhibitors are currently in clinical

trials as anti-cancer candidates.33, 76

Figure 1.6. FDA approved HDAC inhibitors for treatment of cancer, with year of
approval in parenthesis.
Most HDAC inhibitors share a common pharmacophore that is essential for
binding and inhibition. The pharmacophore is composed of three important structural
regions: the metal binding group, the linker region, and the capping group (Figure
1.6, see SAHA).25 Three of the FDA approved drugs (SAHA, Belinostat and
Panobinostat) have a hydroxamic acid moiety as the metal binding group and an
aromatic ring system as the capping group. SAHA has a saturated six carbons
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linker, while Belinostat and Panobinostat have unsaturated linkers with an aromatic
rings. Romidepsin is a bicyclic depsipeptide prodrug that releases a thiol metal
binding group upon reductive cleavage of the disulfide bond (Figure 1.6).
Despite the successes of HDAC inhibitors in cancer treatment, they manifest
side effects in patients, including gastrointestinal symptoms, bone marrow
suppression, fatigue, cardiac arrhythmia, nausea, dehydration, thrombocytopenia,
and anorexia.77-80 One hypothesis accounting for the observed side effects is the
poor selectivity of the clinically tested HDAC inhibitors; most compounds inhibit all or
many of the eleven HDAC isoforms (Table 1.1, see first four entries).12,

78

For

example, the FDA approved drugs, including SAHA, inhibit most or all the eleven
metal-dependent HDAC isoforms (Table 1.1). In addition, the non-selectivity of the
FDA approved drugs limits their use as biological tools to probe HDAC function in
cancer biology.
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Table 1.1. IC50 values of the FDA-approved drugs and some selective HDAC
inhibitors discussed in text.a
HDAC isoforms and the corresponding IC50 values (nM)
Compound
1

2

3

4

5

6

7

8

9

10

11

68

164

48

101

ND

90

104

1534

107

58

35

40

50

41

125

3

3

181

1,155

78

>10,000

120

84

7

49

78, 81-82

SAHA

Romidepsin
Belinostat

83

78

Panobinostat

78

78

Entinostat
Apicidin
Cpd-60

RGFP-966
Tubastatin

85

>15,000 >15,000

510

14,000

30

115

82

67

216

128

4

12

61

14

248

3

2,311 >10,000
43

>10,000

80

16,400 >30,000 >30,000 >30,000 >30,000
4,000 >50,000 >50,000

88

BRD-73954

575

>10,000

>15,000 >15,000 >15,000 >15,000 >15,000 >15,000 >15,000 >15,000

87

VAHA

>10,000 >10,000

505

10,000 >10,000 >10000 >10,000 >10,000 >10,000

86

PCI-34051

>10,000 >10,000 >10,000

15

>30,000

2,900

854

>30,000 >30,000 >30,000

10

13,000

560,000 680,000 340,000 170,000 37,000 16,000 99,000 39,000 91,000
89

12,000

Aminotetralin
90
32
acylhydrazone
91
analog 3f

9,000

23,000 >33,000 >33,000

36

13,000

120

>33,000

6,310 >100,000>100,000>100,000>100,000

50

30,800

80

>35,000 >100,000>100,000

>3,000 >3,000

27

a

alues in table were collected from literature.
available.

130

D not determined.

" no data

1.8. Isoform selective HDAC inhibitors
While isoform selective inhibitors would be valuable on the bench top and in
the clinic, only a few highly selective compounds have been identified (Figure 1.7
and Table 1.1). For example, entinostat (KHK2375, SNDX-275, formerly MS-275) is
a benzamide inhibitor currently in phase II clinical trials and is selective for class I
HDAC proteins with 4- to 400-fold selectivity for HDAC1, 2, and 3 over the other
isoforms.62,

78, 92

Apicidin is a cyclic peptide fungal metabolite that inhibits HDAC

proteins with 17-230-fold selectivity towards class I HDAC2, 3, and 8.78 Cpd-60 is
another benzamide inhibitor that displayed at least 204-fold selectivity for HDAC1
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and HDAC2 over HDAC3.84 RGFP966 belongs to the benzamide HDAC inhibitors
and showed more than 188-fold selectivity for HDAC3 over the other isoforms
(Figure 1.7 and Table 1.1).76 Tubastatin, which was developed as an HDAC6selective inhibitor, demonstrated 87-fold or 1000-fold selectivity for HDAC6 over
HDAC1, 2, and 3 according to different reports.86,

93

Finally, PCI-34051 is a

hydroxamic acid based HDAC8 selective inhibitor that was developed in 2008 and
exhibited at least 290-fold selectivity for HDAC8 over HDAC1, 2, 3, 6, and 10 (Figure
1.7 and Table 1.1). 87
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Figure 1.7. Chemical structures of some isoform selective HDAC inhibitors
discussed in the text.
1.9. Dual HDAC6/HDAC8 selective HDAC inhibitors
HDAC inhibitors that target one or two HDAC isoforms will be valuable for
development of new drugs with possibly fewer side effects than the non-selective
inhibitors.94-97 More specifically, recent reports suggested that inhibition of both
HDAC6 and HDAC8 can have several possible synergistic therapeutic applications
in the treatment of various cancers.89-91 In addition, dual inhibition of HDAC6 and
HDAC8 might have potential application in breast cancer angiogenesis and
metastasis.42,

89

Recently, several dual HDAC6/8 selective inhibitors have been

developed (Figure 1.8).88-91
In 2011, Haggarty and co-workers developed valpropylhydroxamic acid
(VAHA), which showed modest selectivity for HDAC6 and HDAC8, but with weak
potency (16 and 39 µM) (Figure 1.8 and Table 1.1).88 Two years later in 2013,
Holson and co-workers reported the first dual HDAC6/HDAC8 selective inhibitor
BRD-73954 (Figure 1.8).89 The dual inhibitor BRD-73954 demonstrated high fold
selectivity towards HDAC6 and 8 (at least 75-fold) over the other metal dependent
HDAC proteins, with IC50 values of 36 and 120 nM with HDAC6 and HDAC8,
respectively (Table 1.1).89 In 2014, Tang et al. reported Aminotetralin 32 as another
dual HDAC6/8 selective inhibitor (Figure 1.8). The compound exhibited at least 79fold selectivity to HDAC6 and 8, and IC50 values in the range of 50-80 nM against
HDAC and HDAC8 (Table 1.1).90 Recently, another group reported the dual
selective inhibitor N-acylhydrazone analog 3f (Figure 1.8), with IC50 values of 27 and
130 nM with HDAC6 and 8, and at least 23-fold dual selectivity.91 The development
of highly selective and potent dual HDAC6/HDAC8 selective inhibitors can possibly
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enhance the efficacy of anti-cancer drugs compared to the current non-selective
drugs. Moreover, selective HDAC inhibitors will be useful as chemical tools to study
cancer-related HDAC cell biology.

Figure 1.8. Chemical structures of dual HDAC6/HDAC8 selective HDAC inhibitors
discussed in the text.
1.10. Binding of HDAC inhibitors to HDAC active sites
Most of HDAC inhibitors have three common important binding interaction
regions (discussed in section 1.7), which are a capping group, a linker, and a metal
binding group (Figure 1.9A). In all the metal-dependent HDAC proteins, these three
regions form several essential interactions with the active site. As an example,
SAHA docked into the active site of the HDAC1 crystal structure shows three
significant binding interactions (Figure 1.9B).98 First, the hydroxamic acid (the metal
binding group) interacts with the metal binding region with five key interactions for
inhibition of the enzyme (Figure 1.9C). The carbonyl group of the hydroxamic acid
moiety chelates with the metal ion in the binding site with two electrostatic
interactions, in addition to three hydrogen bonding interactions of the hydroxamic
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acid group with H140, H141, and Y303 amino acids of the active site (Figure 1.9B
and C). Moreover, the non-polar six carbons linker of SAHA interacts with the
hydrophobic side chains of the amino acids lining the 11 Å channel (Figures 1.9A
and 1.9B). Finally, the anilinamide capping group interacts with the solvent exposed
region (Figures 1.9A and 1.9B). Another important part of the active site is the 14 Å
channel, which is located at the bottom of the active site and helps in acetate escape
(Figure 1.9B).98
HDAC inhibitors bind similarly to all the HDAC isoforms, with few variations
with different HDAC isoforms active sites that impart isoform selectivity. Most of the
metal-dependent HDAC crystal structures have been revealed, including HDAC1,
HDAC2, HDAC3, HDAC4, HDAC7, and HDAC8 crystal structures 15, 19-21, 99-100, along
with homology models of the other HDAC isoforms

22-23

. Recently, several crystal

structures of both catalytic domains of HDAC6 were reported (see section 1.4).13, 101
All crystal structures have the three common binding interaction regions, with high
similarity in both sequence and binding site shape. Some of the isoforms lack the 14
Å channel (Figure 1.9B), including HDAC6 and HDAC8. On the other hand, several
HDAC isoforms have a relatively wide 14 Å channel, such as HDAC1 and HDAC2,
while others have a 14 Å channel with a constriction, like HDAC3.
When comparing the 11 Å channel (Figure 1.9B), HDAC6 and HDAC8 have a
wider and shorter active site entrance (11 Å channel) than HDAC1, HDAC2, and
HDAC3, which helped to develop several HDAC6 or HDAC8 selective inhibitors, or
dual HDAC6/HDAC8 selective inhibitors. The high similarity in the binding site of
both HDAC1 and HDAC2 is a challenge to rationally design and develop a selective
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inhibitor to either HDAC1 or HDAC2. The availability of crystal structures for HDAC
isoforms helped in developing isoform selective HDAC inhibitors, as well as in
explaining the selectivity of several isoform selective HDAC inhibitors.
A

B

C

11 Å channel

Y303

2.7
2.1
2.3

2.6

H141

1.8
H140
14 Å channel

Figure 1.9. The important structural pharmacophore of HDAC inhibitors and binding
to HDAC active sites. A) Structure of SAHA showing key pharmacophoric binding
groups for HDAC inhibition. B and C) Binding of SAHA to HDAC1 crystal structure
(deep blue mesh; PDB: 4BKX). Binding distances between the hydroxamic acid
atoms and active site residues (numbered in figure) or the metal are displayed in
Angstroms. The metal ion (Zn2+) is represented as a grey sphere. Color-coded
SAHA (C=green/white; O=red; N=blue, H=white).
1.11. Thesis Projects
While some selective compounds have been reported, identifying additional
strictly isoform-selective HDAC inhibitors remains a challenge, especially for the
isoforms for which no selective inhibitor has been identified, such as HDAC1.
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Selective inhibitors can be used as a biological tools to elucidate the function of each
isoform in the development and progression of cancer. In addition, isoform selective
HDAC inhibitors will be valuable for the design and development of new promising
drugs with less side effects. Moreover, modification of pan-inhibitors currently used
in clinic can possibly improve their selectivity and reduce their clinical side effects.
Because most of the reported SAHA derivatives focus on modification of the
capping group or metal binding group (Figure 1.9A). We are interested in our lab to
modify the linker or the metal binding group with different groups.102-105 Previously,
our lab published several derivatives modified at C2, C3, C6 and the nitrogen atom
of the metal binding group (Figure 1.10). Some of these derivatives showed isoform
selectivity.103-105 The C3-ethyl SAHA analog showed a modest preference for
HDAC6 over HDAC1 and HDAC3.104 Among the C6-modified SAHA analogs, C6-tbutly SAHA displayed a modest selectivity for HDAC1 and 6 compared to HDAC3.105
In addition, several of the C7-modified SAHA analogs showed selectivity patterns to
different isoforms, but with low fold selectivity.106 More interestingly, one of the C7SAHA analogs exhibited greater potency than SAHA both in vitro and with different
cancer cell lines.
C2-modified SAHA analogs (Figure 1.6) were also generated and showed µM
potency with HeLa cell lysates, but no selectivity assessment was performed. 103 In
Chapter 2, the HDAC isoform selectivity of C2-SAHA analogs, including IC50 values,
were assessed. In cellulo testing has also been performed, and docking studies
were used to explain the observed selectivity of some of the C2-SAHA analogs.
Enantioselective syntheses of both enantiomers of the most interesting derivative
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were performed, and both of the pure enantiomers were screened for potency and
selectivity.

Figure 1.10. Chemical structures of SAHA analogs modified in the linker region and
at the hydroxamic acid moiety created in the Pflum lab.
Chapters 3 and 4 discuss the synthesis of new SAHA derivatives substituted
at the C4 and C5 positions of the linker region (Figure 1.10). The substituents
chosen have different sizes and electronic properties to fit into active site of different
HDAC isoforms (Figure 1.9) and to test the effect of these substituents on activity
and/or selectivity. The newly synthesized derivatives were tested for their activity in
vitro against HeLa cell lysates, as well as their selectivity with different HDAC
isoforms. In cellulo testing was also done.
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In Chapter 5, docking studies for previously synthesized and screened SAHA
analogs modified at the hydroxamic acid moiety was performed. The docking studies
suggested

an explanation based on the analogs structures and the crystal

structures of HDAC1 and HDAC3 the source of the observed HDAC1 preference, as
well as the lower potency of the N-SAHA analogs compared to SAHA. Finally,
Chapter 6 focuses on the development of an HDAC1 selective inhibitor in order to
use it as a biological tool and understand the HDAC1 related cancer biology. The
design, synthesis, and screening of several biaryl indolyl benzamide derivatives as
possible HDAC1-selective inhibitors are described in Chapter 6.
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CHAPTER 2 - IN VITRO AND IN CELLULO SCREENING,
ENANTIOSELECTIVE SYNTHESIS, AND DOCKING OF C2MODIFIED SAHA ANALOGS
Some of the text in this chapter was reprinted or modified from: Negmeldin, A. T.;
Padige, G.; Bieliauskas, A. V.; Pflum, M. K. H., Structural Requirements of HDAC
Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8
Selectivity, ACS Medicinal Chemistry Letters 2017, 8 (3), 281-286; and Padige, G.;
Negmeldin, A. T.; Pflum, M. K. H., Development of an ELISA-Based HDAC Activity
Assay for Characterization of Isoform-Selective Inhibitors, Journal of Biomolecular
Screening 2015, 20 (10), 1277-1285)
2.1. Rationale for synthesis and screening of C2-modified SAHA analogs
Towards development of selective HDAC inhibitors, we previously created
SAHA analogs containing substituents in the linker region between the hydroxamic
acid and the anilide ends (Figure 1.6). A C3-modified SAHA analog showed modest
preference for HDAC6, while C6-modified SAHA analogs displayed selectivity for
HDAC1 and 6 compared to HDAC3.103-105 In addition, modifying the amine of the
hydroxamic acid reduced potency, but enhanced preference for HDAC1. 102 C2modified SAHA analogs (Figure 2.1) were also generated by Dr. Anton Bieliauskas
and screened with HeLa cell lysates by Dr. Sujith Weerasinghe (Scheme 2.1), and
showed µM potency with HeLa cell lysates (Table 2.1) But no selectivity assessment
was performed.103 Because HeLa cell lysates contain all HDAC isoforms, the
observed lower potency of the C2-SAHA analogs against HeLa cell lysates (Table
2.1) suggests that they might be selective for some isoforms over the others
compared to SAHA.

Figure 2.1. Chemical structures of C2-modified SAHA analogs (1a-1i).
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Scheme 2.1. Synthesis of C2-modified SAHA analogs performed by Dr. Anton
Bieliauskas 103

Table 2.1. IC50 values for SAHA, and C2-modified SAHA analogs (1a-g) with HeLa
cell lysates.a
Compound

R

SAHA

IC50 (µM)
0.090 ± 0.004

1a

methyl

134 ± 6

1b

ethyl

449 ± 17

1c

n-propyl

154 ± 7

1d

n-butyl

72 ± 6

1e

allyl

144 ± 9

1f

propargyl

87 ± 5

1g

benzyl

226 ± 11

a

Mean IC50 value and standard error of at least three independent trials are shown.
Data provided by Dr. Sujith Weerasinghe.103
We report here a selectivity assessment of C2-modified SAHA analogs both
in vitro and in cellulo. Modification at the C2 position led to reduced potency but
enhanced selectivity compared to SAHA, with preference for HDAC6 and 8 over
HDAC1, 2, and 3. Enantioselective syntheses of both enantiomers of the most

25
selective analog were also performed, with subsequent screening. Docking studies
provided a structural rationale for the observed HDAC6/8 selectivity. The observed
fold selectivities for some of the analogs were higher compared to known dual
HDAC6/8 selective inhibitors (see section 1.9), but with submicro molar to
micromolar IC50 values. HDAC6/8 dual inhibitors can be used as biological tools to
study breast cancer metastasis.89, 107 In addition, SAHA analogs reported here are
useful lead compounds for further development of pharmacological agents and anticancer drug targeting HDAC6 and 8.
2.2. In vitro screening of C2-modified SAHA analogs
Herein we used the recently developed ELISA-based HDAC activity assay to
screen the C2-modified SAHA analogs against mammalian-derived HDAC1,
HDAC2, HDAC3, and HDAC6.93,

108

The ELISA-based HDAC activity assay was

developed in our lab primarily by Dr. Geetha Padige for screening and identification
of isoform selective HDAC inhibitors. The assay relies on the use of mammalian cell
expressed HDAC proteins, which is more biologically relevant than the widely used
assays that use baclovirus-expressed recombinant HDAC proteins.78 In addition,
compared to other methods that use mammalian cell-expressed HDAC proteins, the
ELISA-based HDAC activity assay is a robust and highly reproducible assay with
much lower error rates.93,

109-110

The assay is modeled after the classic ELISA, in

which antibodies are used to immobilize proteins from mammalian cell extract onto a
plate. In the ELISA-based HDAC activity assay, polystyrene high-binding or
secondary antibody–coated 96-well plates were incubated with a primary HDAC
antibody (Figure 2.2.A), followed by HeLa cell lysates to immunoprecipitate the
respective HDAC isoform (Figure 2.2.B). Once the desired HDAC isoform was
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affixed onto the plate, deacetylase activity was tested using commercially available
HDAC

Glo

I/II

assay,

which

produces

a

highly

stable

and

sensitive

chemiluminescent signal after reaction with the HDAC enzyme (Figure 2.2.C).93, 111
Screening of HDAC inhibitors involved incubation of compounds with the affixed
HDAC protein and monitoring the deacetylase activity remaining in the form of
reduced chemiluminescent signal (Figure 2.2.C).93, 108

Figure 2.2. Principle of the ELISA based HDAC activity assay. A) Secondary
antibody-coated or high binding polystyrene 96 well plates were incubated with
primary HDAC antibody (HDAC) to immobilize the antibody to the well, followed by
washing. B) Incubation with HeLa cell lysates affixed to the well the specific HDAC
isoform recognized by the immobilized antibody, followed by washing. C) Addition of
the HDAC-Glo™ substrate and developer to the active HDAC isoform affixed to the
well generated a quantifiable chemiluminescent signal (yellow star). Inclusion of an
HDAC inhibitor in the reaction reduced the deacetylation activity of the affixed HDAC
enzyme, resulting in a lower chemiluminescent signal.93 Reused with permission
from SAGE publishing group.
SAHA and analogs 1a-f were tested by Dr. Geetha Padige108,

112

, while

analogs 1g-i were tested in this work.112 As an initial test of selectivity, the potency
of each C2-modified SAHA derivative was tested with HDAC1, 2, 3, and 6 at single
concentrations of either 5 or 10 µM using the ELISA-based HDAC activity assay. All
analogs (1a-i) displayed some selectivity for HDAC6 compared to HDAC1, HDAC2,
and HDAC3 (Figure 2.3). Among them, the C2-benzyl (1g), C2-n-pentyl (1h), and
C2-n-hexyl (1i) analogs showed the greatest difference in inhibitory activity
comparing HDAC6 to HDAC1, HDAC2, and HDAC3. In contrast, the C2-methyl
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SAHA analog was least selective, with similar activity against all the four HDAC
isoforms tested (Figure 2.3).112

Figure 2.3. Isoform selectivity screening of SAHA and C2-modifed SAHA analogs
(1a-i) against HDAC1, 2, 3, and 6 using the ELISA-based HDAC activity assay. 93
All analogs were tested at 5 µM concentration, except for 1d, which was tested at 10
µM. SAHA was tested at 1 µM.93 Mean percent deacetylase activities from a
minimum of three independent trials with standard errors were plotted (Table A.1).
The substituent below each compound number corresponds to the R group in C2modified SAHA (Table 2.1). Data for analogs 1a-f was provided by Dr. Geetha
Padige.112
To further assess selectivity, IC50 values for the most selective compounds in
the initial screen, compounds 1g-i, were determined with HDAC1, 2, 3, 6, and 8
(Table 2.2). HDAC8 was also tested due to its similar active site compared to
HDAC6.13 As controls, the IC50 values of both SAHA and tubastatin were included.
As expected, SAHA displayed similar IC50 values with HDAC1-6, but 5-fold reduced
activity with HDAC8, which is consistent with prior reports (see Table 1.1).78,

113

Tubastatin showed at least 87-fold selectivity for HDAC6 over class I HDAC1, 2, and
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3, but only 10-fold selectivity versus HDAC8.93 Interestingly, the C2-modified SAHA
analogs showed selectivity for HDAC6 and HDAC8, with IC50 values in the submicromolar to micromolar range (0.6-2.0 µM, Table 2.2). The C2-benzyl 1g and C2n-pentyl 1h analogs displayed 33 to 92-fold selectivity for HDAC6 and HDAC8 over
the Class I isoforms (Tables 2.2, A.4, and A.5, and Figures A.31 and A.32). The
most selective compound, C2-n-hexyl SAHA 1i displayed 49- to 300-fold selectivity
for HDAC6 and HDAC8 compared to the class I isoforms (Tables 2.2 and A.6 and
Figure A.33).
Table 2.2. IC50 values for SAHA, tubastatin, SAHA analogs 1g-1i against HDAC1, 2,
3, 6 and 8.a
Compound

IC50 values (µM)
HDAC1

HDAC2

HDAC3

HDAC6

SAHA

0.033 ± 0.001

0.096 ± 0.01

Tubastatin

2.7 ± 0.2

3.9 ± 0.4

2.9 ± 0.5

0.031 ± 0.004

0.33 ± 0.01

1g (benzyl)

84 ± 6

110 ± 10

91 ± 4

1.5 ± 0.2

1.2 ± 0.1

1h (pentyl)

48 ± 2

58 ± 2

43 ± 2

0.85 ± 0.05

1.3 ± 0.1

1i (hexyl)

180 ± 20

180 ± 30

98 ± 10

0.60 ± 0.05

2.0 ± 0.1

(S)-1i (hexyl)

330 ± 30

580 ± 30

530 ± 50

ND

3.1 ± 0.1

0.020 ± 0.001 0.033 ± 0.003

HDAC8
0.54 ± 0.01

(R)-1i (hexyl)
ND
ND
ND
ND
0.71 ± 0.01
Mean IC50 value and standard error of at least two independent trials are shown
(Figures A.29-A.35 and Tables A.2-A.8).
a

It is notable that the selectivity of C2-n-hexyl SAHA 1i for HDAC6 (˃163-fold)
is elevated compared to tubastatin (˃87-fold), while showing 20-fold less potency
than tubastatin (0.60 vs. 0.031 µM IC50 values). The conclusion is that C2substituents impart selectivity by discriminating against HDAC1, HDAC2, and
HDAC3.
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2.3. In cellulo selectivity testing
To assess the HDAC6 selectivities of the analogs in a biologically relevant
context, C2-benzyl (1g), C2-n-pentyl (1h), and C2-n-hexyl (1i) SAHA were tested for
their abilities to increase the acetylation levels of HDAC substrates. Acetylated-αtubulin (AcTub) was monitored as a known substrate of HDAC6, whereas
acetylated-histone H3 (AcH3) was observed as a substrate for HDAC1, 2, and 3.
U937 myeloid leukemia cells were used in these cellular HDAC6 selectivity studies.
HDAC6 is overexpressed in several acute myeloid leukemia (AML) cell lines,
suggesting that HDAC6 is a promising target for development of anti-leukemic
drugs.114 SAHA or the analogs were incubated with U937 cells before lysis and
western blot analysis of protein acetylation. As expected, SAHA increased the
acetylation levels of both α-tubulin and histone H3 (Figure 2.4a, lane 2, AcH3 and
AcTub), consistent with its broad inhibition. In contrast, the HDAC6 selective inhibitor
tubastatin affected only α-tubulin acetylation (Figure 2.4a, lane 3, AcTub). Similar to
tubastatin, the three analogs 1h-i increased acetylation levels of α-tubulin to a
greater level than histone H3 (Figure 2.4a, lanes 4-6, AcH3). Quantification
confirmed that 1h-i significantly increased acetylation of α-tubulin compared to
DMSO, but not acetyl histone H3 levels (Figure 2.4b and Table A.9). In addition, the
C2-n-hexyl analog 1i promoted a dose-dependent increase in acetylation of α-tubulin
(Figure 2.4c, lanes 2-7, AcTub), but not histone H3 (Figure 2.4c, lanes 2-7, AcH3),
compared to the DMSO control (Figure 2.4c, lane 1). The HDAC6-dependent
acetylation of tubulin observed in cellulo is consistent with the HDAC6 selectivity
observed in vitro (Table 2.2 and Figure 2.3).
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Figure 2.4. Cell-based selectivity testing of the C2-modified SAHA analogs. U937
cells were treated with (a) DMSO (1%), SAHA (2 µM), tubastatin (2 µM), C2-benzyl
SAHA (1g, 30 µM), C2-n-pentyl SAHA (1h, 30 µM), C2-n-hexyl SAHA (1i, 30 µM), or
(c) increasing concentrations of C2-n-hexyl SAHA analog (1i, 10-60 µM) before lysis,
SDS-PAGE separation, and western blot analysis of acetyl-histone H3 (AcH3) and
acetyl-α-tubulin (AcTub). GAPDH was a load control. Repetitive trials are shown in
Figures A.36 and A.37. (b) Fold increase in AcH3 or AcTub after quantification of
bands intensity from part a, with mean fold increase from four independent trials and
standard error (Table A.9).
2.4. In vitro cell growth inhibition
To test the anti-cytotoxic properties of the HDAC6-selective inhibitors,
analogs 1g-i were tested in cell-based cytotoxicity assays using leukemia cell
lines.114 First, the analogs were tested with the Jurkat cell line (T-cell lymphoma
derived cancer cell line) at 1 and 10 µM concentrations using an MTT assay (Figure
2.5, Table A.10).

SAHA was also tested as a control. All compounds showed

reduced cytotoxicity compared to the SAHA (Figure 2.5). Of the analogs, C2-n-hexyl
SAHA (1i) showed the greatest cytotoxic effect, with only 47% viability at 10 µM
concentration.
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Figure 2.5. Cytotoxicity screening of 1g, 1h, 1i, and SAHA with Jurkat cells.
Inihbitors were tested at 1 and 10 µM concentrations using MTT assay. Mean
percent viability from at least three independent trials with standard error were
plotted (Table A.10).
To further assess cytotoxicity, both SAHA and the most potent analog 1i were
tested to determine EC50 values against three leukemia cancer cell lines: Jurkat,
AML MOLM-13 (Acute myeloid leukemia cell line), and U937 cells. SAHA showed
potent cytotoxicity, with EC50 values of 0.72, 1.2, and 0.88 µM with Jurkat, AML
MOLM-13, and U937 cell lines, respectively (Table 2.3). The observed EC50 values
are consistent with previous reports.115-117 The high potency of SAHA may be due to
its non-selectivity, as well as the high inhibitory activity against class I HDAC1, 2,
and 3. The C2-n-hexyl SAHA analog 1i showed roughly 10-fold reduced cytotoxicity
compared to SAHA, with EC50 values of 11.8, 10.5, and 13.8 µM with Jurkat, AML
MOLM-13, and U937 cell lines, respectively (Table 2.3). The reduced cytotoxicity is
consistent with the 18-fold reduction in potency against HDAC6 compared to SAHA
(Table 2.2). In addition, the selectivity for HDAC6 and 8 over HDAC1, 2, and 3 might
also contribute to the lower cytotoxicity.
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Table 2.3. EC50 values for SAHA and C2-n-hexyl (1i) SAHA analog against Jurkat,
AML MOLM-13, and U937 cells using MTT assay.a
Compound
SAHA

Cellular EC50 values (µM)
Jurkat

AML MOLM-13

U937

0.72 ± 0.13

1.2 ± 0.06

0.88 ± 0.13

1i (hexyl)
11.8 ± 2.2
10.5 ± 3.1
13.8 ± 1.7
Mean EC50 value and standard error of at least three independent trials are shown
(Figures A.38 and A39, and Tables A.11 and A12).
a

2.5. Enantioselective Synthesis and Screening of (R)- and (S)-C2-n-hexyl SAHA
C2-n-hexyl SAHA (1i) contains a stereocenter at the 2 position, and the
compounds tested to this point were racemic mixtures. To test the selectivity of each
enantiomer, an enantioselective synthesis of C2-n-hexyl SAHA (1i) was employed
using Evans chiral auxiliary 8 and octanoyl chloride (Schemes 2.2 and 2.3). Allyl
bromide was added to the resulting amide 9 to generate chiral compound (R)-10
from auxiliary (R)-8 (Scheme 2.2) or (S)-10 from auxiliary (S)-8 (Scheme 2.3). After
olefin metathesis with Grubbs' second-generation catalyst118 and removal of the
auxiliary, the olefin was reduced to generate (S)-11 and (R)-11. Finally, coupling
with hydroxylamine generated the two enantiomers of C2-n-hexyl SAHA, (S)-1i or
(R)-1i in 95 and 92% ee, respectively (Figures A.26-A.28).
Scheme 2.2. Enantioselective synthesis of (S)-C2-n-hexyl SAHA (S)-1i

33
Scheme 2.3. Enantioselective synthesis of (R)-C2-n-hexyl SAHA (R)-1i

With the two C2-n-hexyl SAHA enantiomers in hand, IC50 values were
determined (Table 2.2). As expected, both enantiomers displayed low micromolar to
submicromolar potency with HDAC8 (3.1±0.1 or 0.71±0.01 µM), similar to racemic 1i
(2.0±0.1). The data suggested that (R)-1i is more potent than (S)-1i, although only
by 4-fold. The (S)-1i enantiomer was further tested for selectivity against HDAC 1, 2,
and 3. (S)-1i displayed 106- to 187-fold selectivity for HDAC8, which is greater than
that observed with racemic 1i (49- to 300-fold). In total, studies with the enantiomers
of C2-n-hexyl SAHA indicated that both are low micromolar to submicromolar
potency HDAC8 inhibitors, with the expected HDAC8 selectivity compared to
HDAC1, 2, and 3.
2.6. Docking Studies with HDAC2 and HDAC6 crystal structures
To rationalize the HDAC6/8 selectivity of the C2-n-hexyl SAHA (1i) analog,
we performed docking analysis using the AutoDock 4.2 program.119 Both
enantiomers of the analog were docked into the recently published HDAC6 crystal
structure (pdb:5EEM)101 and both displayed similar binding interactions (Figure 2.6),
consistent with the similar IC50 values observed experimentally. For example, the
hydroxamic acid was positioned in bonding distance (1.9-2.9 Å) of three active site
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residues (H573, H574, and Y745) and the catalytic zinc atom in HDAC6 active site
(Figures 2.6A and E). For comparison, docking of the parent SAHA compound with
HDAC6 showed similar distances between the hydroxamic acid and the active site
(1.6-2.4 Å, Figure 2.7A). To explore the HDAC6 selectivity, compound 1i was also
docked into the HDAC2 crystal structure (pdb ID: 3MAX).19 In contrast to the
bonding distances observed with HDAC6, elongated distances between the
hydroxamic acid group and H145 (5.7-5.9 Å), H146 (3.8 Å), and Y308 (3.0-5.5 Å)
were observed (Figures 2.6B and F). Metal binding was also weakened with longer
bond distances (3.5-4.7 Å, Figures 2.6B and F). One possibility accounting for the
weak binding with HDAC2 is that the bulky C2-n-hexyl substituent cannot favorably
fit into the relatively narrow catalytic active channel of HDAC2.86 Consistent with this
possibility, superimposition of the docked poses of compound 1i and SAHA with
HDAC2 showed that the C2-n-hexyl substituent is positioned towards the solvent
exposed surface of the active site, which consequently places the hydroxamic acid
distant from the metal (Figure 2.6D and H). In contrast, the relatively wide catalytic
pocket in HDAC6 allowed compound 1i and SAHA to similarly position the
hydroxamic acid within bonding distances of the catalytic metal and nearby residues
(Figure 2.6C and G).
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(R)-C2-n-hexyl SAHA
A

HDAC6

B

HDAC2

Y308

Y745

(S)-C2-n-hexyl SAHA
E

Y308

2.2

2.8
2.2

2.2

H573

1.9

2.9

2.6
2.7

H574
H145

C

HDAC2

Y745

2.2

2.5

F

HDAC6

D

H573

H146

G

H574

H145

H146

H

Figure 2.6. Docked poses of (R)-C2-hexyl SAHA (A-D) and (S)-C2-hexyl SAHA (EH) in the crystal structures of HDAC6 and HDAC2 using Autodock 4.2. Binding
distances in HDAC6 (A, E) and HDAC2 (B, F) between the hydroxamic acid atoms
and active site residues (numbered in figure) or the metal are displayed in
Angstroms. The atomic radius of the metal (Zn2+) was set at 0.5 Å for clarity. Atom
color-coding: C2-n-hexyl SAHA (C=purple/white; O=red; N=blue; H=White); amino
acids (C=deep teal; O=red, N=blue); Zn2+ metal ion (grey sphere). C,D and G,H)
Superimposition of SAHA (red) and (R) or (S) C2-n-hexyl SAHA 1i (yellow) in the
crystal structure of HDAC6 (C, G) and crystal structure of HDAC2 (D, H), with the
metal ion (Zn2+) represented as a grey sphere (1.35 Å radius). Notice that the metal
sphere is in close proximity to the hydroxamic acid end of both SAHA and the
analogs in the HDAC6 structures. In contrast, the analogs are positioned farther
from the metal sphere than SAHA in the HDAC2 crystal structure, consistent with the
poor potency observed.
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A

HDAC6

B

H574

HDAC2

H146

Y308 1.8

2.4

Y745

2.4
2.1

2.5
1.9

1.8

2.4

1.6 2.1

H145

H573

Figure 2.7. Docking poses of SAHA in the HDAC6 (A) and HDAC2 crystal
structures (B) using Autodock 4.2. Binding distances between the hydroxamic acid
atoms and active site residues (numbered in figure) or the metal are displayed in
Angstroms. The atomic radii of the metals were set at 0.5 Å for clarity. Color-coded
SAHA (C=green/white; O=red; N=blue; H=White) and amino acid residues (C=deep
teal; O=red, N=blue); Zn2+ metal ion (grey sphere).
Because all HDAC isoforms show high conservation among their active site
residues,98,

120

previous studies suggested that the shape of the active sites might

explain the HDAC6 selectivity of reported compounds.22

In particular, HDAC6

maintains a wider active site entrance compared to the class I isoforms. 86 In
previous work, HDAC6-selective inhibitors were generated by replacing the solventexposed anilide group of SAHA with bulky aryl groups. 86,

121-122

In addition,

compounds with an aryl group attached directly adjacent to the hydroxamic acid
demonstrated HDAC6 selectivity.123 For example, tubastatin is a highly HDAC6selective inhibitor that displays a series of bulky aryl groups near the hydroxamic
acid.86 Based on these prior studies, one hypothesis accounting for the selectivity of
the C2-modified SAHA analogs is that the bulky substituent adjacent to the
hydroxamic acid takes advantage of the wider active site entrance of HDAC6. In
fact, the docking studies with C2-n-hexyl SAHA 1i suggest that the wide active site
entrance of HDAC6 accommodates the C2 substituents (Figures 2.6A, C, E, and G),
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whereas the narrow channel of HDAC2 does not (Figures 2.6B, D, F, and H). In
total, the determination that C2-modified SAHA analogs are HDAC6-selective
inhibitors confirms prior structural analysis suggesting that HDAC6 maintains a wide
active site entrance.
In conclusion, we report the synthesis and screening of several SAHA
analogs substituted at the C2 position. C2-modified SAHA analogs displayed
selectivity for HDAC6 and HDAC8 over HDAC1, 2, and 3. The highest selectivity
observed was with C2-n-hexyl SAHA analog 1i, which displayed 49- to 300-fold
selectivity for HDAC6 and 8 over HDAC1, 2, and 3. Importantly, the selectivity of
C2-n-hexyl SAHA is elevated compared to the widely used HDAC6-selective
inhibitor, tubastatin. Cell-based selectivity testing of analogs 1g-i reproduced the
selectivity observed in vitro. The dual HDAC6/8 selective C2-modified SAHA
analogs reported in this work can be useful as lead compounds to develop
pharmacological tools and anti-cancer drugs targeting HDAC6 and HDAC8. More
generally, these studies with SAHA analogs suggest that modifying known drugs can
significantly improve their properties.
2.7. Experimental Procedures
2.7.1. Materials and instrumentation
Unless otherwise noted, chemicals were purchased from Sigma-Aldrich,
Acros Organics, or Fisher Scientific. “Iron-free” glassware was prepared by rinsing
glassware with 5 M HCl acid twice followed by washing with distilled de-ionized
water. “Iron-free” silica gel was prepared by washing with 5M aqueous HCl, followed
by washing with distilled de-ionized water until colorless, and subsequently drying
under air or in the oven at 80°C. Flash chromatography was carried out using 60 Å,
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230-400 mesh silica gel (Fisher Scientific). NMR spectra were taken on a Varian or
Agilent 400, 500 or 600 MHz instruments. 1HNMR spectra showed NMR solvents
peaks at 3.3 ppm (for CD3OD) and at 4.9 ppm (for trace amounts of water in NMR
solvent), while

13

CNMR spectra showed NMR solvent peaks at 77 (for CDCl 3) or at

47 (for CD3OD).124 Infra red (IR) spectra were taken on Perkin Elmer Spectrum Two
ATR-FTIR. Low resolution mass spectra (LRMS) were taken on Waters ZQ LCSQMS, while high resolution mass spectra (HRMS) spectra were taken on a Waters
LCT-MS premier TOF. HPLC analysis to assess the purity of final compounds was
performed with a Waters 1525 Binary HPLC pump and Waters 2998 Photodiode
Array detector. The separation was performed on a reverse phase HPLC analytical
column (YMC America, 250 x 4.6 mmI.D, 4µm, 8 nm) using a gradient of 90% to
10% of buffer A over 30 minutes (buffer A = 0.1% HPLC grade trifluoroacetic acid
(TFA) in water; buffer B = HPLC grade acetonitrile) at a flow rate of 1.0 mL/min at
room temperature. Purity of the synthesized final compounds is indicated for each
compound in the synthesis procedure. The enantiomeric excess (% ee) discussed in
text was determined with the same HPLC system but with chiral analytical column
(Chiracel OD-H, 250 x 4.6 mmI.D), eluting with 10% isopropanol in hexanes at a flow
rate of 0.5 mL/min at room temperature. Optical rotations were measured in Perkin
Elmer 341 Polarimeter.
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2.7.2. Synthesis procedures for (S)-1i and (R)-1i

Synthesis

of

(S)-4-benzyl-3-octanoyloxazolidin-2-one

((S)-9).

The

compound was synthesized according to the reported procedure. 125 Briefly, (S)-8
(1.44 g, 8.15 mmol) was dissolved in dry THF (25 mL) followed by the addition of
butyl lithium (3.26 mL of 2.5 M solution, 8.16 mmol) drop wise under argon at -78°C.
The reaction was stirred at that temperature for 10 minutes, then octanoyl chloride
(1.53 mL, 8.96 mmol) was added drop wise. Stirring was continued for 30 minutes at
-78°C, then the reaction temperature was gradually raised to room temperature over
30 minutes. The reaction was diluted with saturated solution of ammonium chloride
(30 mL). THF was evaporated at reduced pressure and the reaction was extracted
with ethyl acetate (2 x 30 mL). The organic extracts were then evaporated and the
product was purified by flash silica-gel chromatography (5-10% ethyl acetate in
hexanes) which yielded the product (S)-9 (1.95 g, 79%). 1HNMR (400 MHz, CDCl3) 
(ppm): 0.88 (t, 3H), 1.34 (m, 8H), 1.68 (m, 2H), 2.75 (dd, 2H), 2.93 (m, 2H), 3.29 (dd,
1H), 4.18 (m, 2H), 4.66 (m, 1H), 7.21 (d, 2H), 7.27 (m, 1H), 7.33 (t, 2H);

13

CNMR

(100 MHz, CDCl3) δ (ppm): 14.09, 22.62, 24.26, 29.06, 29.09, 31.69, 35.54, 37.92,
55.15, 66.14, 127.33, 128.95, 129.42, 135.33, 153.46, 173.46. LRMS (LC-SQMS,
m/z); found: [M+H], 304.04, calculated for C18H26NO3, 304.18, found: [M+Na],
326.01, calculated for C18H25NO3Na, 326.17. The spectral data for the synthesized
compound was consistent with the reported data in literature.125
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Synthesis

of

(R)-4-benzyl-3-octanoyloxazolidin-2-one

((R)-9).

The

procedure for (S)-9 was followed, but yielding 2.18 g (84% yield) from (R)-8 (1.5 g,
8.47 mmol). 1HNMR (400 MHz, CDCl3)  (ppm): 0.90 (t, 3H), 1.30 (m, 8H), 1.68 (m,
2H), 2.76 (dd, 2H), 2.91 (m, 2H), 3.29 (dd, 1H), 4.16 (m, 2H), 4.66 (m, 1H), 7.2 (d,
2H), 7.27 (m, 1H), 7.33 (t, 2H);

13

CNMR (100 MHz, CDCl3) δ (ppm): 14.1, 22.62,

24.26, 29.06, 29.09, 31.69, 35.54, 37.92, 55.15, 66.14, 127.32, 128.94, 129.42,
135.33, 153.46, 173.44. LRMS (LC-SQMS, m/z); found: [M+H], 304.08, calculated
for C18H26NO3, 304.18, found: [M+Na], 325.99, calculated for C18H25NO3Na, 326.17.
The spectral data for the synthesized compound was consistent with the reported
data in literature. 125

Synthesis of (S)-3-((R)-2-allyloctanoyl)-4-benzyloxazolidin-2-one ((S)-10).
To compound (S)-9 ( 1.95 g, 6.43 mmol) was added dry THF (25 mL) followed by
reduction of the temperature to -78°C. NaHMDS (3.53 mL of 2 M solution, 7.07
mmol) was added drop wise under Argon and the reaction was stirred at -78°C for 1
hour. Allyl bromide (1.65 mL, 19.28 mmol) was then added drop wise, and the
reaction was stirred at -78°C for 45 minutes, then the temperature was increased
gradually to 0°C and stirring was continued for 1 hour at 0°C. The reaction was then
quenched with saturated ammonium chloride solution (30 mL) and was left to stir at
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room temperature for 15 minutes. The reaction was concentrated under reduced
pressure, and the aqueous layer was extracted with ethyl acetate (3 x 30 mL). The
extracts were evaporated and the product was purified by Flash silica-gel
chromatography (3% ethyl acetate in hexanes) which yielded the product (S)-10
(1.32 g, 60%). 1HNMR (400 MHz, CDCl3)  (ppm): 0.87 (t, 3H), 1.27 (m, 8H), 1.49
(m, 1H), 1.7 (m, 1H), 2.32 (m, 1H), 2.47 (m, 1H), 2.65 (dd, 1H), 3.31 (dd, 1H), 3.91
(m, 1H), 4.16 (m, 2H), 4.66 (m, 1H), 5.05 (dd, 2H), 5.82 (m, 1H), 7.26 (m, 5H);
13

CNMR (100 MHz, CDCl3) δ (ppm): 14.06, 22.58, 27.21, 29.34, 31.58, 31.66, 36.81,

38.11, 42.32, 55.53, 65.90, 117.09, 127.29, 128.93, 129.42, 135.33, 135.46, 153.16,
176.15. LRMS (LC-SQMS, m/z); found: [M+H], 344.04, calculated for C21H30NO3,
344.21, found: [M+Na], 365.99, calculated for C21H29NO3Na, 366.20. []D23 = +74.5
(c .76, CH2Cl2).

Synthesis of (R)-3-((S)-2-allyloctanoyl)-4-benzyloxazolidin-2-one ((R)-10).
The procedure for (S)-10 was followed, but yielding 1.56 g (64% yield) from (R)-9
(2.15 g, 7.08 mmol). 1HNMR (400 MHz, CDCl3)  (ppm): 0.87 (t, 3H), 1.27 (m, 8H),
1.49 (m, 1H), 1.72 (m, 1H), 2.32 (m, 1H), 2.45 (m, 1H), 2.66 (dd, 1H), 3.29 (dd, 1H),
3.91 (m, 1H), 4.15 (m, 2H), 4.68 (m, 1H), 5.06 (m, 2H), 5.82 (m, 1H), 7.27 (m, 5H);
13

CNMR (100 MHz, CDCl3) δ (ppm): 14.06, 22.58, 27.20, 29.34, 31.58, 31.66, 36.80,

38.11, 42.32, 55.53, 65.89, 117.09, 127.29, 128.93, 129.41, 135.32, 135.46, 153.15,
176.15. LRMS (LC-SQMS, m/z); found: [M+H], 344.02, calculated for C21H30NO3,
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344.21, found: [M+Na], 366.02, calculated for C21H29NO3Na, 366.20. []D23 = 70.7
(c 0.49, CH2Cl2).

Synthesis of (R)-2-hexyl-8-oxo-8-(phenylamino)octanoic acid ((R)-11). To
a solution of (S)-10 (1.32 g, 3.84 mmol) in DCM (30 mL) was added N-phenylpent-4enamide (2.69 g, 15.36 mmol) and Grubbs' second-generation catalyst (261 mg, 8
mol%). The reaction was heated at 50°C for 12 hours. The solvent was evaporated.
Flash silica-gel chromatography (1:6 to 1:4 ethyl acetate in hexanes) which yielded
the alkene intermediate (904 mg, 48%). The intermediate was used in the following
reaction with no characterization.
The intermediate alkene (451 mg, 0.92 mmol) was dissolved in a mixture of
THF (20 mL) and water (5 mL). Hydrogen peroxide (0.42 mL of 30% solution, 3.68
mmol) was added at 0°C, followed by lithium hydroxide monohydrate (78 mg, 1.86
mmol) dissolved in 3 mL water. The reaction was stirred at 0°C for 6 hours, then
sodium sulfite (1 g) in 7 mL water was added. The reaction was stirred for additional
15 minutes at room temperature. The reaction was diluted with 10% HCl to pH 2,
and then extracted with ethyl acetate (2 x 40 mL). The extracts were evaporated and
the crude product was used in the next reaction.
The crude product was dissolved in methanol (15 mL), then 20% Pd/C was
added (22 mg, 10% w/w). Air was replaced with argon (x3) then with hydrogen gas
(3x). The reaction was left to stir under hydrogen overnight. The reaction was then
filtered and the product was purified by Flash silica-gel chromatography (1:6 to 1:2
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ethyl acetate in hexanes) which yielded the product (R)-11 (212 mg, 69% over 2
steps). 1HNMR (400 MHz, CDCl3)  (ppm): 0.87 (t, 3H), 1.28 (m, 14H), 1.68 (m ,4H),
2.32 (m, 3H), 7.08 (t, 1H), 7.27 (m, 2H), 7.52 (m, 3H);

13

CNMR (100 MHz, CDCl3) δ

(ppm): 14.06, 22.59, 25.42, 26.98, 27.34, 28.95, 29.20, 31.65, 31.88, 32.31, 37.14,
45.49, 119.91, 124.22, 128.95, 137.91, 171.66, 182.08. LRMS (LC-SQMS, m/z);
found: [M+H], 334.16, calculated for C20H32NO3, 334.23, found: [M+Na], 355.99,
calculated for C20H31NO3Na, 356.22, found: [M-H], 332.22, calculated for C20H30NO3,
332.23.

Synthesis of (S)-2-hexyl-8-oxo-8-(phenylamino)octanoic acid ((S)-11).
The procedure for (R)-11 was followed, but yielding 922 mg (43% yield) for the cross
metathesis reaction from (R)-10 (1.5 g, 4.4 mmol), and then 174 mg (28% over 2
steps) of (S)-11. 1HNMR (400 MHz, CDCl3)  (ppm): 0.87 (t, 3H), 1.43 (m, 14H), 1.64
(m ,4H), 2.33 (m, 3H), 7.09 (t, 1H), 7.30 (m, 3H), 7.51 (d, 2H);

13

CNMR (100 MHz,

CDCl3) δ (ppm): 14.06, 22.59, 25.39, 26.97, 27.33, 28.94, 29.19, 31.64, 31.96,
32.29, 37.55, 45.39, 119.92, 124.22, 128.97, 137.91, 171.47, 181.79. LRMS (LCSQMS, m/z); found: [M-H], 332.13, calculated for C20H30NO3, 332.23.

Synthesis of (R)-2-hexyl-N1-hydroxy-N8-phenyloctanediamide ((R)-1i). In
an acid washed flask, carboxylic acid (R)-11 (295 mg, 0.87 mmol) was dissolved in
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dry DCM (20 mL), followed by the addition of triethyl amine (247 uL, 1.77 mmol),
HOBt (204 mg, 1.33 mmol) and EDCI HCl (272 mg, 1.42 mmol). The reaction was
stirred for 1 hour, then triethyl amine (618 uL, 4.43 mmol), hydroxyl amine HCl (308
mg, 4.43 mmol) and DMF (5 mL) were added. The reaction was stirred overnight.
The reaction was then concentrated under reduced pressure, diluted with distilled
deionized water, and extracted with ethyl acetate (2 x 30 mL). The product was
purified by Flash silica-gel chromatography (2% methanol in DCM, then 1:8 to 1:4
acetone in DCM) which yielded the product (R)-1i (30 mg, 10%). 1HNMR (400 MHz,
CD3OD) δ (ppm): 0.89 (t, 3H), 1.35 (m, 14H), 1.67 (m, 4H), 2.02 (m, 1H), 2.35 (t,
2H), 7.07 (t, 1H), 7.28 (t, 2H), 7.52 (d, 2H);

13

CNMR (100 MHz, CD3OD) δ (ppm):

13.00, 22.23, 25.34, 26.83, 27.14, 28.75, 28.94, 31.50, 32.28, 32.48, 36.43, 43.58,
119.84, 123.70, 128.34, 138.46, 173.24, 173.98; HRMS (Waters LCT-MS premier
TOF, m/z): found [M+Na], 371.2313, calculated for C20H32N2O3Na, 371.2311. []D23
= 1.74 (c 0.3, EtOH). Chiral HPLC: 92% ee.

Synthesis of (S)-2-hexyl-N1-hydroxy-N8-phenyloctanediamide ((S)-1i).
The procedure for (R)-1i was followed, but yielding 30 mg (25% yield) from (S)-11
(116 mg 0.35 mmol). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.88 (t, 3H), 1.34 (m,
14H), 1.64 (m, 4H), 2.02 (m, 1H), 2.35 (t, 2H), 7.07 (t, 1H), 7.28 (t, 2H), 7.53 (d, 2H);
13

CNMR (100 MHz, CD3OD) δ (ppm): 13.02, 22.24, 25.35, 26.84, 27.15, 28.76,

28.95, 31.51, 32.29, 32.49, 36.44, 43.58, 119.85, 123.71,128.35, 138.46, 173.24,
173.98; HRMS (Waters LCT-MS premier TOF, m/z): found [M+Na], 371.2320,

45
calculated for C20H32N2O3Na, 371.2311. []D23 = +1.45 (c 0.9, EtOH). Chiral HPLC:
95% ee.
2.7.3. Procedures for biological screening
2.7.3.1. HeLa cell lysis
HeLa-S3 cells (purchased from Biovest Inc.) were lysed in lysis buffer (1 x 109
cells in 10 mL lysis buffer; 50mM Tris-HCl, pH 8.0, 10% glycerol, 150 mM NaCl,
0.5% Triton X-100) containing Calbiochem protease inhibitor cocktail set V with
rotation at 4 C for 30 min. Cell debris was removed by centrifugation at 12000 rpm
at 4 C for 30 min. Protein concentration of the supernatant was determined using
Bio-Rad protein assay (BioRad, Bradford reagent).
2.7.3.2. Inhibitors testing with HDAC isoforms
Screening with HDAC1, 2, 3, and 6 was performed according to the reported
procedure.93 Briefly, individual wells of a high binding polystyrene 96-well white
opaque plate (Thermo Scientific) were incubated in binding buffer (100 µL; 0.2M
carbonate/0.2M bicarbonate buffer, pH 9.4) containing primary HDAC1 antibody
(Sigma Aldrich, H3284, 100µL of 10µg/mL), primary HDAC2 antibody (Sigma
Aldrich, H3159, 100µL of 10µg/mL), or primary HDAC6 antibody (Sigma Aldrich,
SAB1404771, 100µL of 2µg/mL) with rocking (3 rpm) for 1 hr at room temperature,
or at 4°C overnight with no rocking. For HDAC3 with compounds 1g-i, primary
HDAC3 antibody (Sigma Aldrich, H3034, 100µL of 25µg/mL) was used following the
same procedure described above. But in the case of HDAC3 with all other
compounds, wells of a secondary antibody coated 96-well white opaque plate (GBiosciences) were incubated with primary HDAC3 antibody (Sigma Aldrich, H3034,
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100µL of 1µg/mL) in TBST buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4, 0.05%
(v/v) Tween-20) containing 0.1% (w/v) bovine serum albumin (BSA, Jackson
Immunoresearch) at 4°C overnight without rocking. For all reactions, unbound
antibody was removed by washing quickly three times with TBST buffer (300 µL),
followed by a fourth wash with TBST (300 µL) with 5 minutes incubation and rocking
(3 rpm) at room temperature. In the case of high binding polystyrene plates
containing HDAC1, 2, 3, or 6 antibodies, the unbound regions of the well were
blocked with 5% non-fat dry milk in TBST buffer (300 µL) for 1 hr at room
temperature with rocking (3 rpm). Because the secondary antibody coated plates
containing HDAC3 were pre-blocked by the manufacturer, no additional blocking
step was included.
To affix HDAC enzyme to the plate, HeLa cell lysates (100µL of 100µg/mL for
HDAC1, 2, and 3 and 100µL of 1 mg/mL for HDAC6 in TBST buffer containing 0.1 %
(w/v) non-fat dry milk) were added to each well and incubated for 1 h at 4 °C without
rocking, followed by washing with TBST, as described previously. For HDAC3 with
compounds 1g-i only, HeLa cell lysates (100µL of 1 mg/mL in TBST buffer
containing 0.1 % (w/v) non-fat dry milk) were used, followed by incubation and
washing as described earlier. Inhibitors in DMSO (1 µL) were mixed with HDACGlo™ buffer (24 µL), then added to the plate and incubated for 15 min at room
temperature without rocking. An uninhibited control reaction was also included that
contained DMSO (1 µL) in HDAC-Glo™ buffer (24 µL). Finally, deacetylase activity
was measured using the HDAC-Glo™ assay kit (Promega) as per the
manufacturer’s protocol.

Specifically, the HDAC-Glo™ substrate (1 mL) and
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developer (1 µL) were first premixed, then to monitor deacetylase activity, the
HDAC-Glo™ reagents (25µL) were added to each well (50 µL total volume) and
incubated for 30-45 min at room temperature without rocking. The deacetylase
activity was measured as luminescent signal using a GeniosPlus Fluorimeter
(Tecan) at optimal gain. The concentrations of inhibitors reported in the single dose
screen and dose-dependent studies are final concentrations after addition of HDACGlo™ reagent. For the single concentration screen, the percent deacetylase activity
remaining was calculated by dividing the signal with inhibitor by the signal without
inhibitor (DMSO negative control reaction), and then multiplying by 100. For dosedependent reactions to determine IC50, the luminescent signal was first background
corrected with the signal from a negative control reaction where the HDAC antibody
was absent in the initial antibody binding step before the percent deacetylase activity
was calculated. The mean percent deacetylase activity along with standard error of
three independent trials is reported.
Inhibitory activity with HDAC8 with all compounds was measured using the
following procedure. In a half area 96-well plate, HDAC8 (75 ng, BPS Bioscience)
was incubated in HDAC-Glo™ buffer (39 μL) with small molecule in DMSO (1 µL), or
DMSO alone (1 µL) as a control, for 15 minutes at room temperature. HDAC-Glo™
reagent (10 μL) was added to each reaction and incubated for 15-30 min at room
temperature. Luminescent signal was measured at 25-30 minutes after adding the
substrate reagent using a GeniosPlus Fluorimeter (Tecan) at optimal gain. To
determine IC50, the luminescent signal was first background corrected with the signal
from a background control reaction where no HDAC8 enzyme was added.
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IC50 values were calculated by fitting the percent deacetylase activity
remaining as a function of inhibitor concentration to a sigmoidal dose-response
curve (y = 100/(1+(x/IC50)z), where y = percent deacetylase activity and x = inhibitor
concentration) using non-linear regression with KaleidaGraph 4.1.3 software.
2.7.3.3. In cellulo target and selectivity validation
U937 cells were grown in RPMI media supplemented with 10% fetal calf
serum and 1% penicillin/streptomycin under humidified conditions (37 °C, 5% CO2).
Cells were added (106 cells/well) to a 12 well flat bottom cell culture plate (Corning™
Costar™) in RPMI-1640 (with or with no phenol red) media, supplemented with 10%
fetal calf serum and 1% penicillin/streptomycin (990 µL final volume). The cells were
treated with DMSO (10 µL) or the small molecule in DMSO (10 µL), and incubated
for 18 hours under humidified conditions (37 °C, 5% CO2). The cells were then
washed once with cold PBS (500 µL) and lysed with lysis buffer (20 µL) containing
1X protease inhibitor for 30 minutes at 0°C. The total protein concentration in the
supernatant was then quantified using the Bradford assay kit (Bio-Rad) with BSA as
the standard.
2.7.3.4. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDSPAGE)
In order to separate proteins, equal quantities of proteins from lysates
prepared in section 2.7.3.3 were mixed with BME (2-mercapto ethanol, 10% of the
final volume) and SDS loading buffer (50 mM Tris-Cl [pH 6.8], 100 mM DTT, 2%
SDS, 0.1% bromophenol blue, and 10% glycerol) before the proteins were
denatured at 95 °C for 3 minutes. The proteins in each sample were separated by
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16% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE gels were
prepared according to the reported procedure.126
2.7.3.5. Western blotting and visualization of proteins levels
To detect and visualize proteins bands, proteins on the SDS-PAGE gel were
transferred to PVDF membrane (Immobilon P, Millipore). The membrane was
blocked with 5% (w/v) nonfat milk in TBST buffer at room temperature for 1 h. The
blocked membrane was incubated with a primary antibody (anti-GAPDH (Cell
Signaling, 5174P); anti-Acetyl-α-tubulin(Lys40) (Cell Signaling, 5335P), or antiAcetyl-histone H3(Lys9) (Cell Signaling, 9649P)) at a 1:1000 dilution in TBST buffer
at 4 °C overnight. Finally, the membrane was incubated with HRP-conjugated goat
anti-rabbit secondary antibody (Cell signaling, 7074S; 7:10000 dilution) at room
temperature

for

1

h.

HRP

activity

was

detected

using

an

enhanced

chemiluminescence light-based detection substrate, SuperSignal West Dura
Extended Duration Substrate (ThermoFisher Scientific, 34075) and Alpha Innotech
FluorChem imaging system. The western blots were quantified using AlphaView
FluorChem 3.2.2 program.
2.7.3.6. In vitro cell growth inhibition
Jurkat, AML-MOLM-13, or U937 cells were grown in RPMI media supplemented
with 10% fetal calf serum and 1% penicillin/streptomycin under humidified conditions
(37°C, 5% CO2). Cells were seeded in 96-well cell culture plates with a density of
4x104 cells in 99 μL of media composed of RPMI-1640 (no phenol red),
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. The cells
were treated with 1 µM or 10 µM single concentrations or serial dilution (2-fold) of
compounds 1g-i in DMSO (1 µL). DMSO only was used in the no inhibitor control. A
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negative control was also included where no cells were added. The plate was
incubated for 44 hours at 37 °C in humid 5% CO2 atmosphere. A solution of 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 10 µL of 5 mg/mL in
DPBS buffer (HyClone™ Dulbecco's Phosphate Buffered Saline)) was added to
each well. The cells were incubated for another 4 h at 37 °C in humid 5% CO 2
atmosphere for development to take place. The resulting purple formazan crystals
were dissolved by addition of DMSO (150 µL), and the absorbance was measured at
595 nm using a GeniosPlus Fluorimeter (Tecan). For all wells containing inhibitor,
the signal was background corrected with the signal from a negative control reaction
(media and MTT only) before the percent viable cells was calculated. The percent
viable cells was calculated by dividing the absorbance with inhibitor by the
absorbance without inhibitor (DMSO, cells, and MTT). The assay was performed at
least three independent times. For the single concentrations experiment, the mean
percent viable cells along with standard error of three independent trials is reported
in Figure 2.5. EC50 values were calculated by fitting the percent viable cells as a
function of inhibitor concentration to a sigmoidal dose-response curve (y =
100/(1+(x/EC50)z), where y = percent viable cells and x = inhibitor concentration)
using non-linear regression with KaleidaGraph 4.1.3 software (Table 2.3).
2.7.4. Docking procedure
The AutoDock 4.2 program119,

127

was used to perform the docking calculations.

The HDAC2 crystal structure was downloaded from the protein data bank (pdb ID:
3MAX).128 The PyMOL program was used to delete two chains and remove water
molecules, metal ions (calcium and sodium), and the cocrystallized ligand in the
active site from the crystal structure; only the zinc atoms remained. For HDAC2, a
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grid box of size 60 X 60 X 60 Å3 with a spacing of 0.375 Å and centered at (69.643,
30.937, -0.989) was used. HDAC6 crystal structure was downloaded from protein
databank. (pdb: 5EEM).101 PyMOL program was used to manually delete potassium
and sodium ions, and all water molecules. A grid box of size 42 X 44 X 40 Å 3 with a
spacing of 0.375 Å and centered at (7.000, 17.000, -22.000) was used. For both
HDAC2 and HDAC6, AutoDockTools-1.5.4119 was used to add all polar hydrogen
atoms, compute Gasteiger charges, merge all nonpolar hydrogen, and generate
pdbqt files. The charge of the zinc atom was manually changed from zero to +2. The
map type was set by choosing the ligand and then AutoGrid 4.2 was used to precalculate and generate the grid map files required for the docking calculations. All
the docked compounds were drawn in ChemBioDraw Ultra 12.0, and Chem 3D Pro
12.0 was used to run MM2 job for energy minimization. Then AutoDockTools-1.5.4
program was used to choose torsions, compute Gasteiger charges, and generate
the pdbqt files. All acyclic bonds were made rotatable, except the amide bonds. The
generated pdbqt files for the enzymes were set as a rigid macromolecule and the
genetic algorithm search parameters were set to 100 GA runs for each ligand with a
population size of 150, a maximum number of 2.5 x 10 5 energy evaluations, a
maximum number of 2.7 x 104 generations, a mutation rate of 0.2 and a crossover
rate of 0.8. The docking parameters were set to default. All output DLG files were
converted to pdbqt format and the results were visualized in PyMOL. Among the
100 docked poses generated, the ones shown in Figures 2.5 and 2.6 displayed
optimal distances between the hydroxamic acid group of the inhibitor and the
catalytic metal of the protein.
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CHAPTER 3 - SYNTHESIS, BIOLOGICAL EVALUATION AND
DOCKING OF SAHA DERIVATIVES SUBSTITUTED AT C4 POSITION
Some of the text in this chapter was reprinted or modified from: Negmeldin, A. T.
and Pflum, M. K. H., The structural requirements of histone deacetylase inhibitors:
SAHA analogs modified at the C4 position display dual HDAC6/HDAC8 selectivity.
European Journal of Medicinal Chemistry (Submitted)
3.1. Rationale for synthesis of C4-modified SAHA analogs
After we observed a promising dual HDAC6/HDAC8 selectivity with some of
the C2-modified SAHA analogs, we extended the modifications to the fourth carbon
of the linker of SAHA in order to explore the effect on both potency and isoform
selectivity (Figure 3.1). In this chapter, several new SAHA derivatives substituted in
the linker region at the C4 position were synthesized and screened (Figure 3.1). The
substituents chosen have different sizes to fit into the active sites of different HDAC
isoforms (Figure 3.1). Similar to the C2-modified SAHA analogs, several C4-SAHA
analogs showed substantial improvement in selectivity towards HDAC6 and HDAC8
over HDAC1, 2, and 3, but with a modest reduction in potency, compared to SAHA.
Enantioselective syntheses of both enantiomers of the most interesting analog were
performed and the pure enantiomers were tested for potency and selectivity.
Docking studies provided a structural rationale for the HDAC6 selectivity. This study
along with the previous studies discussed in this thesis emphasize that modification
of the SAHA linker region can enhance isoform selectivity with different effects on
potency.

Figure 3.1. Chemical structures of C4-modified SAHA analogs (19a-f).
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3.2. Synthesis of C4-substituted SAHA derivatives
Synthesis of the C4-SAHA analogs started from a cross metathesis reaction
of methyl-4-pentenoate 12 with crotonaldehyde 13 using Grubbs' second-generation
catalyst to afford the α,β-unsaturated aldehyde 14 (Scheme 3.1). Different
substituents were appended to 14 via 1,4-addition using organolithium cuprates,
followed by Horner–Wadsworth–Emmons reaction with benzyl phosphonoacetate to
give the unsaturated benzyl esters 16a-f. Reduction and hydrogenolysis of 16a-f
gave free acids 17a-f, which were coupled with aniline to afford 18a-f. Intermediates
18a-f were reacted with hydroxylamine to afford the C4-substituted SAHA
derivatives 19a-f as racemic mixtures.
Scheme 3.1. Synthesis of C4-SAHA analogs (19a-f).
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3.3. In vitro screening of C4-modified SAHA analogs
The analogs were tested for global HDAC inhibition with HeLa cell lysates as
the source of all HDAC proteins (Table 3.1). HDAC activity was measured using the
commercially available HDAC-Glo™ I/II substrate (Promega) (see section 2.2). The
results of the screening showed that all of the synthesized derivatives were less
potent than SAHA (Table 3.1

and B.1, and Figure B.140). The most potent

derivative was C4-methyl SAHA (19a), which showed an IC50 value of 3.3 µM.
Compared to the parent molecule SAHA, C4-methyl SAHA is 18-fold less potent
than SAHA, while the rest of the analogs showed 78- to 344-fold reduction in
potency. Because HeLa cell lysates contain all HDAC isoforms, the poor potency of
the C4-SAHA analogs suggests that they may be selective for some HDAC
isoforms, similar to prior C2-modified SAHA analogs (see sections 2.1 and 2.2).
Table 3.1. IC50 values for SAHA and C4-SAHA analogs (19a-19f) with HeLa cell
lysates.a
Compound
SAHA
19a
19b
19c
19d
19e
19f

R
methyl
ethyl
n-butyl
n-hexyl
phenyl
benzyl

IC50 (µM)
0.20 ± 0.02
3.3 ± 0.1
14 ± 1
53 ± 2
60 ± 1
65 ± 6
62 ± 1

a

Mean IC50 value and standard error of at least three independent trials are shown
(Figure B.140 and Table B.1).
To assess selectivity, an initial screen was performed with analogs 19a-f and
the parent molecule SAHA at a single concentration against HDAC1, 2, 3, and 6
using the recently developed ELISA-based HDAC activity assay (see section 2.2).93
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SAHA, as expected, showed no selectivity among HDAC1, 2, 3, and 6, inhibiting
their activity to a similar extent (Figure 3.2). Interestingly, all C4-SAHA analogs (19af) displayed more potent inhibition against HDAC6 compared to HDAC1, HDAC2,
and HDAC3 (Figure 3.2 and Table B.2). The analogs that showed the greatest
difference in potency with HDAC6 versus the other isoforms were C4-n-butyl (19c)
and C4-benzyl (19f). Among the analogs, the C4-methyl SAHA analog (19a) showed
the smallest difference in potency comparing HDAC6 to HDAC1 and HDAC3 (Figure
3.2 and Table B.2). This single concentration screen suggested that C4-modification
on the SAHA structure results in selectivity for HDAC6.
HDAC1

HDAC2

HDAC3

HDAC6

Percentage Deacetylase Activity

100

80

60

40

20

0
SAHA

19a
(Me)

19b
(Et)

19c 19d 19e
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19f
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Figure 3.2. In vitro isoform selectivity screening of C4-modified SAHA analogs (19af) against HDAC1, HDAC2, HDAC3, and HDAC6 using the ELISA-based HDAC
activity assay. Analogs 19a-f were tested at 0.75, 0.75, 2.5, 1.25, 2.5, and 5 µM final
concentration, respectively. SAHA was tested at 1 µM concentration. 93 Mean
percent deacetylase activities from a minimum of two independent trials with
standard errors were plotted (Table B.2).
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To further assess selectivity, IC50 values for derivatives 19b-f were
determined with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms (Table
3.2). In addition, the non-selective parent molecule SAHA, and the HDAC6-selective
inhibitor tubastatin, were tested as control compounds (Table 3.2).93 The nonselective inhibitor SAHA showed similar IC50 values with HDAC1, 2, 3, 6, and 8,
which is expected for a non-selective inhibitor.93 The HDAC6-selective inhibitor
tubastatin displayed 87- to 130-fold selectivity for HDAC6 over HDACs 1, 2, and 3,
and 11-fold selectivity for HDAC6 over HDAC8.93, 112 Interestingly, the analogs 19b-f
had similar IC50 values compared to SAHA with HDAC6 and HDAC8, which were in
the 57 to 290 nM range (Tables 3.2 and B.10). Moreover, analogs 19b-f showed 28to 740-fold selectivity for both HDAC6 and HDAC8 over HDAC1, 2, and 3. The C4ethyl SAHA (19b) and C4-phenyl SAHA (19e) displayed the lowest selectivity among
the analogs, with at least 28- and 38-fold selectivities for HDAC6 and 8 over HDAC1,
2, and 3 (Tables 3.2 and B.10). Modifying SAHA at the C4 position with long alkyl or
bulky groups (n-butyl, n-hexyl, and benzyl groups in analogs 19c, 19d, and 19f) led
to substantial enhancement of selectivity with at least 170-fold selectivity for HDAC6
and 8 over HDAC1, 2, and 3 isoforms (Tables 3.2 and B.10). In addition, the
modifications in analogs 19c, 19d, and 19f led to modest reductions in HDAC6
potency (2.5 to 3-fold reduced), but more potent inhibition of HDAC8 (7- to 9.5-fold
increased) compared to SAHA (Table 3.2).
In terms of structure-activity relationship (SAR) analysis, modifying SAHA at
the C4 position with long alkyl substituents led to enhanced selectivity; the C4-hexyl
19d analog with the longest alkyl chain demonstrated elevated selectivity (210- to
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480-fold) compared to the C4-butyl 19c analog (170- to 310-fold), which were both
more selective that the C4-ethyl analog 19b with the smallest alkyl chain (28- and
46-fold, Tables 3.2 and B.10). The length of the substituent also influenced the
selectivities of the analogs with aryl groups at the C4 position; the lack of a
methylene in C4-phenyl analog 19e led to decreased selectivity (38- to 350-fold)
compared to the C4-benzyl analog 19f (210- to 740-fold). The reduced selectivity of
C4-phenyl analog 19e was due to both decreased potency against HDAC8 (290 nM)
and greater potency with HDAC1 and 2 (11 and 12 µM) compared to C4-benzyl
analog 19f (57 nM, 29 µM, and 32 µM IC50 values with HDAC1, 2, and 8, Table
3.2). In total, the SAR analysis indicated that longer substituents at the C4 position
led to greater HDAC6/8 selectivity.
Table 3.2. IC50 values for SAHA, tubastatin, SAHA analogs 19b-19f, and pure
enantiomers of the C4-benzyl SAHA (R)-19f and (S)-19f against HDAC1, 2, 3, 6 and
8.a

Compound

HDAC1

b

33 ± 1
SAHA
2,700 ± 200
Tubastatinb
4,400 ± 300
19b (ethyl)
19c (n-butyl) 15,000 ± 1000
19d (n-hexyl) 35,000 ± 1000

19e (phenyl)
19f (benzyl)
(R)-19f
(S)-19f
a

IC50 values (nM)a
HDAC2
HDAC3

HDAC6

HDAC8

96 ± 10

20 ± 1

33 ± 3

540 ± 10

3,900 ± 400

2,900 ± 500

31 ± 4

330 ± 10

4,900 ± 400

6,000 ± 1200

160 ± 10

130 ± 3

18,000 ± 2000

23,000 ± 3000

88 ± 7

74 ± 2

38,000 ± 3000

30,000 ± 3000

140 ± 10

79 ± 3

11,000 ± 1000

12,000 ± 1000

23,000 ± 2000

110 ± 10

290 ± 20

29,000 ± 1000

32,000 ± 2000

42,000 ± 4000

140 ± 10

57 ± 2

25,000 ± 2000

36,000 ± 3000

27,000 ± 2000

48 ± 8

27 ± 2

40,000 ± 1000

51,000 ± 1000

37,000 ± 2000

95 ± 9

150 ± 10

Mean IC50 value and standard error of at least three independent trials are shown
(Figures B.141-B.147 and Tables B.3-B.9). b Previously reported IC50 values using
the same assay procedure.93, 112
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Compared to previously reported selective inhibitors, the observed HDAC6
selectivities with the analogs 19c, 19d, and 19f were higher (at least 170-, and 210fold) than the selectivity observed with the HDAC6 selective inhibitor tubastatin (at
least 87-fold) (Table B.10). Moreover,

19c, 19d, and 19f

showed comparable

selectivities (at least 200-, 380-, and 510-fold) relative to the HDAC8 selective
inhibitor PCI-34051 (at least 400-fold).87 Interestingly, C4-benzyl analog 19f showed
higher dual HDAC6/8 selectivity (at least 210- and 510-fold) than the known
HDAC6/8 dual selective inhibitor BRD-73954 (at least 75-, and 250-fold selectivity to
HDAC6, and 8 over HDAC1, 2, and 3).89
3.4. In cellulo selectivity testing
To further assess the observed HDAC6 selectivity in cellulo, C4-benzyl (19f)
SAHA analog was tested for selectivity to inhibit HDAC6 over HDAC1, HDAC2, and
HDAC3 in cells. The inhibition of HDAC6 was monitored by detecting the levels of its
known substrate acetyl-α-tubulin (AcTub), whereas Class I HDAC proteins (HDAC1,
2, and 3) inhibition was monitored through the levels of their known substrate acetylhistone H3 (AcH3). SAHA or the analogs 19c, 19d, or 19f were incubated with U397
leukemia cells before lysis and western blot analysis of protein acetylation. As
expected, SAHA showed an increase in the levels of both acetyl-α-tubulin and
acetyl-histone H3 (Figure 3.3, lane 2), which is consistent with its non-selective
inhibition of HDAC1, 2, 3, and 6 isoforms. In contrast, C4-benzyl (19f) showed a
dose-dependent selective increase in levels of acetyl-α-tubulin (Figure 3.3, lanes 35, AcTub) over the levels of acetyl histone H3 (Figure 3.3, lanes 3-5, AcH3),
compared to the DMSO control (Figure 3.3, lane 1). The observed HDAC6 selectivity

59
in cells is consistent with the selectivity observed in the in vitro screening (Table 3.2
and Figure 3.2).
DMSO SAHA
5

19f (Benzyl)
20

40

60 µM
AcH3

AcTub

GAPDH
1
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5

Figure 3.3. Cell based selectivity testing of the C4-benzyl SAHA analog 19f.
Western blots analysis of acetyl-histone H3 (AcH3) and acetyl-α-tubulin (AcTub)
after treatment with SAHA or the C4-modified SAHA analogs. U937 cells were
treated with DMSO (1%), SAHA (5 µM), or increasing concentrations of C4-benzyl
SAHA (19f) analog (20-60 µM), before lysis, SDS-PAGE separation, transfer to a
PVDF membrane, and western analysis with AcH3 or AcTub antibodies. GAPDH
levels in the samples were also probed as a gel load control. A DMSO control
sample was included for comparison to inhibitor treated samples. Repetitive trials
are shown in Figure B.148.
3.5. In vitro cancer cell growth inhibition
To assess the cytotoxic effect of the HDAC6/8 selective inhibitors in cancer
cells, SAHA derivatives 19c, 19d, and 19f were tested with the leukemia cell lines
U937 and Jurkat due to the prominent role of HDAC6 in leukemia.114 To assess
cytotoxicity, the EC50 values of SAHA and the three analogs 19c, 19d, and 19f were
determined with U937 cell line.114 SAHA showed an EC50 value of 0.88 µM (Table
3.3), which is consistent with the cytotoxicity previously reported.117 The nonselective inhibition of SAHA to all the HDAC proteins likely contributes to its high
cytotoxicity. The C4-n-butyl (19c), C4-n-hexyl (19d), and C4-benzyl (19f) SAHA
analogs displayed 34, 16, and 28 µM EC50 values with the U937 cell line,
respectively (Table 3.3). Compared to SAHA, the analogs were 18- to 39-fold less
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cytotoxic. To confirm the cytotoxicity study in U937 cells, SAHA and the analogs
were also tested for cytotoxicity with the Jurkat cell line. The analogs showed
reduced cytotoxicity compared to SAHA (Figure B.152, Table B.12), consistent with
the study in U937 cells. The reduced cytotoxicity of the analogs in U937 and Jurkat
cells compared to SAHA might be due to their selectivity toward HDAC6 and 8.
Consistent with this hypothesis, similar lower cytotoxicities compared to the nonselective inhibitor SAHA were also observed with HDAC6 and dual HDAC6/8selective inhibitors in previous reports.91, 129-130
Table 3.3. EC50 values of SAHA and C4-butyl, C4-hexyl and C4-benzyl SAHA
analogs with U937 cells.a
Compound
SAHA
19c (n-butyl)
19d (n-hexyl)
19f (benzyl)

EC50 (µM)
0.88 ± 0.13
34 ± 2
16 ± 3
28 ± 7

a

Mean EC50 value and standard error of at least three independent trials are shown.
Data in table is associated with Figures B.149-B.151 and Table B.11.
3.6. Enantioselective synthesis and screening of (R)- and (S)-C4-benzyl SAHA
analog (19f).
Since all analogs were synthesized and screened as racemic mixtures,
enantioselective syntheses were performed to test the selectivity of both
enantiomers of the most selective C4-benzyl SAHA analog (Schemes 3.2-3.4). The
asymmetric synthesis was carried out utilizing Evan's oxazolidinone chiral auxiliary
(R)-8 to synthesize both enantiomers.131 To synthesize the (RS)-21 intermediate, 4pentenoyl chloride was reacted with the chiral auxiliary (R)-8 using n-butyllithium,
which yielded pentenoyl oxazolidinone intermediate (R)-20 (Scheme 3.2A).
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Enantioselective addition of a benzyl group to (R)-20 was achieved via a reaction
with benzyl bromide, which gave (RS)-21. A similar procedure was employed to
synthesize (RR)-21 (Scheme 3.2B), but starting with 3-phenylpropanoyl chloride and
the same chiral auxiliary (R)-8, followed by enantioselective addition of the allyl
group using allyl bromide that gave (RR)-21. Both diastereomers were obtained in
high diastereomeric ratios (dr), which were assessed from the 1HNMR spectra of
both diastereomers (99:1 dr for (RS)-21, and 97:3 dr for (RR)-21 (see Figures B.78
and B.85). To remove the chiral auxiliary, each diastereomer was subjected to
lithium aluminum hydride at 0°C, which produced alcohols (S)-22 and (R)-22 from
(RS)-21 and (RR)-21, respectively (Scheme 3.2). In order to assess the optical purity
and the enantiomeric excess (ee) of the alcohol intermediates (S)-22 and (R)-22,
Mosher esters of both alcohols were synthesized by coupling each alcohol with (R)(+)-α-Methoxy-α-trifluoromethylphenylacetic acid (R)-MTPA using EDCI and DMAP
(Scheme B.1).132 Analysis of the

1

HNMR spectra (obtained with 600 MHz

instrument) showed that both Mosher esters were observed in high diastereomeric
ratios (99:1 dr for (S)-22-(R)-MTPA, and 98:2 dr for (R)-22-(R)-MTPA, Figures B.93,
B.94, B.99 and B.100), which implies that the alcohol intermediates (S)-22 and (R)22 were obtained in high enantiomeric ratios (98% ee for (S)-22 and 96% ee (R)-22).
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Scheme 3.2. Enantioselective synthesis of intermediate alcohols (S)-22 (Part A) and
(R)-22 (Part B)

To synthesize the enantiopure C4-benzyl SAHA analogs (R)-19f and (S)-19f, both
alcohols (S)-22 and (R)-22 were then converted to the methanesulfonate esters,
followed by substitution with dimethyl malonate to give diesters (R)-24 and (S)-24,
respectively (Schemes 3.3 and 3.4). Krapcho decarboxylation afforded methyl ester
intermediates (S)-25 and (R)-25. Cross metathesis of the methyl esters with Nphenyl acrylamide 26 using Grubbs' second-generation catalyst afforded ester
amides

(S)-27 and (R)-27.118 Finally, reduction, followed by substitution with

hydroxyl amine, gave both enantiomers of C4-benzyl SAHA analog, (R)-19f and (S)19f.
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Scheme 3.3. Synthesis of (R)-C4-benzyl SAHA analog (R)-19f

Scheme 3.4. Synthesis of (S)-C4-benzyl SAHA analog (S)-19f

To assess the selectivity of each enantiomer, IC50 values of both the (R)-C4benzyl SAHA (R)-19f and the (S)-C4-benzyl SAHA (S)-19f were determined with
HDAC1, 2, 3, 6, and 8 (Table 3.2). Similar to the racemic mixture, both enantiomers
showed dual HDAC6/HDAC8 selectivity. (R)-C4-benzy SAHA (R)-19f exhibited more
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potent inhibition against HDAC6 and HDAC8 compared to the (S)-C4-benzyl SAHA
(S)-19f, with IC50 values of 48 and 27 nM for (R)-19f and 95 and 150 nM for (S)-19f
(Table 3.2). In addition, (R)-19f showed greater fold preference for HDAC6 and 8
over HDAC1, 2, and 3 (520- to 1300-fold) compared to the racemic mixture (210- to
740-fold). In contrast, (S)-19f showed lower fold selectivities (240- to 540-fold)
compared to both (R)-19f and the racemic mixture (Tables 3.2 and B.10). In vitro
screening revealed that both (R)-C4-benzyl SAHA and (S)-C4-benzyl SAHA are
highly selective to HDAC6 and 8 over HDAC1, 2, and 3, with nanomolar potency.
However (R)-19f was more potent and selective than (S)-19f (Tables 3.2 and B.10).
3.7. Docking Studies
Docking studies for both enantiomers of the C4-benzyl SAHA (19f) were
performed using the AutoDock 4.2 and Autodock tools programs 119,

127

in order to

explain the observed selectivity. The recently reported crystal structures of HDAC6
(PDB: 5G0H)13 and HDAC3 (PDB: 4A69)100 were used in these studies. SAHA, the
parent molecule, was docked in both crystal structures as a validation step for the
docking procedure and for comparison (Figure 3.5). With HDAC6, both enantiomers
of the C4-benzyl SAHA were positioned similar to SAHA, as expected, with the
hydroxamic acid moiety near the catalytic metal, the linker region in the 11 Å
channel, and the anilide group in the solvent exposed region. In addition, the
hydroxamic acid groups bound within 1.9-2.7 Å of the active site residues (H573,
H574, and Y745) and the active site catalytic zinc atom (Figures 3.4A and 3.4C),
similar to that of the parent molecule SAHA (1.7-2.7 Å) (Figure 3.5A). Docking with
the HDAC6 crystal structure was consistent with the high binding affinity of C4benzyl SAHA and SAHA (Table 3.2). Superimposition of each enantiomer and SAHA
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showed a similar binding and positioning of the hydroxamic acid moiety (Figures
3.4E and 3.4G).
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Figure 3.4. Docked pose of (S)-C4-benzyl SAHA (A, B, E, F) and (R)-C4-benzyl
SAHA (C, D, G, H) in the crystal structures of HDAC6 (PDB: 5G0H) and HDAC3
(PDB: 4A69). Binding distances in HDAC6 (A,C) or HDAC3 (B,D) between the
hydroxamic acid atoms and active site residues (numbered in figure) or the metal
are displayed in Angstroms. The atomic radius of the metal (Zn 2+) was set at 0.6 Å
for clarity. Atom color-coding: C4-benzyl SAHA 19f (C=purple/white; O=red; N=blue;
H=White); amino acids (C=deep teal; O=red, N=blue); Zn 2+ metal ion (grey sphere).
E,G and F,H) Shown is the superimposition of SAHA (yellow) and (S)- or (R)-C4benzyl SAHA 19f (red) in the crystal structures of HDAC6 (E, G) and HDAC3 (F, H),
with the metal ion (Zn2+) represented as a grey sphere (1.39 Å radius).
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Figure 3.5. Docking poses of SAHA in the crystal structures of HDAC6 (PDB: 5G0H)
(A) and HDAC3 (PDB: 4A69) (B). Binding distances between the hydroxamic acid
atoms and active site residues (numbered in figure) or the metal are displayed in
Angstroms. The atomic radii of the metals were set at 0.6 Å for clarity. Color-coded
SAHA (C=green/white; O=red; N=blue; H=White) and amino acid residues (C=deep
teal; O=red, N=blue); Zn2+ metal ion (grey sphere).
To explain the observed selectivity, (R)-19f and (S)-19f were also docked into
the HDAC3 crystal structure. Longer and weaker binding interactions (2.1-5.0 Å)
were observed with HDAC3 (Figures 3.4B and 3.4D) compared with HDAC6 (1.9-2.7
Å). Superimposition of both enantiomers with SAHA showed a shift in the position of
the hydroxamic acid moieties away from the metal binding region compared to
SAHA (Figure 3.4F and 3.4H). The docking analysis suggests that the presence of a
bulky substituent on the C4 position weakens binding to HDAC3 due to steric
clashes with the relatively narrow and long 11Å channel of HDAC3 (Figures 3.6B,
see white and blue arrows), which placed the hydroxamic acid moiety away from the
metal binding region (Figures 3.4B, 3.4D and 3.6B). On the other hand, HDAC6
maintains a wider and shorter V-shaped 11Å channel (Figure 3.6A, see white and
blue arrows), which can accommodate relatively large C4 substituents with no effect
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on binding of the hydroxamic acid group to the metal binding region (Figures 3.4A,
3.4C and 3.6A).
A

B

Figure 3.6. Docked poses of (R)-C4-benzyl SAHA (R)-19f in the crystal structures of
HDAC6 (A) HDAC3 (B). The white arrows show the difference in the width of the
active site entrances discussed in text (11 Å channel). The blue arrow in part A show
how the benzyl group can be accommodated in HDAC6 active site with no effect on
binding of the hydroxamic acid group In part B the benzyl group sterically interact
with the relatively narrow 11 Å channel, which positioned the hydroxamic acid group
distant from the metal (see blue arrow). The binding site for both HDAC6 and
HDAC3 are shown as deep blue mesh. Atom color-coding: (R)-C4-benzyl SAHA
(C=green/white; O=red; N=blue; H=white).
Recent studies reporting the HDAC6 crystal structure and prior docking
studies demonstrated that HDAC6 maintain a wider and shorter 11Å channel
compared to HDAC1, 2, and 3.13, 86 In previous work, compounds with bulky aryl or
cyclic groups in the linker region near the hydroxamic acid group had restricted
access to the active site due to steric clash with the relatively narrower 11Å channel,
which placed the metal binding group distant from the catalytic metal for weaker or
no binding of the inhibitor.13 In contrast, HDAC6 active site allowed such inhibitors
to reach the metal binding region in the active, which led to preferential inhibition of
HDAC6 over HDAC1, 2, and 3. In other recent reports, the presence of a bicyclic
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linker or phenyl linker displayed dual HDAC6 and HDAC8 selectivity. 89-91 Moreover,
valpropylhydroxamic acid with a propyl substituent showed selectivity to HDAC6 and
8, but with micromolar potency and low fold selectivity (only 9-17-fold selectivity
against with HDAC1, 2, and 3).88 SAHA analogs with a hexyl or benzyl substituent at
the C2 linker also demonstrated dual HDAC6 HDAC8 selectivity. 112 Based on these
reports and the docking studies, one possibility that accounts for selectivity is that
substituting the C4 of SAHA linker with different groups can be accommodated in the
relatively wider and shorter V-shaped 11Å cavity of HDAC6 active site (Figures 3.4A,
3.4C, 3.4E, 3.4G, and 3.6A), but not the narrower and relatively longer 11Å cavity of
HDAC1, HDAC2, and HDAC3 (Figures 3.4B, 3.4D, 3.4F, and 3.4H). In addition, the
size of the substituent plays a critical role in the selectivity. For example, analogs
bearing smaller substituents (as methyl or ethyl in 19a or 19b) demonstrated lower
selectivity compared to analogs comprising bulkier substituents (as butyl, hexyl,
phenyl, and benzyl 19c-19f) (Figure 3.2 and Table 3.2). In total, the docking results
confirmed the previously reported structural analyses suggesting that the wider
HDAC6 active site entrance is the source of selectivity.
In conclusion, SAHA analogs modified at the C4 position of the linker were
synthesized and screened. The C4-SAHA analogs showed up to 1300-fold dual
selectivity for HDAC6 and HDAC8 over HDAC1, HDAC2, and HDAC3. The best
analogs were C4-n-butyl SAHA (19c) and C4-benzyl SAHA (19f). C4-n-butyl SAHA
(19c), which showed 170- to 310-fold selectivity for HDAC6 and 8 compared to
HDAC1, 2, and 3, with 88 and 74 nM IC50 with HDAC6 and HDAC8, respectively.
C4-benzyl SAHA (19f) showed the highest fold selectivity with 210- to 740-fold
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selectivity for HDAC6 and 8 compared to HDAC1, 2, and 3, and 140 and 57 nM IC50
with HDAC6 and HDAC8. Interestingly, the fold selectivity of C4-butyl and C4-benzyl
SAHA analogs were higher than the recently reported dual HDAC6/8 selective
inhibitors (at least 23-, 75-, and 79-fold).89-91 Furthermore, in cellulo testing of C4benzyl analog showed consistency with the in vitro screening. Enantioselective
synthesis and screening of both enantiomers of the C4-benzyl SAHA revealed that
(R)-C4-benzyl SAHA is more potent and selective than the (S) enantiomer, with 48
and 27 nM IC50 with HDAC6 and HDAC8, and 520- to 1300-fold selectivity for
HDAC6 and 8 over HDAC1, 2, and 3. The dual HDAC6/HDAC8 selective C4-SAHA
analogs reported in this work have the potential to be useful pharmacological tools
for biomedical research and lead compounds for anti-cancer drug development.
More generally, these studies with SAHA analogs suggest that modifying current
drugs can significantly improve their properties.
3.8. Experimental Procedures
3.8.1. Materials and instrumentation
Details were provided in Section 2.7.1 of Chapter 2. Enantiomeric excess
(ee%) was calculated in this chapter based on the NMR spectra of Mosher's esters
of intermediate alcohols (Section 3.6).
3.8.2. Synthesis procedure
3.8.2.1. Synthesis procedures for 19a-19f

Synthesis of methyl (E)-6-oxohex-4-enoate (14): The compound was
synthesized according to the reported procedure, with the use of a different
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catalyst.133 Briefly, in a flame dried 2-neck 100 mL flask, purged with argon,
Grubbs' second generation catalyst (26.65 mg, 0.0314 mmol, 0.5 mol%) was
dissolved in dry dichloromethane (20 mL). Crotonaldehyde 13 (2.6 mL, 31.38 mmol)
and methyl pent-4-enoate 12 (0.78 mL, 6.28 mmol) were added, and the reaction
was stirred with reflux for 3.5 hours under argon. The reaction was then cooled to
room temperature, concentrated, and purified by silica gel flash chromatography
(ethyl acetate:hexanes 1:4) to afford aldehyde 14 as an orange oily product (97%).
The spectral data for the synthesized compound was consistent with the reported
data in literature.133

Synthesis of 1-benzyl 8-methyl (E)-5-ethyloct-2-enedioate (16b): In a 200
mL, 2-neck flame dried flask, copper(I)bromide dimethyl sulfide (2.17 g, 10.56 mmol)
was dissolved in dry THF (20 mL). Air was purged with argon, and then the
temperature was reduced to -15°C. Ethyllithium (12.35 mL of a 1.7M solution in
dibutyl ether, 756 mg, 21.0 mmol) was added drop wise with stirring and the
mixture was allowed to stir for additional 20 minutes at -15°C. The
temperature was then reduced to -78°, followed by drop wise addition of
chlorotrimethylsilane (3.44 g, 31.66 mmol) and methyl pent-4-enoate 14 (500 mg,
3.52 mmol). The reaction was stirred for 5 hours at -78°C. The reaction was then
quenched by addition of a saturated ammonium chloride:ammonia solution (1:1)
portion wise until the reaction color turned blue. The organic layer was collected,
and the aqueous layer was extracted with ethyl acetate (3 x 30 mL). The combined
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organic layers were dried over anhydrous Na2SO4, filtered, and rotavaped to an oily
crude product, which was used in the next reaction without purification.
In a 200 mL 2-neck flame dried flask, air was purged with argon, NaH (169 mg of
60% NaH in mineral oil, 7.04 mmol) was dissolved in dry THF (20 mL). The reaction
was then cooled to 0°C and benzyl diethyl phosphonoacetate 15b (1.80 mL, 7.04
mmol) was added drop wise with stirring. The reaction was allowed to stir for 15
minutes at 0°C, then the crude product from the previous reaction was added. The
reaction was stirred for another 30 minutes at 0°C, followed by stirring for 90
minutes at room temperature. The reaction was quenched with a saturated
ammonium chloride solution (20 mL). The organic layer was collected, and the
aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined organic
layers were dried over anhydrous MgSO4, filtered, and concentrated. The product
was purified by flash silica gel chromatography (ethyl acetate:hexanes 1:9) to afford
16b (375 mg, 35% over two steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.86-0.90
(t, J = 7.2 Hz, 3H), 1.28-1.34 (m, 2H), 1.47 (m, 1H), 1.55-1.61 (m, 2H), 2.18-2.22 (m,
2H), 2.30-2.34 (t, J = 7.2 Hz, 2H), 3.63 (s, 3H), 5.15 (s, 2H), 5.89-5.93 (d, J = 16
Hz, 1H), 6.92-6.98 (m, 1H), 7.29-7.35 (m, 4H).

13

CNMR (100 MHz, CD3OD) δ

(ppm): 9.69, 25.31, 27.86, 30.79, 35.24, 35.33, 38.07, 50.66, 65.69, 122.02, 127.80
(2C), 128.15, 136.28, 148.47, 166.31, 174.4. IR: 2957, 2931, 2875, 1723, 1655,
1437 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C18H24O4H+, 305.2, found 305.2;
calculated for [M+Na]+ C18H24O4Na+, 327.2, found 327.1.
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Synthesis of 1-benzyl 8-methyl (E)-5-ethyloct-2-enedioate (16c): The
procedure was similar to that of 16b except the following reagents were used:
copper(I)bromide dimethyl sulfide (4.34 g, 21.10 mmol), n-butyllithium (16.86 ml of a
2.5 M solution in hexanes, 2.7 g, 42.2 mmol), chlorotrimethylsilane (6.87 g, 63.3
mmol), methyl pent-4-enoate 14 (1 g, 7.03 mmol), NaH (478 mg of 60% NaH in
mineral oil, 11.95 mmol) and benzyl diethyl phosphonoacetate 14b (3.42 g, 11.95
mmol). The reaction was left to stir at room temperature for 10 hours. The product
was purified by flash silica gel chromatography (5% ethyl acetate in hexanes) to
afford 16c (602 mg, 26% over two steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.91
(t, J = 6.8 Hz, 3H), 1.29 (m 7H), 1.58 (m, 3H), 2.22 (t, J = 6.0 Hz, 2H), 2.33 (t, J =
7.2 Hz, 2H), 3.63 (s, 3H), 5.16 (s, 2H), 5.91 (d, J = 15.2 Hz, 1H), 6.97 (dt, 1H), 7.34
(m, 4H).

13

CNMR (100 MHz, CD3OD) δ (ppm): 12.96, 22.05, 28.35, 28.38, 30.78,

32.60, 35.77, 36.51, 50.64, 65.68, 122.01, 127.76 (2C), 128.12, 136.29, 148.47,
166.33, 174.44. IR: 3057, 3033, 2954, 2928, 2860, 1720, 1654, 1456, 1436 cm-1.
LRMS (ESI, m/z): calculated for [M+Na]+ C20H28O4Na+, 355.19, found 355.16.

Synthesis of 1-benzyl 8-methyl (E)-5-phenyloct-2-enedioate (16e): The
procedure was similar to that of 16b except the following reagents were used:
copper(I)bromide dimethyl sulfide (4.61 g, 22.40 mmol), phenyllithium (22.4 ml of a
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2M in dibutyl ether, 44.8 mmol), chlorotrimethylsilane (8.53 mL, 76.24 mol), methyl
pent-4-enoate 14 (1.06 g, 7.49 mmol), NaH (0.51 g of 60% NaH in mineral oil, 12.70
mmol) and benzyl dimethyl phosphonoacetate 15a (2.67 mL, 12.70 mmol). The
reaction was heated to reflux for 1 hour 45 minutes. The product was purified by
column chromatography (diethyl ether:petroleum ether 1:6 to 1:4) to afford 16e as an
orange yellow oil (1.64 g, 62% over two steps). 1HNMR (400 MHz, CDCl3): 1.87 (m,
1H), 2.05 (m, 1H), 2.15 (m, 2H), 2.53 (t, J = 7.6 Hz, 2H), 2.67 (m, 1H), 3.61 (s, 3H),
5.14 (s, 2H), 5.82 (d, J = 15.2 Hz, 1H), 6.88 (dt, J = 15.6 Hz, and 7.2 Hz, 1H), 7.12
(d, J = 7.6 Hz, 2H), 7.22 (m, 1H), 7.37 (m. 7H).

13

CNMR (100 MHz, CDCl3): 30.94,

31.96, 39.61, 44.50, 51.56, 66.05, 115.33, 120.33, 126.81, 127.53, 128.15, 128.53,
128.71, 136.04, 142.81, 147.45, 166.19, 173.82. IR: 3063, 3030, 2951, 1718, 1654,
1495, 1454, 1437 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C22H24O4H+, 353.2;
found 353.4; calculated for [M+Na]+ C22H24O4Na+, 375.2; found 375.3.

Synthesis of 8-methoxy-5-ethyl-8-oxooctanoic acid (17b): In a 50 mL
flask, 16b (375 mg, 1.2 mmol) was dissolved in MeOH (20 mL), then Pd(OH) 2 (87
mg of 20 wt. % Pd(OH)2 on carbon, 0.12 mmol) was added. The air inside the flask
was purged with argon (three times), then with hydrogen gas (three times). The
reaction was stirred under hydrogen for 4 hours. The reaction was filtered through a
celite plug, and the solvent was evaporated. The product was purified by silica gel
flash chromatography (ethyl acetate:hexanes 1:1.5) to afford 17b (299 mg, 94%);
1

HNMR (400 MHz, CD3OD) δ (ppm): 0.84 (t, J = 7.2 Hz, 3H), 1.28 (m, 5H), 1.60 (m,
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4H), 2.30 (m, 4H), 3.66 (s, 3H) 11.40 (br s, 1H). 13CNMR (100 MHz, CD3OD) δ (ppm):
10.58, 21.69, 25.28, 28.00, 31.47, 32.11, 34.27, 38.12, 51.55, 174.52, 179.89. IR:
2956, 2930, 2873, 1738, 1709, 1614, 1459, 1439 cm-1. LRMS (ESI, m/z): calculated
for [M+Na]+ C11H20O4Na+, 239.1, found 239.2.

Synthesis

of

8-methoxy-8-oxo-5-phenyloctanoic

acid

(17e):

The

procedure was similar to that of 17b except the following reagents were used: 16e
(1.40 g, 3.98 mmol), Pd(OH)2 (1.12 g of 20 wt. % Pd(OH)2 on carbon, 1.59 mmol).
The product was purified by column chromatography (ethyl acetate:petroleum ether
1:6 then 1:3) to afford 17e (764 mg, 73%); 1HNMR (400 MHz, CD3OD): 1.40 (m, 2H),
1.63 (m, 2H), 1.80 (m, 1H), 1.98 (m, 1H), 2.10 (m, 2H), 2.20 (m, 2H), 2.54 (m, 1H),
3.60 (s, 3H), 7.17 (m, 3H), 7.28 (m, 2H);

13

CNMR (100 MHz, CDCl3): 22.30, 31.80,

32.20, 33.95, 35.90, 45.15, 51.80, 126.40, 127.50, 128.30, 143.95, 174.30, 179.90.
IR: 3028, 2948, 1734, 1705, 1603, 1494, 1453, 1437 cm-1. LRMS (ESI, m/z):
calculated for [M+H]+ C15H20O4H+, 265.1; found 265.4; calculated for [M+Na]+
C15H20O4Na+, 287.1; found 287.4.

Synthesis of methyl 4-methyl-8-oxo-8-(phenylamino)octanoate (18a):
The procedure was similar to 16b except the following: copper(I)bromide dimethyl
sulfide complex (2.26 g, 10.98 mmol), dry THF (40 mL), methyllithium (13.7 ml of a
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1.6M solution in diethyl ether, 482 mg, 21.9 mmol), chlorotrimethylsilane (3.58 g,
32.94 mmol), methyl pent-4-enoate 14 (520 mg, 3.66 mmol). NaH (293 mg of 60%
NaH in mineral oil, 7.32 mmol), dry THF (20 mL), benzyl diethyl phosphonoacetate
15b (2.10 g, 7.32 mmol). The reaction was stirred for 3.5 hours. The product was
used in the next step without purification.
The procedure was similar to 17b except the following: Crude 16a from prior
step, MeOH (20 mL) and Pd(OH) 2 (413 mg of 20 wt. % Pd(OH)2 on carbon, 0.59
mmol). The reaction was stirred under hydrogen for 3.5 hours. The reaction was
filtered through a celite plug, and the solvent was evaporated. The crude product
was used in the following reaction.
The crude product 17a was dissolved in acetonitrile (10 mL), followed by
addition of DIPEA (946 mg, 7.32 mmol) and TBTU (1.76 g, 5.49 mmol), and the
reaction was left to stir for 20 minutes. Aniline (0.51 g, 5.49 mmol) was added, and
the reaction was left to stir for 4.5 hours. The reaction was quenched with 10%
aqueous HCl (20 mL). The aqueous layer was extracted with ethyl acetate (4 x 20
mL). The combined organic extracts were washed with a saturated NaHCO 3 (10 mL)
and then dried over anhydrous Na2SO4, filtered, and evaporated. The product was
purified by silica flash chromatography (ethyl acetate:hexanes 1:4) to afford 18a
(434 mg, 43% over four steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.90 (d, J = 6.4
Hz, 3H), 1.21 (m, 1H), 1.43 (m, 3H), 1.74 (m, 3H), 2.67 (m, 4H), 3.63 (s, 3H), 7.06 (t,
J = 7.6 Hz, 1H), 7.28 (t, J = 8.4 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H). 13CNMR (100 MHz,
CD3OD) δ (ppm): 18.15, 22.90, 31.13, 31.50, 31.98, 35.79, 36.71, 50.61, 119.83,
123.69, 128.36, 138.50, 173.12, 174.72. IR: 3302, 3137, 3061, 2953, 2940, 2869,

76
1736, 1662, 1600, 1542, 1499, 1442 cm-1. LRMS (ESI, m/z): calculated for [M+H]+
C16H23NO3H+, 278.18, found 278.17; calculated for [M+Na] + C16H23O3Na+, 300.16,
found 300.10.

Synthesis of methyl 4-ethyl-8-oxo-8-(phenylamino)octanoate (18b): The
procedure was similar to the last step of 18a except the following reagents were
used: DIPEA (319 mg, 2.47mmol), TBTU (594 mg, 1.85 mmol) and aniline (172 mg,
185 mmol). The extraction was done with dichloromethane (4 x 20 mL). The product
was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:4) to afford
18b (250 mg, 75%). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.87 (t, J = 7.2 Hz, 3H),
1.34 (m, 5H), 1.60 (m, 2H), 1.68 (m, 2H), 2.33 (m, 4H), 3.64 (s, 3H), 7.07 (t, 1H),
7.29 (t, J = 7.2 Hz, 2H), 7.53 (d, J = 7.2 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ

(ppm): 9.35, 22.23, 24.83, 27.55, 30.56, 31.63, 36.48, 37.83, 50.32, 119.55, 123.40,
128.06, 138.19, 172.82, 174.49. IR: 3302, 3198, 3137, 3062, 2955, 2930, 2862, 1737,
1663, 1600, 1542, 1499, 1442 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C17H25O3H+,
292.19, found 292.19; calculated for [M+Na]+ CI7H25O3Na+, 314.17, found 314.17.

Synthesis of methyl 4-butyl-8-oxo-8-(phenylamino)octanoate (18c): The
procedure was similar to that of 17b except the following reagents were used: 16c
(1.2 g, 3.6 mmol) Pd(OH)2 (504 mg of 20 wt. % Pd(OH)2 on carbon, 0.72 mmol).
The crude product was used in the following reaction.
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The procedure was similar to that of 18a except the following reagents were
used: Crude 17c from prior reaction, DIPEA (464 mg, 3.59 mmol), TBTU (865 mg,
2.69 mmol) and aniline (250 mg, 2.69 mmol). The product was purified by silica gel
flash chromatography (ethyl acetate:hexanes 1:6) to afford 18c (250 mg, 44% over
two steps).

1

HNMR (400 MHz, CD3OD) δ (ppm): 0.89 (t, J = 6.4 Hz, 3H), 1.31 (m,

9H), 1.60 (m, 2H), 1.68 (m, 2H), 2.32 (m, 4H), 2.82 (s, 3H), 7.06 (t, J = 7.2 Hz, 1H),
7.28 (t, J = 8 Hz, 2H), 7.53 (d, J = 8 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ (ppm):

13.07, 22.48, 22.66, 28.29, 28.46, 30.84, 32.37, 32.55, 36.56, 36.77, 50.63, 119.84,
123.69, 128.36, 138.49, 173.10, 174.77. IR: 3302, 3198, 3137, 3041, 2953, 2928,
2859, 1737, 1661, 1600, 1541, 1499, 1441 cm-1. LRMS (ESI, m/z): calculated for
[M+H]+ C19H29NO3H+, 320.22, found 320.21; calculated for [M+Na] + C19H29NO3Na+,
342.20, found 342.17.

Synthesis of methyl 4-hexyl-8-oxo-8-(phenylamino)octanoate (18d): The
procedure was similar to that of 16b except the following reagents were used: 14
(460 mg, 3.24 mmol) dry THF (20 mL), copper(I)bromide dimethyl sulfide (2 g, 9.73
mmol), n-hexyllithium (8.46 ml of a 2.3 M solution in hexanes, 1.792 g, 19.46 mmol),
chlorotrimethylsilane (3.17 g, 29.19 mmol), NaH (259 mg of 60% NaH in mineral oil,
6.48 mmol), benzyl diethyl phosphonoacetate 15b (1.85 g, 6.48 mmol). The reaction
was heated to reflux for 4.5 hours. The product was purified by silica gel flash
chromatography (ethyl acetate:hexanes 1:10). The purified product was used in the
following reaction.
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The procedure was similar to that of 17b except the following reagents were
used: 16d from prior reaction, Pd(OH)2 (228 mg of 20 wt. % Pd(OH)2 on carbon,
0.32 mmol). The crude product was used in the following reaction.
The procedure was similar to that of 18a except the following: 17d from prior
reaction, acetonitrile (15 mL), DIPEA (838 mg, 6.48 mmol), TBTU (1.56 g, 4.86
mmol) and aniline (452 mg, 4.86 mmol). The reaction was quenched with 10%
aqueous HCl (10 mL). The product was purified by silica gel flash chromatography
(ethyl acetate:hexanes 1:6) to afford 18d (214 mg, 19% over four steps). 1HNMR
(400 MHz, CD3OD) δ (ppm): 0.88 (t, J = 6.8 Hz, 3H), 1.31 (m, 13H), 1.60 and 1.68
(overlapped quartet and quintet, J = 7.6 and 7.6 Hz, 4H), 2.32 (m, 4H), 3.64 (s, 3H),
7.07 (t, J = 7.2 Hz, 1H), 7.28 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 2H).

13

CNMR

(100 MHz, CD3OD) δ (ppm): 13.02, 22.30, 22.47, 26.14, 28.32, 29.34, 30.85, 31.61,
32.35, 32.86, 36.57, 36.75, 50.61, 119.86, 123.70, 128.34, 138.47, 173.13, 174.81.
LRMS (ESI, m/z): calculated for [M+H]+ C21H33NO3H+, 348.25, found 348.26;
calculated for [M+Na]+ C21H33NO3Na+, 370.24, found 370.22.

Synthesis of methyl 8-oxo-4-phenyl-8-(phenylamino)octanoate (18e): 8Methoxy-8-oxo-5-phenyloctanoic acid 17e (0.763 g, 2.89 mmol) was dissolved in
dichloromethane (25 mL), then aniline (0.32 mL, 3.47 mmol) was added, followed by
4-(dimethylamino)pyridine (0.424 g, 3.47 mmol). The mixture was stirred until 4(dimethylamino)pyridine was completely dissolved, then dicyclohexyl carbdiimide
(0.716 g, 3.47 mmol) was added, and the reaction was stirred for 4 hours at room
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temperature. The reaction was quenched with 10% aqueous HCl (40 mL), the
organic layer was washed with a saturated NaHCO3 solution, and then brine, dried
over anhydrous Na2SO4, concentrated, and purified by column chromatography
(acetone:petroleum ether 1:6) to give 18e (704 mg, 72%). 1HNMR (400 MHz,
CD3OD): 1.46 (m, 2H), 1.65 (m, 2H), 1.80 (m, 1H), 1.98 (m, 1H), 2.11 (m, 2H), 2.28
(m, 2H), 2.53 (m, 1H), 3.55 (s, 3H), 7.05 (t, J = 7.6 Hz, 1H), 7.16 (m, 3H), 7.26 (m,
4H), 7.52 (d, J = 8.4 Hz, 2H);

13

CNMR (100 MHz, CD3OD): 23.59, 31.55, 31.58,

35.92, 36.50, 45.05, 50.59, 119.83, 123.71, 126.10, 127.41, 128.21, 128.39, 138.48,
144.07, 172.96, 174.34. IR: 3301, 3197, 3135, 3061, 3027, 2949, 2865, 1734, 1663,
1600, 1543, 1499, 1442 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C21H25NO3H+,
340.2; found 340.2; calculated for [M+Na]+ C21H25O3Na+, 362.2; found 362.2.

Synthesis of methyl 4-benzyl-8-oxo-8-(phenylamino)octanoate (18f):
The procedure was similar to that of 16b except the following reagents were
used: 14 (500 mg, 3.52 mmol), dry THF (20 mL), copper(I)bromide dimethyl sulfide
(2.17 g, 10.56 mmol), benzylmagnesium chloride (21.11 ml of a 1.0 M solution in
methyl THF, 3.189 g, 21.12 mmol), chlorotrimethylsilane (3.44 g, 31.68 mmol), NaH
(282 mg of 60% NaH in mineral oil, 7.04 mmol) and benzyl diethyl phosphonoacetate
15b (2.02 g, 7.04 mmol). The reaction was heated to reflux for 1 hour 45 minutes.
The crude product was purified by silica gel flash chromatography (ethyl
acetate:hexanes 1:9). The purified product was used in the following reaction.
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The procedure was similar to that of 17b except the following: 16f from prior
reaction, Pd(OH)2 (247 mg of 20 wt. % Pd(OH)2 on carbon, 0.35 mmol). The
reaction was stirred for 4.5 hours under hydrogen, then it was filtered, and the solvent
was evaporated. The crude product was used in the following reaction.
The procedure was similar to that of 18a except the following: Crude 17f from
prior reaction, DIPEA (464 mg, 3.59 mmol), TBTU (865 mg, 3.59 mmol), and aniline
(250 mg, 2.69 mmol). The reaction was stirred for 4 hours 45 minutes. The combined
organic extracts were dried over anhydrous Na2CO3. The product was purified by
silica gel flash chromatography (ethyl acetate:hexanes 1:3) to afford 18f (340 mg,
27% over four steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.35 (m, 2H), 1.60 and
1.72 (overlapped m and m, 5H), 2.34 (m, 4H), 2.55 (d, J = 6.8 Hz, 2H), 3.61 (s, 3H),
7.10 (m, 4H), 7.21 (t, J = 7.6 Hz, 2H), 7.28 (t, J = 7.2 Hz, 2H), 7.51 (d, J = 7.6 Hz,
2H).

13

CNMR (100 MHz, CD3OD) δ (ppm): 22.35, 28.00, 30.84, 31.97, 36.66, 38.87,

39.61, 50.62, 119.90, 123.71, 125.47, 127.86, 128.34, 128.79, 138.44, 140.65,
173.04, 174.65. IR: 3302, 3026, 2929, 2863, 1734, 1661, 1599, 1542, 1498, 1441
cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C22H27NO3H+, 354.21, found 354.22;
calculated for [M+Na]+ C22H27NO3Na+, 376.19, found 376.21.

Synthesis of N1-hydroxy-4-methyl-N8-phenyloctanediamide (19a): In an
acid washed flask, hydroxylamine HCl (1.09 g, 15.67 mmol) was dissolved in MeOH
(10 mL). KOH (1.76 g, 31.33 mmol) was added at 0°C and allowed to stir for 20
minutes. An alcoholic solution of 18a (434 mg, 1.57 mmol, in 10 mL MeOH) was
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added, and the reaction was stirred for 4.5 hours at 0°C. The pH of the reaction
mixture was adjusted to 6 with concentrated aqueous HCl, followed by dilution with
distilled de-ionized water (30 mL). The reaction was extracted with ethyl acetate (3 x
30 mL). The organic extracts were collected together and dried over anhydrous
Na2SO4.

The

product

was

purified

by

silica

gel

flash

chromatography

(acetone:dichloromethane 1:3) using iron-free silica gel to afford 19a (312 mg, 72%).
1

HNMR (400 MHz, CD3OD) δ (ppm): 0.92 (d, J = 6.0 Hz, 3H), 1.23 (m, 1H), 1.44 (m,

3H), 1.72 (m, 3H), 2.15 (m, 2H), 2.35 (t, J = 7.6 Hz, 2H), 7.07 (t, J = 7.2 Hz, 1H),
7.28 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ

(ppm): 18.19, 22.89, 29.98, 32.01, 32.26, 35.76, 36.64, 119.87, 123.72, 128.35,
138.45, 171.79, 173.21. IR: 3308, 3138, 3063, 3030, 2954, 2930, 2861, 1737, 1695,
1663, 1601, 1543, 1500, 1443 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+
C15H22N2O3Na+, 301.1528, found 301.1520. HPLC analytical purity analysis 98.4%.

Synthesis of 4-ethyl-N1-hydroxy-N8-phenyloctanediamide (19b): The
procedure was similar to that of 19a except the following: hydroxylamine HCl (597
mg, 8.59 mmol), KOH (964 mg, 17.18 mmol), and 18b (250 mg, 0.86 mmol). The
reaction was left to stir for 4 hours at 0°C, then at room temperature overnight.
The product was purified by silica gel flash chromatography (ethyl acetate:hexanes
1:4 to 1:3) using iron-free silica gel to afford 19b (116 mg, 46%). 1HNMR (400 MHz,
CD3OD) δ (ppm): 0.87 (t, J = 6.4 Hz, 3H), 1.32 (m, 5H), 1.59 and 1.67 (overlapped
m and m, 4H), 2.08 (t, J = 7.2 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 7.06 (t, J = 7.2 Hz,
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1H), 7.28 (t, J = 7.6 Hz, 2H), 7.54 (d, J = 8 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ

(ppm): 9.72, 22.52, 25.16, 28.67, 29.82, 31.90, 36.76, 38.14, 119.90, 123.76,
128.39, 138.45, 171.89, 173.25. IR: 3252, 3199, 3061, 2960, 2932, 2872, 1658,
1600, 1546, 1500, 1444 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+
C16H24N2O3Na+, 315.1685, found 315.1669. HPLC analytical purity analysis 97.5%.

Synthesis of 4-butyl-N1-hydroxy-N8-phenyloctanediamide (19c): The
procedure was similar to that of 19a except the following: hydroxylamine HCl (538
mg, 7.74 mmol), KOH (869 mg, 15.49 mmol), and 18c (247 mg, 0.77 mmol). The
product was purified by silica gel flash chromatography (acetone:dichloromethane
1:4) using iron-free silica gel to afford 19c (167 mg, 67%) 1HNMR (400 MHz,
CD3OD) δ (ppm): 0.90 (t, J = 7.6 Hz, 3H), 1.33 (m, 9H), 1.60 and 1.69 (overlapped
m and quintet, J = 7.2 Hz, 4H), 2.08 (t, J = 7.2 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 7.07
(t, J = 8.0 Hz, 1H), 7.29 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H).

13

CNMR (100

MHz, CD3OD) δ (ppm): 13.06, 22.45, 22.68, 28.48, 29.11, 29.76, 32.30, 32.62, 36.62,
36.72, 119.86, 123.73, 128.36, 138.45, 171.87, 173.23. IR: 3288, 2972, 2927, 2872,
1647, 1600, 1545, 1499, 1443 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+
C18H28N2O3Na+, 343.1998, found 343.1985. HPLC analytical purity analysis 97.7%.

Synthesis of 4-hexyl-N1-hydroxy-N8-phenyloctanediamide (19d): The
procedure was similar to that of 19a except the following: hydroxylamine HCl (573
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mg, 8.24 mmol), KOH (925 mg, 16.48 mmol), and 18d (286 mg, 0.82 mmol). The
reaction was stirred for 2 hours at 0°C, then pre-incubated solution of
hydroxylamine HCl (573 mg, 8.24 mmol) and KOH (925 mg, 16.48 mmol) was
added followed by stirring for 1.5 hour at 0°C. The product was purified by
sequential silica gel flash chromatography (acetone:dichloromethane 1:3 and a
second purification with acetone:dichloromethane 1:2) using iron-free silica gel. The
compound was further purified by HPLC on a reverse phase HPLC semi-preparative
column (YMC America, 250 x 10 mmI.D., 4µm, 8 nm) using a gradient of 60% to
10% of buffer A over 90 minutes (buffer A = 0.1% HPLC grade TFA in water; buffer
B = HPLC grade acetonitrile) at a flow rate of 3.0 mL/min at room temperature to
yield 19d (49 mg, 17%). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.88 (t, J = 6.8 Hz,
3H), 1.33 (m, 13H), 1.59 (m, 2H), 1.69 (quintet, J = 7.6 Hz, 2H), 2.08 (t, J = 8.0 Hz,
2H), 2.35 (t, J = 7.6 Hz, 2H), 7.07 (t, J = 7.6 Hz, 1H), 7.29 (t, J = 7.6 Hz, 2H), 7.52 (d,
J = 7.6 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ (ppm): 13.01, 22.30, 22.44, 26.20,

29.14, 29.38, 29.78, 31.63, 32.29, 32.96, 36.66, 36.71, 119.89, 123.71, 128.34,
138.45, 171.85, 173.21. IR: 3254, 3064, 2957, 2927, 2858, 1660, 1601. 1547, 1500,
1444 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ C20H32N2O3Na+,
371.2311, found 371.2319. HPLC analytical purity analysis 98.2%.

Synthesis of 4-hexyl-N1-hydroxy-N8-phenyloctanediamide (19e): The
procedure was similar to that of 19a except the following: hydroxylamine HCl (1.38 g,
19.91 mmol), MeOH (50 mL), KOH (2.23 g, 39.82 mmol), and 18e (675 mg, 1.99
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mmol). The reaction was stirred overnight. The product was purified by silica gel
flash chromatography (5% MeOH in dichloromethane) using iron-free silica gel,
followed by crystallization from MeOH to afford 19e (350 mg, 52%). 1HNMR (400
MHz, CD3OD): 1.53 (m, 2H), 1.68 (m, 2H), 1.85 (m, 3H), 2.01 (m, 1H), 2.30 (m, 2H),
2.57 (m, 1H), 7.06 (t, J = 7.6 Hz, 1H), 7.18 (m, 3H), 7.28 (m, 4H), 7.50 (d, J = 7.2 Hz,
2H).

13

CNMR (100 MHz, CD3OD): 23.58, 30.50, 32.22, 35.90, 36.43, 45.14, 119.84,

123.69, 126.04, 127.40, 128.21, 128.34, 138.42, 144.19, 171.5, 173.02. IR: 3253,
3199, 3061, 3027, 2929, 2866, 1657, 1600, 1545, 1499, 1444 cm-1. HRMS (ESITOF, m/z): calculated for [M+Na]+ C20H24N2O3Na+, 363.1685, found 363.1686. HPLC
analytical purity analysis 98.8%.

Synthesis of 4-benzyl-N1-hydroxy-N8-phenyloctanediamide (19f): The
procedure was similar to that of 19a except the following: hydroxylamine HCl (600
mg, 8.64 mmol), KOH (970 mg, 17.28 mmol), and 18f (305 mg, 0.86 mmol). The
reaction was stirred for 2 hours at 0°C, then another premixed solution of
hydroxylamine HCl (600 mg, 8.64 mmol) and KOH (970 mg, 17.28 mmol) was
added followed by stirring for 1.5 hour at 0°C. The product was purified by silica gel
flash chromatography (acetone:dichloromethane 1:2) using iron-free silica gel to
afford 19f (158 mg, 51%). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.33 (m, 2H), 1.67
(m 5H), 2.12 (m, 2H), 2.29 (m, 2H), 2.56 (m, 2H), 7.15 (m, 6H), 7.28 (t, J = 7.6 Hz,
2H), 7.51 (d, J = 7.6 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ (ppm): 22.28, 28.83,

29.77, 31.72, 36.64, 38.93, 39.57, 119.91, 123.73, 125.46, 127.86, 128.352, 128.846,
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138.43, 140.65, 171.70, 173.13. IR: 3253, 3063, 3027, 2972, 2927, 1660, 1600,
1547,

1499, 1444

cm-1.

HRMS

(ESI-TOF,

m/z):

calculated

for

[M+Na]+

C21H26N2O3Na+, 377.1841, found 377.1824. HPLC analytical purity analysis 98.9%.
3.8.2.2. Enantioselective synthesis procedures for (R)-19f and (S)-19f

Synthesis of (R)-4-benzyl-3-(pent-4-enoyl)oxazolidin-2-one ((R)-20). The
compound was synthesized in a similar way to the reported procedure. 134 Briefly,
(R)-8 (1.0 g, 5.64 mmol) was dissolved in dry THF (25 mL) followed by the addition
of n-butyl lithium (2.5 mL of 2.5 M solution, 5.64 mmol) drop wise under argon at 78°C. The reaction was stirred at that temperature for 10 minutes, then 4-pentenoyl
chloride (0.81 mL, 6.77 mmol) was added drop wise. Stirring was continued for 30
minutes at -78°C, then the reaction temperature was raised to gradually room
temperature over 30 minutes. The reaction was diluted with saturated solution of
ammonium chloride (30 mL) and saturated solution of sodium carbonate (30 mL)
and stirred for 15 minutes at room temperature. The solution was extracted with
ethyl acetate (3 x 40 mL). The organic extracts were combined, evaporated and the
product was purified by Flash silica-gel chromatography (ethyl acetate:hexanes 1:91:3) which yielded the product (R)-20 (954 mg, 65%). 1HNMR (400 MHz, CDCl3) 
(ppm): 2.45 (q, J = 6.8 Hz, 2H), 2.61 (dd, J = 3.6 Hz and 13.2, 1H), 3.04 (m, 2H),
3.31 (dd, J = 2.8 and 13.2 Hz, 1H), 4.17 (m, 2H), 4.68 (m, 1H), 5.07 (overlapped d
and d, J = 10.4 and 17.2 Hz, 2H), 5.87 (m, 1H), 7.21 (d, J = 7.2 Hz, 2H), 7.31 (m,
3H);

13

CNMR (100 MHz, CDCl3) δ (ppm): 28.16, 34.81, 37.92, 55.16, 66.21, 115.74,
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127.36, 128.96, 129.42, 135.26, 136.69, 153.46, 172.55. LRMS (LC-SQMS, m/z);
found: [M+H], 260.01, calculated for C15H18NO3, 260.13, found: [M+Na], 281.97,
calculated for C15H17NO3Na, 282.11. Spectral data were consistent with the reported
spectra.134

Synthesis of (R)-4-benzyl-3-((S)-2-benzylpent-4-enoyl)oxazolidin-2-one
((RS)-21). To compound (R)-20 (951 mg, 3.67 mmol) was added dry THF (20 mL)
followed by reduction of the temperature to -78°C. NaHMDS (2.0 mL of 2 M solution,
4.04 mmol) was added drop wise under Argon and the reaction was stirred at -78°C
for 30 minutes. Benzyl bromide (0.86 mL, 7.34 mmol) was then added drop wise,
and the reaction was stirred at -78°C for 5 hours, then the temperature was
increased gradually to room temperature overnight. The reaction was then quenched
with saturated ammonium chloride solution (15 mL) and was left to stir at room
temperature for 15 minutes. The reaction was extracted with ethyl acetate (2 x 30
mL). The extracts were combined, evaporated, and the product was purified by
Flash silica-gel chromatography (ethyl acetate:hexanes 1:15-1:10) which yielded
(RS)-21 as a white solid (730 mg, 57%). 1HNMR (400 MHz, CDCl3)  (ppm): 2.29
(m, 1H), 2.47 (m, 2H), 2.83 (dd, J = 6.8 and 13.6 Hz, 1H), 3.03 (overlapped dd and
dd, J = 3.2, 13.2, 8.4, and 13.6 Hz, 2H), 4.05 (dd, J = 3.2, and 9.2 Hz, 1H), 4.11 (t, J
= 7.6 Hz, 1H), 4.35 (m, 1H), 4.62 (m, 1H), 5.05 (m, 2H), 5.81 (m, 1H), 7.01 (dd, J =
2.4, and 8.0 Hz, 2H), 7.20 (m, 1H), 7.25 (m, 3H), 7.28 (m, 4H);

13

CNMR (100 MHz,

CDCl3) δ (ppm): 36.34, 37.56, 38.13, 44.27, 55.05, 65.77, 117.28, 126.47, 127.24,
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128.38, 128.88, 129.37, 129.38, 135.18, 138.90, 153.07, 175.26. LRMS (LC-SQMS,
m/z); found: [M+H], 349.98, calculated for C22H24NO3, 350.18, found: [M+Na],
371.95, calculated for C22H23NO3Na, 372.16. []D23 = -48.40 (c = 1.00, CH2Cl2).
Spectral data were consistent with the reported spectra. 135 Diastereomeric ratio of
99:1 was calculated from the integration of peaks of both the major and the minor
diastereomers in the 1HNMR spectrum (See Figure B.78).

Synthesis of (R)-4-benzyl-3-(3-phenylpropanoyl)oxazolidin-2-one ((R)23). The procedure was similar to that of (R)-20 except the following reagents were
used: (R)-8 (1.5 g, 8.47 mmol), n-butyl lithium (4.1 mL of 2.5 M solution, 10.16
mmol), and 3-phenyl propanoyl chloride (1.64 mL, 11 mmol). The reaction gave (R)23 in 90% yield (2.36 g). 1HNMR (400 MHz, CDCl3)  (ppm): 2.75 (dd, J = 9.6 Hz
and 13.2, 1H), 3.03 (m, 2H), 3.29 (m, 3H), 4.16 (m, 2H), 4.67 (m, 1H), 7.22 (m, 3H),
7.32 (m, 7H); 13CNMR (100 MHz, CDCl3) δ (ppm): 30.26, 37.13, 37.82, 55.11, 66.18,
126.28, 127.36, 128.48, 128.58, 128.96, 129.42, 135.19, 140.44, 153.41, 172.41.
LRMS (LC-SQMS, m/z); found: [M+H], 310.31, calculated for C19H20NO3, 310.14,
found: [M+Na], 332.31, calculated for C19H19NO3Na, 332.13. Spectral data are
consistent with the reported spectra.136

Synthesis of (R)-4-benzyl-3-((R)-2-benzylpent-4-enoyl)oxazolidin-2-one
((RR-21). The procedure was similar to that of (RS)-21 except the following reagents
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were used: (R)-23 (2.35 g, 7.59 mmol), NaHMDS (4.18 mL of 2 M solution, 8.35
mmol), and allyl bromide (1.97 mL, 22.8 mmol). The product was purified by Flash
silica-gel chromatography (ethyl acetate:hexanes 1:15) which yielded (RS)-21 as an
oily product (1.84 g, 69%). 1HNMR (400 MHz, CDCl3)  (ppm): 2.37 (m, 1H), 2.522.67 (overlapped m and dd, J = 10.0 and 13.2 Hz, 2H), 2.84 (dd, J = 6.4 and 13.2
Hz, 1H), 2.96 (dd, J = 8.8 and 13.2 Hz, 1H), 3.23 (dd, J = 3.2, and 13.2 Hz, 1H),
3.82 (t, J = 8.4 Hz, 1H), 4.01 (d, J = 9.2 Hz, 1H), 4.33 (m, 1H), 4.45 (m, 1H), 5.10
(m, 2H), 5.86 (m, 1H), 7.17-7.33 (m, 10H);

13

CNMR (100 MHz, CDCl3) δ (ppm):

36.32, 38.03, 38.29, 43.95, 55.49, 65.84, 117.41, 126.41, 127.29, 128.35, 128.90,
129.11, 129.42, 135.05, 135.36, 138.91, 153.01, 175.30. LRMS (LC-SQMS, m/z);
found: [M+H], 350.45, calculated for C22H24NO3, 350.18, found: [M+Na], 372.47,
calculated for C22H23NO3Na, 372.16. []D23 = -121.5 (c = 1.00, CH2Cl2). Spectral
data were consistent with the reported spectra.135-136 Diastereomeric ratio of 97:3
was calculated from the integration of peaks of both the major and the minor
diastereomers in the 1HNMR spectrum (See Figure B.87).

Synthesis of (S)-2-benzylpent-4-en-1-ol ((S)-22). A solution of (RS)-21 (901
mg, 2.58 mmol) in dry THF (7 mL) was cooled and stirred at 0°C in ice bath for 15
minutes. Lithium aluminum hydride (295 mg, 7.77 mmol) was added portion wise
and the reaction was stirred at 0°C for 2 hours. The reaction was quenched by
careful drop wise addition of 1M solution of NaOH until no effervescence was
observed, then diluted with water (3 mL). Extraction of the aqueous layer was done
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with ethyl acetate (3 x 40 mL). The organic extracts were combined, evaporated,
and the product

was purified

by Flash

silica-gel chromatography (ethyl

acetate:hexanes 1:15-1:10) which afforded (S)-22 (402 mg, 88%). 1HNMR (400
MHz, CDCl3)  (ppm): 1.38 (br s, 1H), 2.14 (t, J = 7.2 Hz, 2H), 2.64 (m, 2H), 3.55
(m, 2H), 5.06 (m, 2H), 5.83 (m, 1H), 7.19 (m, 3H), 7.28 (m, 2H);

13

CNMR (100 MHz,

CDCl3) δ (ppm): 35.50, 37.24, 42.37, 64.74, 116.61, 125.97, 128.35, 129.17, 136.83,
140.48. []D23 = -13.96 (c = 0.824, CH2Cl2). Compound characterization and specific
rotation were consistent with literature.137

Synthesis of (R)-2-benzylpent-4-en-1-ol ((R)-22). The procedure was
similar to that of (S)-22 except the following reagents were used: (RR)-21 (1.83 g,
5.23 mmol) in dry THF (25 mL), Lithium aluminum hydride (595 mg, 15.68 mmol).
The reaction afforded (R)-22 in 70% yield (645 mg). 1HNMR (400 MHz, CDCl3) 
(ppm): 42 (t, J = 5.6 Hz, 1H), 1.92 (m, 1H), 2.15 (m, 2H), 2.65 (m, 2H), 3.55 (m, 2H),
5.07 (m, 2H), 5.83 (m, 1H), 7.21 (m, 3H), 7.28 (m, 2H);

13

CNMR (100 MHz, CDCl3) δ

(ppm): 35.49, 37.24, 42.37, 64.71, 116.62, 125.97, 128.35, 129.18, 136.84, 140.50.
[]D23 = +15.80 (c = 1, CH2Cl2). Compound characterization and specific rotation
were consistent with its enantiomer ((S)-22) and with literature.137-138
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3.8.2.3. Synthesis procedure for Mosher's esters of (S)-11-(R)-MTPA and (R)11-(R)-MTPA

Synthesis of (S)-2-benzylpent-4-en-1-yl (R)-3,3,3-trifluoro-2-methoxy-2phenylpropanoate ((S)-22-(R)-MTPA). Alcohol (S)-22 (35 mg, 0.2 mmol) was
dissolved in dry DCM (4 mL) followed by replacement of air with argon. and (R)-(+)a-Methoxy-a-trifluoromethylphenylacetic acid ((R)-MTPA) (71 mg, 0.3 mmol), EDCI
(116 mg, 0.6 mmol), and 4-(dimethylamino)pyridine (73 mg, 0.6 mmol). The reaction
was stirred overnight at room temperature. Solvent was evaporated and the residue
was suspended in 1N HCl (5 mL) and then extracted with ethyl acetate (2 x 15 mL).
The combined extracts were combined, evaporated, and purified by silica gel flash
chromatography (ethyl acetate:hexanes 1:15) to afford (S)-22-(R)-MTPA (49 mg,
63%). 1HNMR (600 MHz, CDCl3) δ (ppm): 2.03 (m, 3H), 2.51 (m, 2H), 3.49 (s, 3H),
4.06-4.13 (overlapped dd and dd, J = 2.8 and 7.2 Hz, 2H), 4.99 (m, 2H), 5.68 (m,
1H), 6.96 (d, J = 4.8 Hz, 2H), 7.12 (t, J = 5.2 Hz, 1H), 7.18 (d, J = 5.6 Hz, 2H), 7.35
(m, 3H), 7.46 (m, 2H).

13

CNMR (150 MHz, CDCl3) δ (ppm): 35.15, 36.97, 39.26,

55.46, 67.18, 117.45, 121.99, 124.85, 126.23, 127.38, 128.45, 129.07, 129.67,
132.31, 135.48, 139.38, 166.57.

19

FNMR (400 MHz, CDCl3) δ (ppm): -71.30. LRMS

(LC-SQMS, m/z); found: [M+Na], 415.13, calculated for C22H23F3O3Na, 415.15.
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Synthesis of (R)-2-benzylpent-4-en-1-yl (R)-3,3,3-trifluoro-2-methoxy-2phenylpropanoate ((R)-22-(R)-MTPA). The procedure was similar to that of (SR)18 except the following reagents were used (R)-22 (15.8 mg, 0.09 mmol), (R)-(+)-aMethoxy-a-trifluoromethylphenylacetic acid ((R)-MTPA) (46 mg, 0.2 mmol), EDCI
(35 mg, 0.27 mmol), and 4-(dimethylamino)pyridine (33 mg, 0.27 mmol). The
reaction was stirred at room temperature for 3 hours. The product was purified by
silica gel flash chromatography (ethyl acetate:hexanes 1:50) and afforded (R)-22(R)-MTPA in 89% yield (32 mg). 1HNMR (600 MHz, CDCl3) δ (ppm): 2.03 (m, 3H),
2.54 (m, 2H), 3.48 (s, 3H), 4.01 (dd, J = 2.8 and 7.2 Hz, 1H), 4.20 (dd, J = 2.8 and
7.2 Hz, 1H), 4.97 (m, 2H), 5.66 (m, 1H), 7.01 (d, J = 4.8 Hz, 2H), 7.13 (t, J = 5.2 Hz,
1H), 7.20 (d, J = 5.6 Hz, 2H), 7.35 (m, 3H), 7.46 (m, 2H).

13

CNMR (150 MHz, CDCl3)

δ (ppm): 34.99, 37.05, 39.15, 55.41, 67.19, 117.48, 121.98, 124.85, 126.26, 127.43,
128.45, 129.10, 129.67, 132.28, 135.42, 139.34, 166.55.

19

FNMR (400 MHz, CDCl3)

δ (ppm): -71.26. LRMS (LC-SQMS, m/z); found: [M+Na], 415.17, calculated for
C22H23F3O3Na, 415.15.

Synthesis of dimethyl (R)-2-(2-benzylpent-4-en-1-yl)malonate ((R)-24). A
solution of (S)-22 (400 mg, 2.27 mmol) in dry DCM (10 mL) was cooled to 0°C in ice
bath followed by addition of triethyl amine (265 µL, 3.41 mmol), then
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methanesulfonyl chloride (476 µL, 3.41 mmol) drop wise. The reaction was stirred
for 10 minutes at 0°C, then for 1 hour at room temperature. The reaction was diluted
with water (10 mL) followed by concentration at reduced pressure. The aqueous
layer was extracted with ethyl acetate (3 x 20 mL). The organic extracts were
combined, dried over anhydrous sodium sulfate, and evaporated. The crude product
was used in the following reaction with no purification.
In a 2-neck flame dried flask, air was purged with argon, NaH (273 mg of
60% NaH in mineral oil, 6.82 mmol) was dissolved in dry THF (20 mL). The reaction
was then cooled to 0°C and dimethyl malonate (0.78 mL, 6.82 mmol) was added
drop wise with stirring. The reaction was allowed to stir for 15 minutes at 0°C, then
the crude product from previous reaction was added (in 10 mL dry THF). The
reaction was heated under reflux for 20 hours, then another solution of malonate
anion (prepared in the same way as described above) was added to the reaction
and reflux was continued for another 20 hours. The reaction was then quenched
with saturated ammonium chloride solution (20 mL) and extracted with ethyl acetate
(3 x 30 mL). The extracts were combined, evaporated, and the product was purified
by Flash silica-gel chromatography (ethyl acetate:hexanes 1:9) which yielded (R)-24
in 49% yield (269 mg) over two steps. 1HNMR (400 MHz, CDCl3)  (ppm): 1.67 (m,
1H), 1.83-2.12 (m, 4H), 2.58 (m, 2H), 3.50 (t, J = 7.6 Hz, 1H) 3.69 (s, 3H), 3.73 (s,
3H), 5.05 (m, 2H), 5.76 (m, 1H), 7.13 (d, J = 7.2 Hz, 2H), 7.19 (m, 1H), 7.24 (m ,2H);
13

CNMR (100 MHz, CDCl3) δ (ppm): 32.47, 37.16, 37.37, 39.85, 49.70, 52.48, 52.50,

117.22, 126.02, 128.30, 129.16, 135.70, 140.16, 169.82, 169.89. IR: 3065, 3027,
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2953, 2924, 2853, 1733, 1651, 1623, 1592, 1575, 1496, 1436 cm -1. LRMS (LCSQMS, m/z); found: [M+H], 291.19, calculated for C17H23O4, 291.16,

Synthesis of dimethyl (S)-2-(2-benzylpent-4-en-1-yl)malonate ((S)-24).
The procedure was similar to that of (R)-24 except the following reagents were used:
(R)-22 (597 mg, 3.34 mmol), triethyl amine (710 µL, 5.09 mmol), methanesulfonyl
chloride (394 µL, 5.09 mmol), and the reaction was stirred at room temperature for 3
hours. For the next reaction, the following reagents were used once only, NaH (407
mg of 60% NaH in mineral oil, 10.17 mmol), dimethyl malonate (1.16 mL, 10.17
mmol) and the reaction was refluxed for 20 hours. The reaction afforded (S)-13 in
66% yield (648 mg) over two steps. 1HNMR (400 MHz, CDCl3)  (ppm): 1.74 (m,
1H), 1.88-2.08 (m, 4H), 2.56 (m, 2H), 3.50 (t, J = 7.6 Hz, 1H) 3.69 (s, 3H), 3.72 (s,
3H), 5.05 (m, 2H), 5.75 (m, 1H), 7.13 (d, J = 6.8 Hz, 2H), 7.19 (m, 1H), 7.29 (m ,2H);
13

CNMR (100 MHz, CDCl3) δ (ppm): 32.47, 37.16, 37.37, 39.85, 49.70, 52.48, 52.50,

117.22, 126.02, 128.30, 129.16, 135.70, 140.16, 169.82, 169.89. IR: 3066, 3028,
2953, 2924, 1733, 1657, 1638, 1621, 1605, 1497, 1436 cm -1. LRMS (LC-SQMS,
m/z); found: [M+H], 291.37, calculated for C17H23O4, 291.16, found: [M+Na], 313.38,
calculated for C17H22O4Na, 313.34.
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Synthesis of methyl (S)-4-benzylhept-6-enoate ((S)-25). (R)-24 (269 mg,
0.93 mmol) was dissolved in DMSO (15 mL) followed by addition of LiCl (394 mg,
9.3 mmol) and water (167 µL, 9.3 mmol). The reaction was heated under reflux (150160 °C) overnight. Water (20 mL) was added to the reaction and the product was
extracted with ethyl acetate (2 x 30 mL). The organic layer was evaporated and the
product was purified by Flash silica-gel chromatography (ethyl acetate:hexanes
1:15) which yielded (S)-25 in 75% yield (162 mg). 1HNMR (400 MHz, CDCl3) 
(ppm): 1.64 (m, 2H), 1.77 (m, 1H), 2.04 (m, 2H), 2.33 (m, 2H), 2.57 (m, 2H), 3.65 (s,
3H), 5.04 (m, 2H), 5.78 (m, 1H), 7.19 (m, 3H), 7.24 (t, J = 7.2 Hz, 2H); 13CNMR (100
MHz, CDCl3) δ (ppm): 28.14, 31.61, 37.20, 39.07, 39.91, 51.52, 116.76, 125.89,
128.27, 129.17, 136.29, 140.67, 174.17. IR: 3062, 3027, 2953, 2924, 2855, 1735,
1658, 1640, 1595, 1574, 1511, 1497, 1445 cm -1. LRMS (LC-SQMS, m/z); found:
[M+Na], 255.12, calculated for C15H20O2Na, 255.14.

Synthesis of methyl (R)-4-benzylhept-6-enoate ((R)-25). The procedure
was similar to that of (S)-25 except the following reagents were used (S)-24 (617 mg,
2.13 mmol), LiCl (270 mg, 6.38 mmol), water (115 µL, 6.38 mmol). The reaction
afforded (R)-25 in 65% yield (321 mg). 1HNMR (400 MHz, CDCl3)  (ppm): 1.63 (m,
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2H), 1.77 (m, 1H), 2.05 (m, 2H), 2.33 (m, 2H), 2.56 (m, 2H), 3.65 (s, 3H), 5.04 (m,
2H), 5.77 (m, 1H), 7.17 (m, 3H), 7.26 (m, 2H);

13

CNMR (100 MHz, CDCl3) δ (ppm):

28.13, 31.61, 37.19, 39.07, 39.91, 51.53, 116.76, 125.89, 128.26, 129.16, 136.29,
140.67, 174.19. IR: 3063, 3027, 2924, 2856, 1736, 1657, 1640, 1596, 1511, 1497,
1436 cm-1. LRMS (LC-SQMS, m/z); found: [M+Na], 255.26, calculated for
C15H20O2Na, 255.14.

Synthesis of N-phenylacrylamide (26). The compound was synthesized
similar to the reported procedure.139 Briefly, aniline (3.03 mL, 33.15 mmol) and
triethyl amine (6 mL, 66.29 mmol) were dissolved in dry DCM (30 mL) and the
temperature of the solution was lowered to 0°C. A solution of acryloyl chloride (2.69
mL, 33.15 mmol) in dry DCM (10 mL) was added drop wise. The reaction
temperature was increased gradually from 0°C to room temperature and stirring was
continued overnight at room temperature. Solvent was evaporated and the residue
was suspended in 10% HCl (20 mL) and then extracted with DCM (2 x 30 mL). The
combined organic extracts were washed with saturated solution of sodium carbonate
(20 mL), dried over anhydrous sodium sulfate and evaporated to give the product 26
as a yellow solid (4.44 g, 91%). 1HNMR (400 MHz, CDCl3)  (ppm): 5.71 (dd, J = 1.6
and 10.0 Hz, 1H), 6.30 (dd, J = 10.0 and 16.8 Hz, 1H), 6.41 (dd, J = 1.6 and 16.8
Hz, 1H), 7.12 (t, J = 7.6, 1H), 7.28 (m, 2H), 7.60 (d, J = 8.0 Hz, 2H), 7.98 (s, 1H);
13

CNMR (100 MHz, CDCl3) δ (ppm): 120.15, 124.51, 127.69, 128.99, 131.29,

96
137.85, 163.86. The spectral data for the synthesized compound was consistent with
the reported data in literature.139

Synthesis of methyl (S,E)-4-benzyl-8-oxo-8-(phenylamino)oct-6-enoate
((S)-27). To a solution of (S)-25 (162 mg, 0.7 mmol) in dry DCM (20 mL) was added
26 (103 mg, 0.7 mmol), then air was replaced with argon. Grubbs' secondgeneration catalyst (35 mg, 5 mol%) was added and the reaction was heated to 5060°C for 20 hours. A second addition of Grubbs' second generation catalyst (35 mg,
5 mol%) was done and the reaction was heated to 50-60°C for 28 hours. The solvent
was evaporated and the product was purified by Flash silica-gel chromatography
(ethyl acetate:hexanes 1:15 followed by 1:7-1:3) which yielded (S)-27 in 46% yield
(112 mg). 1HNMR (400 MHz, CDCl3)  (ppm): 1.67 (m, 2H), 1.88 (m, 1H), 2.18 (m,
2H), 2.33 (t, J = 8.0 Hz, 2H), 2.51 (dd, J = 7.6 and 13.6 Hz, 1H), 2.63 (dd, J = 6.4
and 13.6 Hz, 1H), 3.66 (s, 3H), 5.92 (d, J = 15.2 Hz, 1H), 6.91 (m, 1H), 7.12 (m, 3H),
7.21 (t, J = 7.2 Hz, 1H), 7.31 (m, 4H), 7.36 (s, 1H), 7.57 (dd, J = 7.6 Hz, 2H);
13

CNMR (100 MHz, CDCl3) δ (ppm): 28.45, 31.67, 35.61, 38.93, 40.07, 51.65,

119.81, 124.27, 126.00, 126.16, 128.41, 129.01, 129.13, 138.02, 140.03, 143.84,
163.75, 173.97. IR: 3301, 3136, 3062, 3027, 2926, 1733, 1670, 1640, 1600, 1542,
1497, 1441 cm-1. LRMS (LC-SQMS, m/z); found: [M+H], 352.07, calculated for
C22H26NO3, 352.19, found: [M+Na], 374.05, calculated for C22H25NO3Na, 374.17.
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Synthesis of methyl (R,E)-4-benzyl-8-oxo-8-(phenylamino)oct-6-enoate
((R)-27). A similar to that of (S)-27 was followed except the following reagents were
used (R)-25 (321 mg, 1.38 mmol), 26 (204 mg, 1.38 mmol), and Grubbs' secondgeneration catalyst (59 mg, 5 mol%). The reaction afforded (R)-27 in 48% yield (233
mg). 1HNMR (400 MHz, CDCl3)  (ppm): 1.66 (m, 2H), 1.87 (m, 1H), 2.17 (m, 2H),
2.34 (t, J = 8.0 Hz, 2H), 2.52 (dd, J = 7.6 and 13.6 Hz, 1H), 2.62 (dd, J = 6.4 and
13.6 Hz, 1H), 3.65 (s, 3H), 5.93 (d, J = 15.2 Hz, 1H), 6.91 (m, 1H), 7.11 (m, 3H),
7.20 (t, J = 7.6 Hz, 1H), 7.30 (m, 4H), 7.51 (s, 1H), 7.58 (d, J = 7.2 Hz, 2H); 13CNMR
(100 MHz, CDCl3) δ (ppm): 28.43, 31.66, 35.60, 38.92, 40.04, 51.66, 119.85,
124.26, 126.01, 126.15, 128.41, 129.00, 129.13, 138.06, 140.03, 143.79, 163.83,
173.00. IR: 3401, 3062, 3026, 2924, 2856, 1736, 1658, 1640, 1597, 1574, 1512,
1437 cm-1. LRMS (LC-SQMS, m/z); found: [M+H], 352.07, calculated for C22H26NO3,
352.19, found: [M+Na], 374.02, calculated for C22H25NO3Na, 374.17.

Synthesis of (R)-4-benzyl-N1-hydroxy-N8-phenyloctanediamide ((R)-19f).
(S)-27 (112 mg, 0.32 mmol) was dissolved in MeOH (15 mL), then Pd (30 mg of 20
wt.% Pd on carbon) was added to the solution. Air inside the flask was purged with
argon (three times), then with hydrogen gas (three times). The reaction was stirred
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under hydrogen overnight. The reaction was filtered, and the solvent was
evaporated. The crude product was used in the next reaction with no purification.
In an acid washed flask, hydroxylamine HCl (222 mg, 3.19 mmol) was
dissolved in MeOH (10 mL). KOH (358 mg, 6.38 mmol) was added at 0°C and
allowed to stir for 10 minutes. An alcoholic solution of the crude product from the
previous reaction (in 5 mL MeOH) was added, and the reaction was stirred for 3.5
hours at 0°C, then another premixed solution of hydroxylamine HCl (222 mg, 3.19
mmol) and KOH (358 mg, 6.38 mmol) was added followed by stirring for 4 hour at
0°C. The pH of the reaction mixture was adjusted to 6 with concentrated aqueous
HCl, followed by dilution with distilled de-ionized water (10 mL). The reaction was
extracted with ethyl acetate (2 x 20 mL). The product was purified by silica gel flash
chromatography (acetone:dichloromethane 1:4-1:2) using iron-free silica gel to afford
(R)-19f (84 mg, 74% over two steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.32 (m,
2H), 1.69 (m 5H), 2.12 (m, 2H), 2.29 (m, 2H), 2.52 (dd, J = 7.2 and 13.2 Hz, 2H),
2.61 (dd, J = 6.4 and 13.6 Hz, 2H), 7.05-7.15 (m, 4H), 7.21 (t, J = 7.2 Hz, 2H), 7.28
(t, J = 7.6 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ (ppm):

22.28, 28.84, 29.77, 31.72, 36.63, 38.93, 39.57, 119.92, 123.73, 125.46, 127.86,
128.35, 128.85, 138.43, 140.65, 171.70, 173.13. IR: 3230, 3061, 3026, 2925, 2864,
1648, 1598, 1543, 1497, 1443 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+
C21H26N2O3Na+, 377.1841, found 377.1837. HPLC analytical purity analysis 95.6%.
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Synthesis of (S)-4-benzyl-N1-hydroxy-N8-phenyloctanediamide ((S)-19f).
similar to that of (R)-19f was followed except the following reagents were used (R)-27
(283 mg, 0.8 mmol), Pd (58 mg of 20 wt.% Pd on carbon). Hydroxylamine HCl (557
mg, 8.02 mmol) and KOH (900 mg, 16.03 mmol) were added once only and the
reaction was stirred for 3 hours at 0°C. The product was purified by silica gel flash
chromatography (acetone:dichloromethane 1:4-1:2) using iron-free silica gel to afford
(S)-19f (133 mg, 47% over two steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.33 (m,
2H), 1.59-1.82 (m 5H), 2.14 (m, 2H), 2.30 (m, 2H), 2.53 (dd, J = 7.2 and 13.6 Hz,
2H), 2.61 (dd, J = 6.8 and 13.6 Hz, 2H), 7.05-7.16 (m, 4H), 7.21 (t, J = 7.2 Hz, 2H),
7.28 (t, J = 7.6 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ

(ppm): 22.28, 28.83, 29.76, 31.71, 36.62, 38.93, 39.57, 119.91, 123.73, 125.46,
127.86, 128.34, 128.84, 138.43, 140.65, 171.70, 173.13. IR: 3232, 3026, 2926, 2865,
1645, 1598, 1543, 1497, 1443 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+
C21H26N2O3Na+, 377.1841, found 377.1848. HPLC analytical purity analysis 95.6%.
3.8.3. Procedures for biological screenings
3.8.3.1. HeLa cell lysis
Details were provided in Section 2.7.3.1 of Chapter 2.
3.8.3.2. Global HDAC inhibition
To measure global HDAC inhibition, HeLa cell lysates (1 µg total protein)
were mixed with HDAC-Glo™ buffer (Promega) in polystyrene 96-well half area
white plate (Corning) to a final volume of 12 µL, followed by addition of inhibitors in
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DMSO (0.5 µL) and incubation for 15 min at room temperature without rocking. An
uninhibited control reaction was also included that contained DMSO (0.5 µL) in
HDAC-Glo™ buffer (12 µL). Deacetylase activity was measured using the HDACGlo™ assay kit as per the manufacturer’s protocol (Promega). Specifically, the
HDAC-Glo™ substrate (1 mL) and developer (1 µL) were first premixed to form the
HDAC-Glo™ reagents. Then, to monitor deacetylase activity, HDAC-Glo™ reagent
(5µL) and HDAC-Glo™ buffer (7.5 µL) were added to each well (25 µL total volume)
and incubated for 35 min at room temperature without rocking. The deacetylase
activity was measured as luminescent signal using a GeniosPlus Fluorimeter
(Tecan) at optimal gain. The concentrations of inhibitors reported in the dosedependent studies are final concentrations after addition of HDAC-Glo™ reagent
and HDAC-Glo™ buffer. The luminescent signal was first background corrected with
the signal from a negative control reaction where no lysates was added to that
reaction. Percent deacetylase activity was calculated by dividing the background
corrected signal for each reaction by the background corrected signal of the
uninhibited control, and then multiplying by 100. IC50 values were calculated by fitting
the percent deacetylase activity remaining as a function of inhibitor concentration to
a sigmoidal dose-response curve (y = 100/(1+(x/IC50)z), where y = percent
deacetylase activity and x = inhibitor concentration) using non-linear regression with
KaleidaGraph 4.1.3 software. Results are reported in Tables 3.1, and B.1, and
Figure B.140.

101
3.8.3.3. Inhibitor testing with HDAC isoforms

93

Details were provided in Section 2.7.3.2 of Chapter 2. Results are reported in
Figures 3.2 and B.141-B.147, and Tables 4.2 and B.2-B.9.
3.8.3.4. In cellulo selectivity testing
Details were provided in Sections 2.7.3.3-2.7.3.5 of Chapter 2. Results are
reported in Figures 3.3 and B.148.
3.8.3.5. In vitro cell growth inhibition
Details were provided in Section 2.7.3.6 of Chapter 2. Results are reported in
Figures B.149-B.152 and Tables 3.3 B.11-B.12.
3.8.4. Docking procedure
The AutoDock 4.2 and Autodock tools programs

119, 127

were used to perform

the docking studies. HDAC6 catalytic domain 2 (CD2) (PDB: 5G0H)13 and HDAC3
(PDB: 4A69)100 crystal structures were downloaded from the protein data bank.
PyMOL program (Schrodinger, LLC) was used to delete the co-crystallized inhibitor
(S-trichostatin A), ethylene glycol molecules, potassium ions and all water molecules
in HDAC6 crystal structure. With HDAC3 crystal, chain A, deacetylase-activationdomain (DAD) (from the SMRT corepressor), glycerol, D-myo-inositol-1,4,5,6tetrakisphosphate and glycerol molecules, acetate, potassium and sulfate ions, and
all water molecules were deleted. Only the zinc atom remained in both crystal
structures. AutoDockTools-1.5.4 program

119, 127

was used to add all polar hydrogen

atoms, modify histidine protonation (H573 and H574 residues of HDAC6, and H134
and H135 of HDAC3) by adding only HD1, compute Gasteiger charges, and merge
all non polar hydrogen, followed by generation of the pdbqt output file. The charge of
the zinc atom was manually changed from zero to +2. For HDAC6, a grid box with a
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spacing of 0.375 Å, size of 42 x 40 x 44, and coordinates for the center of the grid
box (-13.000, -2.000, -5.000) were used. For HDAC3, a grid box of size 58 X 58 X
54 Å3 with a spacing of 0.375 Å and centered at (8.166, 76.663, 21.318) were used.
The rest of binding sites preparation procedure and all docking parameters were
similar to was mentioned in Section 2.7.4 of Chapter 2.
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CHAPTER 4 - SYNTHESIS AND BIOLOGICAL EVALUATION OF
SAHA DERIVATIVES SUBSTITUTED AT C5 POSITION
Some of the text in this chapter was reprinted or modified from: Negmeldin, A. T.
and Pflum, M. K. H., The structural requirements of histone deacetylase Inhibitors:
SAHA analogs modified at the C5 Position Display dual HDAC6/8 Selectivity,
Bioorganic & medicinal chemistry letters 2017 (Accepted).
4.1. Rationale for synthesis and screening of C5-modified SAHA analogs
Guided by the promising modifications of the C4 position in the linker of
SAHA that led to substantial improvement in selectivity with a modest reduction in
potency compared to SAHA, we explored the effect of modifications on the C5
position in the linker (Figure 4.1). Based on the experimental and computational
studies done for the C4-modified SAHA analogs, we expected that the C5-modified
SAHA analogs would show similar selectivity to HDAC6 and HDAC8. As discussed
in the previous two chapters, some of the C2-SAHA analogs showed about 30-fold
reduction in potency against HDAC6, while some of the C4-SAHA analogs showed
only about 2.5-fold reduction in potency against HDAC6 compared to SAHA. The
question that needed to be answered was to what extent modification of SAHA at
the C5 position would affect both potency and selectivity. In this chapter, SAHA
analogs substituted at the C5 of the linker region were synthesized (Figure 4.1 and
scheme 4.1) and tested for potency and selectivity both in vitro and in cellulo.
Several analogs showed dual HDAC6/8 selectivity over HDAC1, 2, and 3, with a
modest reduction in HDAC6 inhibition but enhanced HDAC8 inhibition compared to
SAHA. This chapter documents that modifying the linker region of SAHA can alter its
selectivity with minimal effect on potency.
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Figure 4.1. Chemical structures of C5-modified SAHA analogs (34a-e).
4.2. Synthesis of C5-substituted SAHA derivatives
C5-modified SAHA analogs 43a-e were synthesized as shown in Scheme 4.1.
The synthesis started from a coupling reaction of 4-pentenoic acid 28 with aniline
using TBTU to obtain amide 92. Intermediate amide 29 was then reacted with
crotonaldehyde 13 via a cross metathesis reaction using Grubbs' second-generation
catalyst to afford the α,β-unsaturated aldehyde 43. Aldehyde 43 was substituted with
different

groups through

organomagnesium

a

cuprates,

1,4-conjugate
which

yielded

addition

using organolithium

intermediates

31a-e.

or

Horner–

Wadsworth–Emmons olefination of 31a-e with trimethyl phosphonoacetate 32
followed by reduction gave amide esters 33a-e with a saturated linker. Finally, amide
esters 33a-e were reacted with hydroxylamine to afford the C5-substituted SAHA
derivatives 34a-e as racemic mixtures.140
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Scheme 4.1. Synthesis of C5-SAHA analogs (34a-e)

4.3. In vitro screening of C5-modified SAHA derivatives
As a preliminary screen, the new analogs were tested for their global HDAC
inhibition with HeLa cell lysates as the source of all HDAC proteins (Table 4.1).
SAHA was also tested as the parent unsubstituted control molecule. The inhibitory
activities of the analogs were measured with the HDAC-Glo™ I/II substrate (see
section 2.2). C5-methyl SAHA analog 34a showed greater potency compared to
SAHA (100 nM vs. 200 nM IC50 values, Table 4.1). However, all other analogs
showed weaker potency than SAHA (11- to 33-fold reduction in potency), with IC50
values from 2.2 to 6.5 µM (Table 4.1). The observed lower potencies of compounds
34b-34e may be due to selectivity for specific HDAC isoform(s), which lowered the
potency against lysates that contain all HDAC isoforms. The lower potency observed
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here was similar to what was observed with both the C2- and the C4-modified SAHA
analogs (see sections in 2.2 and 3.3 Chapters 2 and 3).
Table 4.1. IC50 values for SAHA, and C5-modified SAHA analogs (34a-e) with HeLa
cell lysates.a
Compound

R

SAHA

IC50 (µM)
0.20 ± 0.02

34a

methyl

0.10 ± 0.01

34b

n-butyl

5.0 ± 0.4

34c

n-hexyl

6.5 ± 0.1

34d

Phenyl

2.2 ± 0.1

34e

benzyl

6.2 ± 0.2

a

Mean IC50 value and standard error of at least three independent trials are shown
(Figure C.52 and Table C.1).
To test isoform selectivity, the parent molecule, SAHA, and all the C5modified SAHA analogs were tested at a single concentration using the recently
developed ELISA-based HDAC activity assay (see section 2.2).93 SAHA, as
expected, showed no selectivity among HDAC1, 2, 3, and 6 (Figure 4.2).93
Interestingly, several C5-SAHA analogs displayed more potent inhibition against
HDAC6 compared to HDAC1, HDAC2, and HDAC3 (Figure 4.2). The analogs that
showed the greater difference in potency with HDAC6 versus the other isoforms
were C5-n-butyl (34b), C5-n-hexyl (34c), and C5-benzyl (34e). The C5-methyl SAHA
(34a) and C5-phenyl SAHA (34d) showed only a small difference in potency
comparing HDAC6 to the others (Figure 4.2).
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Figure 4.2. In vitro isoform selectivity screening of C5-modified SAHA analogs (34ae) against HDAC1, HDAC2, HDAC3, and HDAC6 using the ELISA-based HDAC
activity assay. Analogs 34a-e were tested at 0.025, 0.25, 1.25, 0.125, and 1.25 µM
final concentrations, respectively. SAHA was tested at 1 µM concentration in a
previous report using the same assay procedure.93 Mean percent deacetylase
activities from a minimum of two independent trials with standard errors were plotted
(Table C.2).
IC50 values for the most selective derivatives 34b, 34c, and 34e were
determined with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms to
quantitatively assess the selectivity (Table 4.2). The IC50 values of SAHA as the
parent compound were included as well (Table 4.2).93 SAHA displayed similar IC50
values against HDAC1, 2, 3, and 6, with 6- to 27-fold selectivity against HDAC8
(Tables 4.2 and C.6).93,
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Both C5-n-butyl (34b) and C5-n-hexyl (34c) SAHA

analogs displayed the modest selectivity, with 3- to 5-fold and 5- to 7-fold
selectivities for HDAC6 and HDAC8 over HDAC1, 2, and 3 (Tables 4.2, C.3, C.4 and
C.6 and Figures C.53 and C.54). In addition, 34b and 34c showed modest reduction
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in HDAC6 potency (IC50 values of 320 nM and 410 nM), but similar potency against
HDAC8 (430 and 420 nM) compared to SAHA. The most potent and selective
analog was C5-benzyl SAHA (34e), which displayed 8- to 21-fold selectivity for
HDAC6 and HDAC8 over HDAC1, 2, and 3 and IC50 values of 270 and 380 nM with
HDAC6 and HDAC8, respectively (Tables 4.2, C.5 and C.6, and Figure C.55). The
selectivity was due to a dramatic reduction in potency with HDAC1, 2, and 3 (14- to
80-fold), but only a modest potency reduction in HDAC6 (8.5- to 12-fold) and similar
potency with HDAC8 (380 – 540 nM), compared to SAHA. Modification of SAHA at
the C5 position of the linker region led to selectivity for HDAC6 and 8 over HDAC1,
2, and 3.
Table 4.2. IC50 values for SAHA and C5-modified SAHA analogs 34c, 34d, and 34e
against HDAC1, 2, 3, 6 and 8.a
Compound

IC50 values (µM)
HDAC1

HDAC2

HDAC3

HDAC6

HDAC8

33 ± 1

96 ± 10

20 ± 1

33 ± 3

540 ± 10

1,100 ± 100 1,300 ± 100 1,600 ± 100

320 ± 30

430 ± 10

34c (n-hexyl) 2,100 ± 100 2,500 ± 100 2,900 ± 300

410 ± 60

420 ± 20

SAHAb
34b (n-butyl)

34e (benzyl) 2,900 ± 300 3,500 ± 100 5,800 ± 800
270 ± 20
380 ± 20
Mean IC50 value and standard error of at least three independent trials are shown
(Figures C.53-C.55 and Tables C.3-C.5). b Previously reported IC50 values using the
same assay procedure.93
a

4.4. In cellulo selectivity testing
To test the analogs in a more biological context, the C5-benzyl (34e) SAHA
analog was tested for selectivity in cells. The inhibition of HDAC6 was monitored by
detecting the levels of its known substrate acetyl-α-tubulin (AcTub), whereas Class I
HDAC (HDAC1, 2, and 3) inhibition was monitored by observing the known
substrate, acetyl-histone 3 (AcH3). SAHA or C5-benzyl SAHA 34e were incubated
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with U937 leukemia cells before lysis and western blot analysis of protein acetylation
(Figure 4.3). As expected, SAHA increased the levels of both acetyl-α-tubulin and
acetyl-histone H3 to a similar extent (Figure 4.3, lane 1), which is consistent with its
non-selective inhibition of HDAC1, 2, 3, and 6 isoforms. On the other hand, C5benzyl SAHA analog 34e showed a dose-dependent selective increase in levels of
acetyl-α-tubulin (Figure 4.3, lanes 3-5, AcTub), which was greater than the increased
levels of acetyl histone H3 (Figure 4.3, lanes 3-5, AcH3) compared to the DMSO
control (Figure 4.3, lane 2). The observed HDAC6 selectivity of the C5-benzyl SAHA
34e in cells is consistent with the selectivity observed in the in vitro screening (Table
4.2 and Figure 4.3).
SAHA DMSO
5

34e (Benzyl)
10

20

40
AcH3
AcTub
GAPDH

1

2

3

4

5

Figure 4.3. Cell based selectivity assessment of the C5-benzyl SAHA analog.
Western blot analysis of acetyl-lysine 9 of histone H3 (AcH3), and acetyl-lysine 40 of
α-tubulin (AcTub) after treatment with SAHA or C5-benzyl SAHA 34e. U937 cells
were treated with DMSO (1%), SAHA (5 µM), or increasing concentrations of C5benzyl SAHA (34e) analog (10-40 µM), before lysis, SDS-PAGE separation, transfer
to a PVDF membrane, and western analysis with AcH3 or AcTub antibodies.
GAPDH levels in the samples were also probed as a gel load control. A DMSO
control sample was included for comparison to inhibitor-treated samples. Repetitive
trials are shown in Figure C.56.
4.5. In vitro cancer cell growth inhibition
To evaluate the ability of the C5-modified SAHA analogs to influence cell
growth, the most selective analogs were tested. C5-n-butyl (34b), C5-n-hexyl (34c),
and C5-benzyl (34e) SAHA analogs were tested at single concentrations using the
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MTT assay with T-cell lymphoma derived cancer Jurkat cell line (Figure 4.4). The
tested analogs displayed cytotoxicity against the cell line, with 39%, 24%, and 50%
cell viability with C5-n-butyl SAHA (34b), C5-n-hexyl SAHA (34c), and C5-benzyl
SAHA (34e) at 10 µM concentrations, respectively (Figure 4.4 and Table C.7). On
the other hand, SAHA demonstrated higher cytotoxicity than the C5-modified SAHA
analogs, with 49% cell viability at 1 µM. The reduced cytotoxicity of the analogs
compared to SAHA can be due to their lower potency (8- to 12-fold reduction in IC50
values with HDAC6 compared to SAHA, Table 4.2). In addition, the nonselective
inhibition of most HDAC isoforms by SAHA might contribute to its higher cytotoxicity
(Table 4.2 and Figure 4.4).

Percentage viable cells

1 µM

10 µM

100
80
60
40
20
0

SAHA

34b
(Bu)

34c
(Hex)

34e
(Bn)

Figure 4.4. Cytotoxicity screening of SAHA and C5-modified SAHA analogs 34b,
34c, and 34e with the Jurkat cells. Compounds were tested at 1 and 10 µM
concentrations using MTT assay. Mean percent cell viability from a minimum of
three independent trials with standard errors were plotted (Table C.7).
In conclusion, C5-modified SAHA analogs displayed dual HDAC6/8
selectivity. The best compound was C5-benzyl SAHA (34e), which showed up to 21fold selectivity for HDAC6 and 8 compared to HDAC1, 2, and 3, and IC 50 values of
270 and 380 nM with HDAC6 and 8, respectively. Compared to SAHA C5-modified
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SAHA analogs 34b-e exhibited 8- to 12-fold reduction in potency towards HDAC6,
while similar IC50 values with HDAC8 were observed. C5-benzyl SAHA (34e) was
tested for isoform selectivity in cells and showed selectivity consistent to what was
observed in vitro. The fold selectivities observed with the C5-modified SAHA analogs
were reduced compared to previously reported HDAC6/8-selective C2-modified
SAHA analogs (49- to 300- fold selective for HDAC6 and 8 over HDAC1, 2, and 3 for
the C2-hexyl SAHA).112 On the other hand, the C5-modified SAHA analogs were
more potent against HDAC6 and 8 (270 to 430 nM IC 50 values) compared to C2modifed SAHA analogs (600 to 2,000 nM IC50 values for C2-hexyl SAHA). Moreover,
by comparing the effect of modifications on the C5 position of the linker region of
SAHA to the C4 analogs mentioned in Chapter 3, we can conclude that modifying
the C4 position led to more potent inhibition of both HDAC6 and HDAC8 compared
to the C5 analogs (57 to 140 nM vs. 270 to 430 nM IC50 values for HDAC6 and 8)
(Tables 3.2 and 4.2). In addition, the fold selectivities of the C4-SAHA analogs to
HDAC6 and HDAC8 over HDAC1, 2, and 3 were higher compared to C5-SAHA
analogs with the same modifications (171- to 740-fold vs. 3- to 21-fold for C4- and
C5- butyl, hexyl, and benzyl)(Tables 3.2, 4.2, B.10 and C.6). The position of the
modification in the linker region of SAHA is critical and can greatly affect both
potency and selectivity of the analogs. In general, this study, along with chapters 2,
3, and previous reports104-105,
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, indicate that modifying SAHA in the linker region

can alter the selectivity of HDAC inhibitors. In particular, the reduced potency of
SAHA against HDAC8 was switched in the C5-modified analogs to poor potency
with HDAC1, 2, and 3, which resulted in dual HDAC6/8 preference. HDAC6/8 dual
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selective inhibitors can be used as biological tools to study both HDAC6 and
HDAC8-related cancer biology, and as leads for development of more effective anticancer agents targeting both HDAC6 and HDAC8.
4.6. Experimental Procedures
4.6.1. Materials and instrumentation
Details were provided in Section 2.7.1 of Chapter 2.
4.6.2. Synthesis procedure

Synthesis of N-phenylpent-4-enamide (29): TBTU (614 mg, 1.91 mmol)
was dissolved in dry dichloromethane (10 mL), followed by addition of pent-4-enoic
acid 28 (127 mg, 1.27 mmol), DIPEA (329 mg, 2.55 mmol), and aniline (178 mg,
1.91 mmol). The reaction was stirred for 4.5 hours. The reaction was quenched with
1M HCl (20 mL) and extracted with dichloromethane (3X30 mL). The organic extract
was dried over anhydrous Na2SO4 and concentrated. The product was purified by
silica-gel flash chromatography (ethyl acetate/hexanes 1:4) to afford 29 (162 mg,
73%). 1HNMR (400 MHz, CDCl3) δ (ppm): 2.38 (m, 4H), 4.96 (d, J = 9.6 Hz, 1H),
5.02 (d, J = 16.4 Hz, 1H), 5.80 (m, 1H), 7.01 (t, J = 7.2 Hz, 1H), 7.22 (t, J = 8.0 Hz,
2H), 7.43 (d, J = 8.4 Hz, 2H), 7.57 (br s, 1H).

13

CNMR (100 MHz, CDCl3) δ (ppm):

29.48, 36.74, 115.88, 119.99, 124.27, 128.95, 136.85, 137.90, 170.84. The spectral
data for the synthesized compound was consistent with the reported data in
literature.141
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Synthesis of (E)-6-oxo-N-phenylhex-4-enamide (30): In a flame dried 2neck 100 mL flask and condenser, air was replaced with argon and Grubbs'
second-generation catalyst (58.2 mg, 0.068 mmol, 1.5 mol%) was dissolved in dry
dichloromethane (20 mL), followed by the addition of crotonaldehyde 13 (3.20 g, 45.68
mmol) and 29 (800 mg, 4.57 mmol). The reaction was heated with reflux for 11 hours
under argon. The reaction was cooled to room temperature, concentrated, and
purified by silica-gel flash chromatography (ethyl acetate /Hexanes 1:1.5) to afford 30
(845 mg, 91%). 1HNMR (400 MHz, CDCl3) δ (ppm): 2.56 (t, J = 7.2 Hz, 2H), 2.74 (q,
J = 6.8 Hz, 2H), 6.14 (dd, J = 7.6 Hz, 1H), 6.91 (dt, J = 15.6 and 6.4 Hz, 1H), 7.11 (t,
J = 7.2 Hz, 1H), 7.31 (t, J = 7.6 Hz, 2H), 7.50 (d, J = 7.6 Hz, 2H), 7.68 (br s, 1H),
9.49 (d, J = 7.6 Hz, 1H).

13

CNMR (100 MHz, CDCl3) δ (ppm): 27.95, 34.94, 119.95,

124.53, 129.04, 133.22, 137.64, 156.71, 169.37, 194.03. IR: 3313, 3064, 2971, 2928,
1668, 1598, 1545, 1498, 757, 694 cm -1. LRMS (ESI, m/z): calculated for [M+H]+
C12H14NO2, 204.10, found 204.14; calculated for [M+Na] + C12H13NO2Na+, 226.08,
found 226.11.

Synthesis of methyl 5-methyl-8-oxo-8-(phenylamino)octanoate (33a): In
a 200 mL 2-neck dry flask, Copper(I)bromide dimethyl sulfide complex (1.52 g, 7.39
mmol) was dissolved in dry THF (20 mL). Air was replaced with argon, and then
the temperature was reduced to -15°C. Methyllithium (9.12 mL of 1.6 M solution,
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321 mg, 14.78 mmol) was added drop wise with stirring, and the mixture was
allowed to stir for additional 20 minutes at -15°C. The temperature was then
reduced to -78°C followed by the addition of chlorotrimethylsilane (2.40 g,
22.17 mmol) drop wise, and then 30 (500 mg, 2.46 mmol). The reaction was
allowed to stir for 3.5 hours at -78°C. The reaction was quenched with a solution
of saturated ammonium chloride in ammonia (1:1) portion wise until the reaction
color turned blue. The organic layer was collected and the aqueous layer was
extracted with ethyl acetate (3X30 mL). The combined organic layers were dried over
anhydrous Na 2SO4, filtered, and rotavaped to an oily crude product 31a, which
was used in the next reaction.
In a 200 mL 2-neck flame dried flask, air was replaced with argon, NaH (168
mg of 60% NaH, 4.19 mmol) dissolved in dry THF (25 mL) was added, and the
reaction was cooled to 0°C. Trimethyl phosphonoacetate (763 mg, 4.19 mmol) was
added dropwise with stirring. The reaction was allowed to stir for 15 minutes at
0°C, and then the crude product 31a from the previous reaction dissolved in dry
THF (8 mL) was added. The reaction was stirred for another 30 minutes at 0°C,
followed by stirring for 90 minutes at room temperature. The reaction was
quenched with a saturated aqueous ammonium chloride solution (15 mL) and
the organic layer was collected. The aqueous layer was extracted with ethyl acetate
(3 times with 30 mL) and the combined organic layers were dried over anhydrous
MgSO4, filtered, and concentrated. The crude product was used in the following
reaction without further purification.
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In a 50 mL flask the crude product from the previous reaction was dissolved
in MeOH (20 mL), and then Pd(OH) 2 (173 mg of 20 wt.% Pd(OH)2 on carbon, 0.25
mmol) was added. Air inside the flask was replaced with argon (3 times), and then
with hydrogen gas (three times). The reaction was allowed to stir under hydrogen
for 3.5 hours at room temperature. The reaction was filtered through a celite plug
and the solvent was evaporated. The product was purified by silica-gel flash
chromatography (ethyl acetate/hexanes 1:4) to afford 33a (295 mg, 43% over three
steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.94 (d, J = 5.6 Hz, 3H), 1.19 (m, 1H),
1.35 (m, 1H), 1.50 (m, 2H), 1.70 (m, 3H), 2.36 (m, 4H), 3.64 (s, 3H), 7.07 (t, J = 7.6
Hz, 1H), 7.28 (t, J = 8.4 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H).

13

CNMR (100 MHz,

CD3OD) δ (ppm): 18.25, 22.04, 32.17, 32.38, 33.53, 34.27, 35.74, 50.58, 119.82,
123.69, 128.35, 138.51, 173.40, 174.52. IR: 3302, 2953, 2930, 2870, 1736, 1719,
1661, 1599, 1543, 1499, 1441, 754, 692 cm-1. LRMS (ESI, m/z): calculated for [M+H]+
C16H24NO3, 278.18, found 278.18; calculated for [M+Na] + C16H23NO3Na+, 300.16,
found 300.17.

Synthesis of methyl 5-(3-oxo-3-(phenylamino)propyl)nonanoate (33b):
The procedure was similar to 33a except n-butyllithium (5.9 mL of 2.5 M solution,
0.95 g, 14.78 mmol) was used in place of methyllithium. The product was purified by
silica-gel flash chromatography (ethyl acetate/hexanes 1:5) to afford 33b (493 mg,
63% over three steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.91 (t, J = 6.80 Hz,
3H), 1.35 (m, 9H), 1.64 (m, 4H), 2.33 (m, 4H), 3.64 (s, 3H), 7.07 (t, J = 7.2 Hz, 1H),
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7.29 (t, J = 7.2 Hz, 2H), 7.53 (d, J = 7.2 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ

(ppm): 13.05, 21.63, 22.70, 28.47, 29.17, 32.37, 32.64, 33.59, 33.95, 36.79, 50.57,
119.82, 123.67, 128.34, 138.51, 173.40, 174.52. IR: 3302, 3138, 3062, 2955, 2928,
2860, 1737, 1721, 1663, 1600, 1543, 1499, 1442, 754, 692 cm-1. LRMS (ESI, m/z):
calculated for [M+H]+ C19H30NO3, 320.22, found 320.26; calculated for [M+Na]+
C19H29NO3Na+, 342.20, found 342.26.

Synthesis of methyl 5-(3-oxo-3-(phenylamino)propyl)undecanoate (33c):
The procedure was similar to 33a except the following reagents were used:
Copper(I)bromide dimethyl sulfide complex (1.37 g, 6.65 mmol), n-hexyllithium
(5.78 mL of 2.3 M solution, 1.23 g, 13.30 mmol), chlorotrimethylsilane (2.16 g, 19.95
mmol), 30 (450 mg, 2.22 mmol), NaH (151 mg of 60% NaH, 3.77 mmol), trimethyl
phosphonoacetate (686 mg, 3.77 mmol), and Pd(OH)2 (156 mg of 20% Pd(OH)2/C,
0.22 mmol). The product was purified by silica-gel flash chromatography (ethyl
acetate/hexanes 1:6 to 1:5) to afford 33c (577 mg, 75% over three steps). 1HNMR
(400 MHz, CD3OD) δ (ppm): 0.89 (t, J = 7.2 Hz, 3H), 1.33 (m, 13H), 1.63 (m, 4H),
2.33 (m, 4H), 3.64 (s, 3H), 7.06 (t, J = 7.6 Hz, 1H), 7.28 (t, J = 7.6 Hz, 2H), 7.54 (d, J
= 7.2 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ (ppm): 13.10, 21.63, 22.36, 26.19,

29.18, 29.42, 31.65, 32.38, 32.95, 33.61, 33.99, 36.79, 50.60, 119.81, 123.66,
128.35, 138.54, 173.40, 174.49. IR: 3302, 3138, 3061, 2953, 2926, 2856, 1737, 1661,
1600, 1543, 1499, 1441, 754, 692 cm-1. LRMS (ESI, m/z): calculated for [M+H]+
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C21H34NO3, 348.25, found 348.28; calculated for [M+Na] + C21H33NO3Na+, 370.24,
found 370.26.

Synthesis of methyl 8-oxo-5-phenyl-8-(phenylamino)octanoate (33d):The
procedure was similar to 33a except the following reagents were used: phenyllithium
(7.38 mL of 2 M solution, 1.24 g, 14.78 mmol) and Pd(OH)2 (692 mg of 20%
Pd(OH)2/C, 0.99 mmol). The product was purified by silica-gel flash chromatography
(ethyl acetate/hexanes 1:3) to afford 33d (539 mg, 64% over three steps). 1HNMR
(500 MHz, CD3OD) δ (ppm): 1.46 (m, 2H), 1.63 (m, 2H), 1.89 (m, 1H), 2.15 (m, 5H),
2.58 (m, 1H), 3.59 (s, 3H), 7.05 (t, 1H), 7.18 (d, J = 7.2 Hz, 3H), 7.27 (m, 4H), 7.48
(d, J = 8.0 Hz, 2H).

13

CNMR (125 MHz, CD3OD) δ (ppm): 22.68, 32.22, 33.27, 34.61,

35.84, 45.24, 50.54, 119.81, 123.63, 126.06, 127.44, 128.21, 128.31, 138.46, 144.25,
172.85, 174.35. IR: 3303, 3137, 3028, 2928, 2859, 1737, 1663, 1600, 1545, 1500,
756, 693 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C21H26NO3, 340.19, found
340.14; calculated for [M+Na]+ C21H25NO3Na+, 362.17, found 362.12.

Synthesis of methyl 5-benzyl-8-oxo-8-(phenylamino)octanoate (33e):The
procedure was similar to 33a except benzylmagnesium chloride (14.78 mL of 1 M
solution, 2.23 g, 14.78 mmol) was used in place of methyllithium. The product was
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purified by silica-gel flash chromatography (ethyl acetate/hexanes 1:3) to afford 33e
(274 mg, 32% over three steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.31 (q, J =
5.6 Hz, 2H), 1.67 (m, 5H), 2.26 (t, J = 7.2 Hz , 2H), 2.39 (m, 2H), 2.60 (m, 2H), 3.61
(s, 3H), 7.07 (t, J = 7.2 Hz, 1H), 7.15 (m, 3H), 7.26 (m, 4H), 7.51 (d, J = 8.4 Hz, 2H).
13

CNMR (100 MHz, CD3OD) δ (ppm): 21.50, 28.93, 31.87, 33.50, 33.94, 39.08,

39.69, 50.54, 119.88, 123.70, 125.47, 127.86, 128.34, 128.81, 138.47, 140.74,
173.24, 174.47. IR: 3302, 3027, 2927, 2866, 1734, 1661, 1599, 1542, 1498, 1442, 755,
694 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C22H28NO3, 354.21, found 354.20;
calculated for [M+Na]+ C22H27NO3Na+, 376.19, found 376.19.

Synthesis of N8-hydroxy-4-methyl-N1-phenyloctanediamide (34a): In an
acid-washed flask, hydroxylamine HCl (877 mg, 12.60 mmol) was dissolved in
MeOH (10 mL). KOH (1.42 g, 25.24 mmol) was added at 0°C and left to stir for
20 minutes. An alcoholic solution of 33a (350 mg, 1.26 mmol, in 10 mL methanol)
was added and the reaction was left to stir for 2.5 hours at 0°C. The pH of the
reaction mixture was adjusted to 6.0 with concentrated aqueous HCl, followed by
dilution with distilled de-ionized water (30 mL). The reaction was extracted with ethyl
acetate (3X30 mL). The organic extracts were collected together and dried over
anhydrous Na2SO4. The product was purified with acid-washed silica-gel flash
chromatography (acetone/DCM 1:3) to afford 34a (214 mg, 61%). 1HNMR (400 MHz,
CD3OD) δ (ppm): 0.94 (d, J = 6.4 Hz, 3H), 1.21 (m ,1H), 1.39 (m, 1H), 1.48-1.78 (m,
5H), 2.08 (t, J = 7.6 Hz, 2H), 2.38 (m, 2H), 7.07 (t, J = 7.2 Hz, 1H), 7.28 (t, J = 7.6

119
Hz, 2H), 7.52 (d, J = 7.6 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 18.26, 22.75,
32.09, 32.37, 32.50, 34.24, 35.68, 119.87, 123.69, 128.33, 138.50, 171.54, 173.43.
IR: 3291, 2955, 2928, 2871, 1736, 1660, 1600, 1546, 1500, 1444, 756, 693 cm-1.
HRMS (ESI-TOF, m/z): calculated for [M+Na]+ C15H22N2O3Na+, 301.1528, found
301.1540. HPLC analytical purity analysis 97.1%.

Synthesis of 4-butyl-N8-hydroxy-N1-phenyloctanediamide (34b): The
procedure was similar to 34a except for the following: MeOH (15 mL), hydroxylamine
HCl (1.0 g, 14.46 mmol), KOH (1.62 g, 28.92 mmol), 33b (462 mg, 1.45 mmol).
The reaction was stirred for 2 hours at 0°C. The product was purified with acidwashed silica-gel flash chromatography (acetone/DCM 1:4) to afford 34b (363 mg,
78%). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.91 (t, J = 6.8 Hz, 3H), 1.34 (m, 9H),
1.65 (m, 4H), 2.08 (t J = 7.6 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 7.07 (t, J = 7.2 Hz, 1H),
7.29 (t, J = 7.2 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ

(ppm): 13.06, 22.34, 22.70, 28.49, 29.18, 32.31, 32.57, 32.70, 33.92, 36.73, 119.85,
123.70, 128.35, 138.51, 171.56, 173.50. IR: 3242, 2955, 2926, 2858, 1645, 1599,
1543, 1499, 1443, 1047, 754, 691 cm-1. HRMS (ESI-TOF, m/z): calculated for
[M+Na]+ C18H28N2O3Na+, 343.1998, found 343.1988. HPLC analytical purity analysis
98.0%.
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Synthesis of 4-hexyl-N8-hydroxy-N1-phenyloctanediamide (34c): The
procedure was similar to 34a except for the following: hydroxylamine HCl (1.06 g,
15.20 mmol), KOH (1.71 g, 30.40 mmol), 33c (529 mg, 1.52 mmol). The reaction
was stirred for 3 hours at 0°C. The product was purified with acid-washed silica-gel
flash chromatography (acetone/DCM 1:4) to afford 34c (326 mg, 61%). 1HNMR (400
MHz, CD3OD) δ (ppm): 0.88 (t, J = 6.8 Hz, 3H), 1.35 (m, 13 H), 1.64 (m, 4H), 2.08 (t,
J = 7.2 Hz, 2H), 2.35 (t, J = 7.6 Hz, 2H), 7.07 (t, J = 7.2 Hz, 1H), 7.28 (t, J = 8.0 Hz,
2H), 7.53 (d, J = 8.0 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ (ppm): 13.04, 22.33,

22.36, 26.22, 29.19, 29.40, 31.63, 32.36, 32.58, 33.04, 33.95, 36.75, 119.89, 123.70,
128.34, 138.50, 171.56, 173.49. IR: 3243, 3199, 3061, 2953, 2925, 2856, 1651, 1600,
1545, 1499, 1443, 755, 692 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+
C20H32N2O3Na+, 371.2311, found 371.2311. HPLC analytical purity analysis 96.7%.

Synthesis

of

N8-hydroxy-N1,4-diphenyloctanediamide

(34d):

The

procedure was similar to 34a except for the following: hydroxylamine HCl (1.08 g,
15.50 mmol), KOH (0.87 g, 15.50 mmol), 33d (526 mg, 1.55 mmol). The reaction
was stirred overnight at room temperature, then another 820 mg KOH was added
and left to stir for 7 hours. The product was purified with acid-washed silica-gel
flash chromatography (acetone/DCM 1:3) to afford 34d (329 mg, 62%). 1HNMR (500
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MHz, CD3OD) δ (ppm): 1.35 (m, 2H), 1.57 (m, 2H), 1.81 (m, 1H), 2.02 (m 5H), 2.49
(m, 1H), 6.95 (t, J = 7.5 Hz, 1H), 7.08 (m, 3H), 7.18 (m, 4H) 7.38 (d, J = 8.5 Hz, 2H).
13

CNMR (125 MHz, CD3OD) δ (ppm): 23.47, 32.14, 32.28, 34.59, 35.92, 45.20,

119.84, 123.66, 126.06, 127.45, 128.22, 128.31, 138.44, 144.26, 171.40, 172.91. IR:
3255, 3065, 3022, 2906, 2847,1683, 1600, 1541, 1499, 1442, 552, 686 cm-1. HRMS
(ESI-TOF, m/z): calculated for [M+Na]+ C20H24N2O3Na+, 363.1685, found 363.1680.
HPLC analytical purity analysis 96.0%.

Synthesis of 4-benzyl-N8-hydroxy-N1-phenyloctanediamide (34e): The
procedure was similar to 34a except for the following: hydroxylamine HCl (522 mg,
7.50 mmol), KOH (842 mg, 15.00 mmol), 33e (265 mg, 0.75 mmol). The reaction
was stirred for 2 hours at 0°C, followed by the second addition of hydroxylamine
HCl (522 mg, 7.50 mmol), KOH (842 mg, 15.00 mmol) and stirring for additional
3.5 hours at 0°C. The product was purified with acid-washed silica-gel flash
chromatography (acetone/DCM 1:3) to afford 34e (183 mg, 69%). 1HNMR (400 MHz,
CD3OD) δ (ppm): 1.32 (q, J = 8.0 Hz, 2H), 1.69 (m, 5H), 2.02 (m, 2H), 2.39 (m, 2H),
2.59 (m, 2H), 7.07 (t, J = 7.6 Hz, 1H), 7.14 (m, 3H), 7.23 and 7.28 (overlapped t and
t, J = 7.2 and 7.6 Hz, 4H), 7.51 (d, J = 7.6 Hz, 2H).

13

CNMR (100 MHz, CD3OD) δ

(ppm): 22.19, 28.91, 31.86, 32.50, 33.90, 39.00, 39.70, 119.89, 123.72, 125.48,
127.89, 128.35, 128.82, 138.46, 140.72, 171.46, 173.29. IR: 3244, 3061, 3026, 2923,
2867, 1638, 1599, 1542, 1498, 1443, 754, 700 cm-1. HRMS (ESI-TOF, m/z): calculated
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for [M+Na]+ C21H26N2O3Na+, 377.1841, found 377.1831. HPLC analytical purity
analysis 98.7%.
4.6.3. Procedures for biological screenings
4.6.3.1. HeLa cell lysis
Details were provided in Section 2.7.3.1 of Chapter 2.
4.6.3.2. Global HDAC inhibition
Details were provided in Section 3.6.3.2 of Chapter 3. Results are reported in
Figures 4.2 and C.52, and Tables 4.2 and C.1.
4.6.3.3. Inhibitor testing with HDAC isoforms 93
Details were provided in Section 2.7.3.2 of Chapter 2. Results are reported in
Figures 4.2 and C.53-C.55, and Tables 4.2 and C.2-C.5.
4.6.3.4. In cellulo selectivity testing
Details were provided in Section 2.7.3.3-2.7.3.5 of Chapter 2. Results are
reported in Figures 4.3 and C.56.
4.6.3.5. In vitro cell growth inhibition
Details were provided in Section 2.7.3.6 of Chapter 2. Results are reported in
Figure 4.4 and Table C.7.
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CHAPTER 5 - DOCKING STUDY OF N-SUBSTITUTED SAHA
ANALOGS 102
Some of the text in this chapter was reprinted or modified from: Bieliauskas, A. V.;
Weerasinghe, S. V. W.; Negmeldin, A. T.; Pflum, M. K. H., Structural Requirements
of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid,
Archiv der Pharmazie (Weinheim, Ger.) 2016, 349, 373-382.
5.1. Rationale for synthesis, screening, and docking of N-substituted SAHA
analogs (35 a-e)
Towards creating isoform selective inhibitors, the three structural regions of
HDAC inhibitors (Figure 5.1) have been modified, focusing primarily on the capping
region and metal binding moiety.12 The high sequence similarity within the active
sites of the isoforms makes inhibitor design problematic.12 Recently, the structures of
HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7 and HDAC8 were reported, 13-21
along with homology models of the other HDAC isoforms.22-23 According to structural
analysis, a 14Å internal cavity exists deep within the HDAC active site near the
catalytic metal atom, which functions as an exit channel for release of the acetate
byproduct after acetyl-lysine deacetylation (see section 1.4 in Chapter 1).98,

142-143

Important for inhibitor development, several compounds have been designed to
target the internal cavity by appending large aromatic groups to the metal binding
moiety.19,

144-145

For example, Cpd-60 (Figure 5.1) displays selectivity for HDAC1

and HDAC2 compared to HDAC3-8 (Table 1.1) .84, 92 Docking studies of Cpd-60 into
the HDAC1 and HDAC3 homology models suggested that selectivity was due to
differential interactions of the aryl group on the metal binding group with residues in
the 14Å internal cavity.84 A significant conclusion of these studies is that the metal
binding moiety can be modified to create selective HDAC inhibitors.
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Cpd-60

Figure 5.1. Structures of select HDAC inhibitors with the structural regions indicated
at the top.
To further exploit the 14 Å internal cavity for selective inhibitor design, we
created SAHA analogs functionalized on the amine of the hydroxamic acid metal
binding moiety. Like the benzamide of Cpd-60

19

, crystallographic and modeling

analyses indicate that the hydroxamic acid is positioned at the base of the active site
channel adjacent to the internal cavity.15-16,
selectivity of Cpd-60

19-23, 25, 99-100

Given the HDAC1/2

84

, we hypothesized that alkyl or aryl groups attached to the

hydroxamic acid of SAHA would also impart selectivity.
In this work, N-substituted SAHA analogs (Figure 5.1) were synthesized by
Dr. Anton Bieliauskas and screened by Dr. Sujith Weerasinghe to explore the effect
of hydroxamic acid substitution on the activity and selectivity of SAHA. 102 The Nsubstituted SAHA analogs displayed reduced potency and solubility, but greater
selectivity, compared to SAHA.
To assess selectivity, the analogs were screened by Dr. Sujith Weerasinghe
against three individual HDAC isoforms, HDAC 1, HDAC3, and HDAC6.102 HDAC1
and HDAC3 were included because Cpd-60 was able to discriminate between them

125
in prior work.84, 92 HDAC6 was also tested to assess class II selectivity. The analogs
were initially screened against the isoforms at a single concentration of 125 M
(Figure 5.2). The compounds containing aliphatic substituents (35a, methyl, and
35b, pentyl) displayed little to no isoform selectivity, similar to SAHA.78 Likewise, the
N-homobenzyl analog 35d also showed roughly similar potency against the
isoforms. In contrast, the N-benzyl 35c and N-biphenyl 35e variants displayed some
degree of HDAC1 selective inhibition, similar to Cpd-60. Among these two analogs,
N-biphenyl SAHA 35e demonstrated the most selectivity, with 58 ± 2% activity
remaining with HDAC1, but statistically insignificant inhibition observed with both
HDAC3 and HDAC6.

The single concentration selectivity screen points to N-

biphenyl 35e as an HDAC1 selective inhibitor, similar to compound Cpd-60.
Based on the observation that the benzyl 35c and biphenyl 35e variants
displayed some level of HDAC1 selectivity at 125 M concentration, IC50 values
were determined by Dr. Sujith Weerasinghe (Table 5.1).102 As expected,78 the paninhibitor SAHA displayed less than a 1.5-fold preference for any HDAC isoform
tested.104 The benzyl variant 35c displayed slightly greater selectivity for HDAC1
versus HDAC3 (2.5-fold).

Interestingly, the N-biphenyl variant 35e displayed

preferential inhibition for HDAC1 with an IC50 for HDAC1 of 233 ± 40 M.
Unfortunately, due to solubility issues at high concentrations, IC50 values for HDAC3
and HDAC6 could not be determined.

However, at the highest concentration

possible (250 µM), no inhibitory activity was observed with either HDAC3 or HDAC6
(Table 5.1), suggesting a preference for HDAC1.
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Docking studies discussed here were done to account for the lower potency
and the enhanced selectivity observed with the N-substituted SAHA analogs.
Docking studies showed that the N-substituent accesses the 14 Å internal cavity to
impart preferential inhibition of HDAC1. These studies with N-substituted SAHA
analogs are consistent with the strategy exploiting the 14Å internal cavity of HDAC
proteins to create HDAC1/2 selective inhibitors.

Figure 5.2. HDAC inhibitory activities of the N-modified SAHA analogs were
measured at 125 μM against HDAC1, HDAC3 and HDAC6. Data provided by Dr.
Sujith Weerasinghe).102
Table 5.1. IC50 values for SAHA, N-benzyl 35c, and N-biphenyl 35e against HDAC1,
HDAC3, and HDAC6.a
HDAC1

HDAC3

HDAC6

SAHA

96 ± 16 nM

146 ± 12 nM

74 ± 9 nM

35c

177 ± 21 µM

440 ± 23 µM

287 ± 9 µM

35e
233 ± 40 µM
105 ± 2 %b
108 ± 3 %b
a
Values are the means of at least three independent trials with standard error.
b
Deacetylase activity remaining at 250 µM concentration of inhibitor is shown
because solubility issues prevented IC50 value determination. Data provided by Dr.
Sujith Weerasinghe.102
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5.2. Docking studies with HDAC1 and HDAC3 crystal structures
Docking studies were performed to rationalize the lower potency and HDAC1
selectivity of the N-modified SAHA analogs. SAHA, along with the N-pentyl 35b and
N-biphenyl 35e analogs, were docked into the HDAC1 crystal structure.99 SAHA
maintained five interactions (1.1 to 3.8 Å distances) with the bound Zn 2+ metal and
nearby amino acids (H140, H141, and Y303, Figure 5.3A, see residues in blue). In
contrast, the N-pentyl 35b variant maintained only three of these interactions (with
Zn2+, H141, and Y303, Figure 5.3B), while the N-biphenyl 2e analog displayed only
two (with Zn2+ and Y303, Figure 5.3C). The loss of hydrogen binding capability of the
hydroxamic acid amine likely accounts for the fewer stabilizing interactions with the
analogs. In addition, the orientation of the hydroxamic acid is also altered by the Nmodification. Specifically, SAHA positions the carbonyl adjacent to Y303, the amine
near H141, and the hydroxyl next to H140. Due to the N-modification, the hydroxyl
amine orientation is flipped, with N-pentyl 35b positioning the hydroxyl near H141.
Likewise, the N-biphenyl analog adopts an alternative pose with the carbonyl
interacting with Zn2+ and the hydroxyl interacting with Y303. The docking
experiments point towards fewer interactions between the hydroxamic acid and the
active site, likely due to flipping of the N-modification into the 14Å cavity and loss of
hydrogen bonding capability of the modified amine, which account for the reduced
potency.
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A.

B.

C.
Y303

Y303
H141
R34

L139
14 Å internal cavity

H140

Active Site Channel

M30

Y303
M30
H141

M30

H141
R34

R34

L139

H140

L139

H140

Figure 5.3. Docking of SAHA (A), N-pentyl SAHA 35b (B), and N-biphenyl SAHA
35e (C) into the HDAC1 crystal structure (PBD 4BKX). The HDAC structure is
represented as blue mesh, the Zn2+ metal as a blue orb, and the inhibitor and amino
acids as ball and sticks. The atoms of the inhibitor are color-coded (C= green/white;
O = red; N = blue, H = white).
In addition to the loss of bonding interactions, another significant observation
from the docking studies is the positioning of the N-modification within the 14Å
internal cavity. The narrowest section of the cavity is created by M30, R34, and L139
(Figure 5.3A and Figure 5.4A, see resides in purple). While the pentyl group of 35b
is positioned up to this constricted point in the cavity (Figure 5.3B), the biphenyl
group of 35e extends beyond the narrow opening (Figure 5.3C). Therefore, the
reduced potency of N-biphenyl SAHA 35e may also be due to the narrowing of the
cavity near M30, R34 and L139 to constrict binding (Figure 5.4A). Consistent with
the extent and orientation of interactions, the energies of the inhibitor/HDAC1
complexes for SAHA, N-pentyl SAHA 35b, and N-biphenyl SAHA 35e were -5.46, 4.25, and -3.28 kcal/mole, respectively. The energies are consistent with the
experimental data indicating that SAHA is the most potent compound, whereas the
N-biphenyl 35e analog is the least potent (Table 5.1).
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HDAC1

HDAC3

A

B
M24
Y303
R34

M30

Y298

R28

H141

H135
H140
L139

L133
H134

Figure 5.4. Docking of N-biphenyl SAHA 35e into the crystal structures of HDAC1
and HDAC3. (A) This image is identical to that in Figure 5.3C, except that SAHA,
M30, R34, and L139 are shown as space filling models. (B) This image is identical to
that in Figure 5.5C, except that SAHA, M24, R28, and L133 are shown as space
filling models. The HDAC structure is represented as blue mesh, while amino acids
interacting with the hydroxamic acid in HDAC1 are shown as blue ball and sticks.
The atoms on the inhibitor are color-coded (C= green/white; O = red; N = blue, H =
white).
The docking studies were further analyzed to explain the enhanced
preference of 35e compared to SAHA and 35b (Table 5.2). Prior docking analysis
with Cpd-60 suggested that selectivity for HDAC1 compared to HDAC3 was a result
of congestion in the 14 Å cavity due to a tyrosine in HDAC3; HDAC1 contains serine
at the same position, which allows the cavity to accommodate bulky aromatic
groups.84 Docking of SAHA into the HDAC3 structure revealed that Y107 is
positioned relatively distant to the 14Å cavity (Figure 5.5A).100 Likewise, S113 in the
HDAC1 crystal structure is also located adjacent to the cavity (Figure 5.6). In
addition, previous mutagenesis studies indicated that S113 is only partially
responsible for the potency of Cpd-60 with HDAC1.98
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A.
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M24
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R28
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H135

R28
H135

H135
L133

H134
L133

Y107
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Figure 5.5. Docking of SAHA (A), N-pentyl SAHA 35b (B), and N-biphenyl SAHA
35e (C) into the HDAC3 crystal structure (PBD 4A69). The HDAC structure is
represented as blue mesh, the Zn2+ metal as a grey orb, and the inhibitor and amino
acids as ball and sticks. The atoms of the inhibitor are color-coded (C= green/white;
O = red; N = blue, H = white).

Y303

M30

R34
H141

L139

H140

S113

Figure 5.6. Docking of N-biphenyl 35e into the HDAC1 crystal structure (PBD 4BKX).
The HDAC structure is represented as blue mesh, the Zn2+ metal as a grey orb, and the
inhibitor and amino acids as ball and sticks. The atoms on the inhibitor are color-coded
(C= green/white; O = red; N = blue, H = white). This image is identical to that in Figure
5.3C, except that S113 is shown here.
An alternative hypothesis explaining the HDAC1 preference of Cpd-60 and
HDAC1 preference of N-biphenyl SAHA 35e emerges when considering the
narrowest point in the 14Å internal cavities of HDAC1 and HDAC3. HDAC3
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maintains a considerably more constricted 14Å internal cavity than HDAC1
(compare Figures 5.3A to Figure 5.5A and 54.A to 5.4B). The residues M24, R28,
and L133 of HDAC3 appear to block the cavity and may restrict access to bulky Nmodified inhibitors. Docking of N-biphenyl 35e into the HDAC3 crystal structure
produced no poses that were consistent with the expected metal/hydroxamic binding
interaction. Instead, the biphenyl group was positioned up to the narrowest section
of the cavity, near M24, R28, and L133 of HDAC3 (Figure 5.4B and Figure 5.5C). In
this case, the biphenyl group is unable to extend beyond the constricted region to
access the 14 Å internal cavity of HDAC3, as was seen with HDAC1 (Figure 5.3C
and Figure 5.4A). As a result of the blocked cavity, the hydroxamic acid is positioned
at the outside edge of the active site channel, unable to interact with the metal ion.
Therefore, docking suggests that the poor potency observed with 35e and HDAC3 is
due to restricted access of the N-biphenyl to the 14Å internal cavity, which prevents
favorable metal/hydroxamic acid interactions. In contrast, the straight chain N-pentyl
analog 35b is positioned up to the constriction point (Figure 5.5B), similar to HDAC1
(Figure 5.3B), which allows effective binding and better potency. In total, the docking
studies are consistent with accessibility of the 14Å cavity to large aromatic groups as
a significant factor leading to the HDAC1 preference of inhibitors bearing
substituents on the metal binding group, including Cpd-60 and N-biphenyl SAHA
35e.
In conclusion, N-modified SAHA analogs (35a-e) displayed significantly
reduced potency compared to the parent SAHA. Interestingly, the benzyl and pentyl
substituents are tolerated to a greater extent than any of the other N-substituted
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analogs. Docking studies are consistent with the pentyl groups accessing the 14Å
internal cavities of HDAC1 and HDAC3 (Figure 5.3B and 5.5B). However, the
additional interactions in the cavity were unable to overcome the lost hydrogen
bonding due to the presence of the N-modification. The results suggest that any
group, regardless of size, incorporated directly on the hydroxamic acid will result in
decreased inhibitory activity compared to the unsubstituted analog. These studies
are consistent with prior work reporting reduced potencies of HDAC inhibitors as a
result of N-methylation of the hydroxamic acid group.146-147
While the N-modified SAHA analogs showed reduced potency compared to
SAHA, one compound displayed selectivity. The N-biphenyl variant 35e showed
preference for HDAC1 over HDAC3 and HDAC6. Docking analysis with the HDAC1
and HDAC3 crystal structures suggests that that accessibility to the 14Å internal
cavity is differentially restricted, leading to preferential binding to HDAC1 over
HDAC3. Therefore, the combined experimental and computation analysis of Nmodified SAHA analogs further validates the concept of creating isoform-selective
HDAC inhibitors by positioning aromatic substituents in the 14Å internal cavity.
These studies guide future inhibitor design by suggesting that additional substituted
metal binding groups can be created to take advantage of the altered cavity
accessibility of the HDAC isoforms.
5.3. Experimental procedure
5.3.1. Docking procedure
Crystal structures for HDAC1 and HDAC3 were downloaded from the RCSB
protein data bank (HDAC1: 4BKX and HDAC3: 4A69). PyMOL (Schrodinger, LLC)
was used to delete the MTA1 corepressor chain, acetate, potassium and sulfate ions
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in HDAC1 crystal structure. In the case of the HDAC3 crystal structure, the water
molecules, chain A, deacetylase-activation-domain (DAD) (from the SMRT
corepressor), glycerol, D-myo-inositol-1,4,5,6-tetrakisphosphate molecules, acetate,
potassium and sulfate ions were deleted. AutoDockTools-1.5.4 program

119, 127

was

used to add all hydrogen atoms, modify histidine protonation (H140 and H141
residues for HDAC1, His134 His135 for HDAC3) by adding only HD1, compute
Gasteiger charges, and merge all non polar hydrogen, followed by generation of the
pdbqt output file. The charge of the zinc atom was manually changed from zero to
+2. A grid box with a spacing of 0.375 Å, size of 56 x 42 x 38, and coordinates for
the center of the grid box (-48.000, 18.000, -3.750) were used for HDAC1, while the
values for HDAC3 were 58 x 58 x 54 and (8.166, 76.663, 21.318). All docking
procedure and parameters were similar to what mentioned in Chapter 2, Section
2.7.4.
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CHAPTER 6 - SYNTHESIS AND SCREENING OF BIARYL INDOLYL
BENZAMIDE HDAC INHIBITORS
6.1. Rationale for design, synthesis and screening of biaryl indolyl benzamide
HDAC inhibitors
The objective of this project was to generate HDAC1-selective inhibitors to
study HDAC1-related cancer biology. No selective inhibitor for HDAC1 has been
identified to date. Rational design of HDAC1-selective inhibitors is a challenge due
to the high sequence similarity and active site similarity between HDAC1 and
HDAC2.12 In addition to studying HDAC1-related cancer biology, creating HDAC1selective inhibitors will be a step forward in the development of HDAC1-selective
anticancer drugs, which can lead to more effective cancer treatment compared to
non-selective inhibitors or inhibitors that are selective for more than one HDAC
isoform.
Several HDAC1/HDAC2 selective inhibitors have been reported.84, 92 Most of
the HDAC1/2 selective inhibitor are benzamide derivatives, where the metal binding
group is a 1,2-diamino benzamide chelating group (such as Cpd-60, an HDAC1/2
selective inhibitors (Figure 6.1)). According to literature, the selectivity of the
HDAC1/2 benzamide inhibitors came from the use of bulky aromatic rings (Figure
6.1, red rings in Cpd-60), which will not fit in the 14 Å channel of HDAC3 protein.84,
102

The presence of the biaryl group can impart selectivity to HDAC1 and 2 over

HDAC3, and can be used to develop an HDAC1-selective inhibitor.
In 2012, several hydroxamic acid derivatives were reported to be
HDAC1/HDAC3 dual selective inhibitors.117 The study showed that the selectivity
came from preferential interaction of the capping group (Figure 6.1, blue part in 36)
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with the solvent exposed region of the active sites of HDAC1 and HDAC3 over
HDAC2.

The capping group that imparted selectivity against HDAC2 can

successfully be used to generate an HDAC1-selective inhibitor.

Figure 6.1. Structures of HDAC1/3 selective inhibitor 36, HDAC1/2 selective
inhibitor Cpd-60, and the biaryl indolyl benzamide HDAC inhibitors Bnz-1, Bnz-2,
and Bnz-3.
In this work we combined both the functional groups from the HDAC1/2
selective inhibitors and HDAC1/3 selective inhibitor in order to generate HDAC1
selective analogs. The hypothesis was to combine the biaryl group (Figure 6.1, red
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part of Cpd-60) which discriminated against HDAC3, with the capping group of the
HDAC1/3 selective inhibitors (Figure 6.1, blue part of 36) which discriminated
against HDAC2. By combining these two fragments we designed three potential
HDAC1-selective inhibitor (Figure 6.1, Bnz-1, Bnz-2, and Bnz-3).
6.2. Docking studies of Cpd-60 with HDAC1, 2, 3, and 7
To validate the design of the HDAC1-selective inhibitors, and to understand
the binding of selective inhibitors to HDAC1, Cpd-60 was docked in the crystal
structures of class I HDAC1 (PDB: 4BKX), HDAC2 (PDB: 3MAX), and HDAC3 (PDB:
4A69), and class II HDAC7 (PDB: 3C0Z) using Autodock program119. The docking
studies revealed the amino acids that are critical for the selectivity, and more
importantly, showed the preference of Cpd-60 binding to HDAC1 and HDAC2
(Figure 6.2). For both HDAC1 and HDAC2, Cpd-60 showed the expected binding,
with the metal binding group of Cpd-60 (Figure 6.1) well positioned in the metal
binding region of the active site and the biaryl ring system positioned in the 14 Å
channel (Figures 6.1, 6.2A and B). It's worth mentioning that the crystal structures of
both HDAC1 and HDAC2 showed a difference in the width of the 14 Å channel
(Figure 6.2A and B). HDAC2 displayed a wider channel than HDAC1, with a slight
constriction in HDAC1 crystal structure 14 Å channel created by M30, R34, and
L139 (gold mesh in Figure 6.2A). But the compound still bound well to both active
sites. On the other hand, in HDAC3 Cpd-60 didn't fit in the active site due to the
presence of a constriction created by M30, R34, and L139 blocking the 14 Å channel
(Figure 6.2, see arrow), similar to the N-library docking results (section 5.4 in
Chapter 5).102 The constriction in the 14 Å cavity of HDAC3 prevented the biaryl ring
system from fitting, which led to a pose that placed the metal binding group of the
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compound away from the metal binding region in HDAC3 active site (gold mesh in
Figure 6.2C). In HDAC7, a similar disfavored binding or no binding was observed
due to the absence or blocking of the 14 Å channel (gold mesh in Figure 6.2D).

Figure 6.2. Docking of Cpd-60 into the crystal structures of (A) HDAC1, (B) HDAC2,
(C) HDAC3 and (D) HDAC7. The Zn2+ metal is represented as a grey orb, the
inhibitor as ball and sticks, and the HDAC structure as color-coded mesh (gold = 14
Å cavity constriction point; green = base of the 14 Å cavity; blue = all other regions).
Residues differing in their position at the cavity surface in HDAC2 versus 1, 3, or 7
are shown in red.
6.3. Synthesis of the biaryl indolyl benzamide HDAC inhibitors
The biaryl indolyl benzamide inhibitors were synthesized according to
Schemes 6.1-6.4. First, synthesis of intermediates 44a and 44b commenced with
reduction of (tert-butoxycarbonyl)-L-tryptophan 37 with LiAlH4, which afforded the
protected tryptophanol 40. Another method for the synthesis of 40 was also followed
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by BOC protection of methyl L-tryptophanate HCl salt 38, then reduction with LiAlH4
(Scheme 6.1). The coupling partner esters 42a and 42b were synthesized from their
corresponding carboxylic acids, (E)-3-(4-hydroxyphenyl)acrylic acid 41a or 4hydroxy benzoic acid 41b, by esterification with methanol. Mitsunobu coupling of 40
with 42a or 42b gave 43a or 43b, respectively. Deprotection of 43a or 43b with
HCl/EtOAc, and coupling with benzoic acid using TBTU and DIPEA afforded 44a or
44b intermediates.
Scheme 6.1. Synthesis of intermediates 44a and 44b

The biaryl fragment of the molecules (biaryl amine 49) was synthesized by
BOC protection of 4-bromo-2-nitro aniline 46 using di-tert-butyl dicarbonate and a
catalytic amount of DMAP to form the mono BOC amine 47 (Scheme 6.2).
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Compound 47 was then subjected to Suzuki coupling using phenyl boronic acid,
potassium carbonate, and bis triphenylphosphine palladium dichloride to give 48,
which was then reduced by Pd/C and hydrogen gas to afford 49 (Scheme 6.2).
Scheme 6.2. Synthesis of the biaryl amine 49

Synthesis of Bnz-1 and Bnz-3 was done according to Scheme 6.3. Hydrolysis
of 44a and 44b with NaOH gave the free carboxylic acids 45a and 45b. Coupling of
45a or 45b with the BOC-protected biaryl amine 49 was achieved with PyBOP and
afforded the BOC-protected 50a and 50b. The final products Bnz-1 and Bnz-3 were
obtained by BOC deprotection of with 50% TFA/DCM. Bnz-2 was synthesized by
reduction of 45a, followed by coupling with the biaryl amine 49 and finally BOC
deprotection with 50%TFA/DCM (Scheme 6.4).

Scheme 6.3. Synthesis of Bnz-1 and Bnz-3
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Scheme 6.4. Synthesis of Bnz-2

6.4. In vitro screening of biaryl indolyl benzamide HDAC inhibitors
To assess isoform selectivity, the three new compounds were screened
against recombinant HDAC1 and HDAC2 using the HDAC-Glo assay (Figure 6.3).
Bnz-3 was further tested with HDAC3 and HDAC6. Cpd-60, as a HDAC1/2 selective
inhibitor, and SAHA, as a non-selective compound, were tested as well with
recombinant HDAC1, 2, 3, and 6. As expected, SAHA showed almost the same
inhibitory activity with HDAC1, 2, 3, and 6 (Figure 6.3). The HDAC1/2 selective
inhibitor Cpd-60 demonstrated selectivity for HDAC1 and 2 over HDAC3 and 6. The
new analogs showed several interesting results. First, Bnz-3 displayed the highest
inhibitory activity among the three analogs, with about ten- to 100-fold higher
potency compared to Bnz-2 and Bnz-1, respectively (compare HDAC1 or HDAC2
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activity at 2 µM for Bnz-3 to 20 and 200µM for Bnz-2 and Bnz-1, or at 0.2 µM for
Bnz-3 to 2 and 20 µM for Bnz-2 and Bnz-1) (Figure 6.3). Second, all the analogs
showed selectivity for HDAC1 over HDAC2, with the best selectivity observed for
HDAC1 with Bnz-3 at 2 µM (Figure 6.3). The presence of the saturated linker in
Bnz-2 led to about 10-fold improvement in potency compared to the unsaturated
linker in Bnz-1 (Figures 6.1 and 6.3). Interestingly, removing the linker in Bnz-3 led
to another 10-fold enhancement in the activity compared to Bnz-2, and about 100fold compared to Bnz-1 (Figures 6.1 and 6.3).

Percentage Deacetylase Activity

HDAC1

HDAC2

HDAC3

HDAC6

100
80
60
40
20
0

SAHA Cpd-60 ------Bnz1------ ------Bnz2------ ------Bnz3-----20nM 28nM 200µM 20µM 20µM 2µM
2µM 0.2µM

Figure 6.3. In vitro isoform selectivity screening of SAHA, Cpd-60, Bnz-1, Bnz-2,
and Bnz-3 against HDAC1, HDAC2, HDAC3, and HDAC6. The concentrations
shown for each compound are final concentrations. Mean percent deacetylase
activities from a minimum of two independent trials with standard errors were plotted
(Table D.1).
To further assess the selectivity of Bnz-3 as the best analog, IC50 values were
determined for both Bnz-3 and Cpd-60 using recombinant HDAC1 and HDAC2
(Table 6.1). Cpd-60 showed about 7.3-fold selectivity for HDAC1 over HDAC2, with
10.4 nM IC50 value with HDAC1. On the other hand, Bnz-3 displayed about 10.6-fold

142
selectivity for HDAC1 over HDAC2, with an IC50 value of 548 nM with HDAC1. The
IC50 values show that the potency of Bnz-3 was about 53-fold less potent than Cpd60 in inhibiting HDAC1, while the selectivity for HDAC1 was modestly enhanced to
10.6-fold compared to 7.3-fold with Cpd-60 (Table 6.1).
In conclusion, several biaryl indolyl benzamide inhibitors were designed,
synthesized, and screened for isoform selectivity. The design was based on
combining two different fragments to discriminate against HDAC2 and HDAC3, to
get a potential HDAC1-selective inhibitor. Bnz-3 was the best analog in terms of
potency and selectivity. Bnz-3 displayed about 10-fold higher potency than Bnz-2,
and about 100-fold higher potency than Bnz-1. Bnz-3 exhibited a modest inhibitory
potency with HDAC1 (548 nM). In terms of selectivity, Bnz-3 showed HDAC1
preference, but the observed fold selectivity to HDAC1 over HDAC2 (7.3-fold) was
far less than what we expected (30- to 50-fold) when we designed these inhibitors.
Table 6.1. IC50 values and fold selectivity for Cpd-60 and Bnz-3 against HDAC1 and
HDAC2
using
recombinant
proteins.a
IC50 values (nM)
Compound
HDAC1

HDAC2

HDAC1/HDAC2
fold selectivity

Cpd-60

10.4 ± 0.7

75.9 ± 7.9

7.3

Bnz-3

548 ± 50

5800 ± 380

10.6

a

Mean IC50 value and standard error of at least three independent trials are shown
(Figures D.24 and D.25 and Tables D.2 and D.3).
6.5. Experimental Procedures
6.5.1. Materials and instrumentation
Details were provided in Section 2.7.1 of Chapter 2.
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6.5.2. Docking procedure
Crystal structures of HDAC1 and HDAC3 were prepared in a similar way as
mentioned previously and all box sizes dimensions were the same (Chapter 5,
section 5.5.1). For HDAC2, a similar preparation procedure, box dimensions and
position to Chapter 2, section 2.7.4 were followed. for HDAC7, the crystal structure
was downloaded from the protein data bank (pdb ID: 3C0Z)21, a grid box of size 26 X
26 X 26 Å3 with a spacing of 0.375 Å and centered at (-32.876, -29.000, -19.000)
was used. The PyMOL program was used to delete all water molecules, metal ions
(potassium), ethanol, and glycerol molecules and the cocrystallized ligand in the
active site from the crystal structure; only the zinc atoms remained. All docking
procedure and parameters were similar to what mentioned in Chapter 2, Section
2.7.4.
6.5.3. Synthesis procedure

Synthesis

of

tert-butyl

(S)-(1-hydroxy-3-(1H-indol-3-yl)propan-2-

yl)carbamate (40): Method A: In a 50 mL flask, (tert-butoxycarbonyl)-L-tryptophan
37 (1 g, 3.29 mmol) was dissolved in dry THF (15 mL). LiAlH4 (499 mg, 13.14 mmol)
was added at 0ºC portion wise, and then the temperature was increased to room
temperature and the reaction was left to stir for 5 hours under argon. The reaction
was quenched with careful dropwise addition of a citric acid solution (10 mL of 1M
solution in water). The organic layer was separated, and the aqueous layer was
extracted with ethyl acetate (2X30 mL). The organic layers were collected, dried
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over anhydrous Na2SO4, and evaporated. The product was purified by silica-gel flash
chromatography (acetone/petroleum ether 1:3) to afford 40 (655 mg, 83%). Melting
point: 117-120 ºC (reported 118-120 ºC)148. 1HNMR (400 MHz, DMSO-d6) δ (ppm):
1.34 (s, 9H), 2.70 (dd, J = 7.2 and 14.4 Hz, 1H), 2.87 (dd, J = 6.4 and 14.4 Hz, 1H),
3.33 (m, 2H), 3.66 (m, 1H), 4.60 (t, J = 5.6 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.95 (t,
J = 8.0 Hz, 1H), 7.04 and 7.07 (overlapped t and s, J = 7.4 Hz, 2H), 7.30 (d, J = 8.0
Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 10.75 (br s, 1H). Spectral data for the synthesized
compound was consistent with the reported data in literature.149
Method B: The compound was synthesized similar to the reported
procedure.149 In a 50 mL flask, methyl L-tryptophanate HCl salt 38 (1g, 3.93 mmol)
was dissolved in dry DCM (10 mL), followed by the addition of triethyl amine (874
mg, 8.64 mmol) and di-tert-butyl dicarbonate (943 mg, 4.32 mmol). The reaction was
stirred overnight, washed with citric acid (2x5mL of 1M solution in water) AND then
brine (10 mL), dried over anhydrous Na2SO4, and evaporated to give 39. Without
purification, 39 was dissolved in dry THF (20 mL), followed by the addition of LiAlH4
(571 mg, 15.04 mmol) portion wise at 0ºC. The same procedure as method A was
followed. The product was purified by silica-gel flash chromatography (ethyl
acetate/hexanes 1/2) to afford 40 (850 mg, 72% over two steps). Melting point: 118119 ºC (reported 118-120 ºC)148.

Synthesis

of

methyl

(E)-3-(4-hydroxyphenyl)acrylate

(42a):

The

compound was synthesized according to the reported procedure. 150 (E)-3-(4-
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hydroxyphenyl)acrylic acid 41a (4 g, 24.37 mmol) was dissolved in methanol (40
mL). p-Toluenesulfonic acid (927 mg, 4.87 mmol) was added and the reaction was
heated at reflux for 19 hours. The solvent was evaporated, and the residue was
dissolved in ethyl acetate (40 mL), washed with saturated NaHCO3 solution (30 mL),
dried over anhydrous Na2SO4, and evaporated to afford 42a (4.14 g, 95%). Melting
point: 134-137 ºC. 1HNMR (400 MHz, CDCl3) δ (ppm): 3.80 (s, 3H), 6.30 (d, J = 16
Hz, 1H), 6.85 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 16 Hz, 1H).
Spectral data for the synthesized compound was consistent with the reported data in
literature.150

Synthesis of methyl 4-hydroxy benzoate (42b): The compound was
synthesized similar to the reported procedure.151 4-hydroxybenzoic acid 41b (4 g,
24.37 mmol) was dissolved in methanol (100 mL), sulfuric acid (0.5 mL) was added,
and the reaction was heated to reflux for 6 hours. The solvent was evaporated, and
the residue was dissolved in ethyl acetate (40 mL), washed with saturated NaHCO3
solution (30 mL), dried over anhydrous Na2SO4, and evaporated to afford 42b (4.14
g, 94%). 1HNMR (400 MHz, CDCl3) δ (ppm): 3.90 (s, 3H), 6.28 (br s, 1H) 6.88 (dd, J
= 2, 4.8 Hz, 2H), 7.95 (dd, J = 2, 4.8 Hz, 2H). Spectral data for the synthesized
compound was consistent with the reported data in literature.151
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Synthesis

of

methyl

(S,E)-3-(4-(2-benzamido-3-(1H-indol-3-

yl)propoxy)phenyl)acrylate (44a): The compound was synthesized according to
the reported procedure.117 In dry THF (10 mL), 40 (850 mg , 2.89 mmol), 42a (567
mg, 3.18 mmol) and triphenyl phosphine (834 mg, 3.18 mmol) were dissolved,
followed by the addition of diethyl azodicarboxylate (554 mg, 3.18 mmol) drop wise
at 0 ºC. The reaction was stirred at room temperature for 4 hours. The solvent was
evaporated, and the product was purified by silica-gel flash chromatography
(EtOAc/Hexanes 1:3) to afford 43a.
Compound 43a was dissolved in EtOAc (10 mL), then EtOAc saturated with
HCl (10 mL) was added. The reaction was left to stir at RT for 8.5 hours. The solvent
was evaporated and the crude product was used in the following reaction directly
with no further purification.
Benzoic acid (493 mg, 4.04 mmol) was dissolved in dry DCM (15 mL), then
DIPEA (1.05 mL, 6.05 mmol) was added, followed by TBTU (1.94 gm, 6.05 mmol).
The reaction was left to stir at room temperature for 30 min, followed by the addition
of the intermediate from previous step and another portion of DIPEA (1.05 mL, 6.03
mmol). The reaction was left to stir for 3.5 hours. The solvent was evaporated and
the product was purified by flash silica-gel chromatography (EtOAc/Hexanes 1:21:1.5) to afford 44a (34% over three steps). 1HNMR (400 MHz, DMSO-d6) δ (ppm):
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3.08 (d, J = 7.2 Hz, 2H), 3.68 (s, 3H), 4.09 (m, 1H), 4.18 (m, 1H), 4.57 (m, 1H), 6.44
(d, J = 16 , 1H), 6.94 (m ,3H), 7.04 (t, J = 7.2 , 1H), 7.16 (s, 1H), 7.30 (d, J = 8, 1H),
7.43 (t, J = 7.2, 2H), 7.50 (t, J = 6.8, 1H), 7.62 (m, 3H), 7.81 (d, J = 7.6, 2H), 8.47 (d,
J = 7.6 , 1H), 8.96 (br s, 1H), 10.78 (br s, 1H). Spectral data for the synthesized
compound was consistent with the reported data in literature.117

Synthesis

of

methyl

(S)-4-(2-benzamido-3-(1H-indol-3-

yl)propoxy)benzoate (44b): The compound was synthesized similar to 44a except
the following, 40 (1.88 g , 6.47 mmol), 42b (1.08 g, 7.12 mmol), triphenyl phosphine
(1.87 g, 7.12 mmol), diethyl azodicarboxylate (1.13 mL, 6.47 mmol), benzoic acid
(210 mg, 1.72 mmol), DIPEA (449 uL, 2.58 mmol), TBTU (828 mg, 2.58 mmol), 43b
(620 mg, 1.72 mmol) and DIPEA (449 uL, 2.58 mmol). The product was purified by
flash silica-gel chromatography (EtOAc/Hexanes 1:2-1:1.5) to afford 44b (44% over
three steps). 1HNMR (400 MHz, DMSO-d6) δ (ppm): 3.10 (d, J = 6.8 Hz, 2H), 3.78
(s, 3H), 4.12 (m, 1H), 4.21 (m, 1H), 4.59 (m, 1H), 6.95 (t, J = 7.2 Hz, 1H), 7.04 (t, J
= 8.8 , 3H), 7.18 (s, 1H), 7.31 (d, J = 8, 1H), 7.43-7.50 (t and t, J = 6.8, and 7.2 3H),
7.62 (d, J = 8, 1H), 7.83 (m, 4H), 8.52 (d, J = 8, 1H), 10.82 (br s, 1H).

Synthesis of tert-butyl (4-bromo-2-nitrophenyl)carbamate (47): The
compound was synthesized according to the reported procedure.152

4-bromo-2-
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nitroaniline 46 (2g, 9.2 mmol) was dissolved in dry DCM (20 mL), followed by
addition of DMAP (113 mg, 0.09 mmol). A solution of di-tert-butyl dicarbonate (2.2 g,
10.13 mmol) in dry DCM (20 mL) was added drop wise over 1 hour. The reaction
was left to stir at room temperature for 3 hours. The solvent was evaporated and the
reaction was purified by flash silica-gel chromatography (EtOAc/Hexanes 1:20) to
afford 47 (1.7 g, 58%). 1HNMR (400 MHz, CDCl3) δ (ppm): 1.54 (s, 9H), 7.67 (dd, J
= 2.3, 9.2 Hz, 1H), 8.32 (d, J = 2.4 Hz, 1H), 8.50 (d, J = 9.2 Hz, 1H), 9.60 (br s, 1H).
Spectral data for the synthesized compound was consistent with the reported data in
literature.152

Synthesis of tert-butyl (3-nitro-[1,1'-biphenyl]-4-yl)carbamate (48): The
compound was synthesized similar to the reported procedure.152 Compound 47 (1.7
g, 5.36 mmol) was dissolved in dry THF (20 mL), followed by degassing with argon
gas for 30 minutes. Phenyl boronic acid (1.05 g, 8.58 mmol), potassium carbonate
(2.37 g, 17.16 mmol), and Pd[PPh3]2Cl2 (85 mg, 5% w/w) were added. The reaction
was heated under reflux for 23 hours, then the solvent was evaporated. The residue
was suspended in diethyl ether (30 mL), filtered, and the solvent was evaporated.
The residue was purified by flash silica-gel chromatography (EtOAc:Hexanes 1:20)
and recrystallization of the impure column fractions from EtOH afforded 48 (1.23 g,
76%). 1HNMR (400 MHz, CDCl3) δ (ppm): 1.56 (s, 9H), 7.37 (m, 1H), 7.48 (m, 2H),
7.58 (m, 2H), 7.85 (dd, J = 2.4, 8.8 Hz, 1H), 8.42 (d, J = 2.0 Hz, 1H), 8.63 (d, J = 8.8
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Hz, 1H), 9.67 (br s, 1H). Spectral data for the synthesized compound was consistent
with the reported data in literature.152

Synthesis of tert-butyl (3-amino-[1,1'-biphenyl]-4-yl)carbamate (49): The
compound was synthesized similar to the reported procedure.152 Compound 48
(1.21 g, 4.26 mmol) was suspended in EtOH (80 mL), and Pd/C (121 mg, 10% w/w)
was added. The air inside the flask was replaced with argon (X3) then with
hydrogen gas (X3). The reaction was allowed to stir under hydrogen overnight at
room temperature. The reaction was filtered and concentrated to afford 49 (1.08 g,
99%). 1HNMR (400 MHz, CDCl3) δ (ppm): 1.51 (s, 9H), 5.28 (br s, 2H), 6.60 (br s,
1H), 7.11 (m, 1H), 7.18 (s, 1H), 7.36 (m, 4H), 7.51 (d, J = 8.4 Hz, 2H). Spectral data
for the synthesized compound was consistent with the reported data in literature. 152

Synthesis

of

(S,E)-N-(1-(4-(3-((4-amino-[1,1'-biphenyl]-3-yl)amino)-3-

oxoprop-1-en-1-yl)phenoxy)-3-(1H-indol-3-yl)propan-2-yl)benzamide

(Bnz-1):

44a (1.82 g, 4 mmol) was dissolved in MeOH (50 mL), followed by the addition of
NaOH (1.6 g, 40 mmol) in water (10 mL). The reaction was left to stir at room
temperature for 18 hours. Then the reaction was concentrated under vacuum. HCl
(10 N solution in water) was added drop wise until the pH was 6. The reaction was
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diluted with water and extracted with ethyl acetate (3X50 mL), dried over MgSO4,
evaporated to give 45a.
Crude product 45a was dissolved in dry DMF (8 mL) followed by the addition
on triethyl amine (0.195 mL, 1.5 mmol). PyBOP (729 mg, 1.5 mmol) was dissolved in
dry DCM (5 mL) and added to the reaction, followed by the biaryl amine 49 (362 mg,
1.36 mmol) in dry DCM (5 mL). The reaction was left to stir for 19 hours at room
temperature, and then was concentrated under reduced pressure, diluted with water
(15 mL), and extracted with ethyl acetate (3x30 mL). The reaction was purified by
flash silica-gel chromatography (EtOAc/Hexanes 1:2-1:1) to afford 50a.
Compound 50a (175 mg, 0.25 mmol) was dissolved in dry DCM (4mL), then
TFA (4 mL) was added. The reaction was left to stir at room temperature for 4 hours.
The reaction was then concentrated under vacuum and a saturated solution of
NaHCO3 was added dropwise until no effervescence was observed. The product
was extracted with EtOAc (3x15mL) and purified by flash silica-gel chromatography
(EtOAc/Hexanes 1:1.5-1:1) to afford Bnz-1 (150 mg, 11% over three steps). 1HNMR
(400 MHz, DMSO-d6) δ (ppm): 3.10 (d, J = 7.2 Hz, 2H), 4.09 (m, 1H), 4.20 (m, 1H),
4.59 (m, 1H), 5.12 (br s, 2H), 6.76 (d, J = 15.6, 1H), 6.82 (d, J = 8.4, 1H), 6.96 (m,
4H), 7.22 (m, 3H), 7.31 (d, J = 8, 1H), 7.37 (t, J = 7.6, 2H), 7.49 (overlapped m, 8H),
7.62 (d, J = 7.6, 1H), 7.71 (br s, 1H), 7.83 (d, J = 8.4 , 2H), 8.50 (d, J = 7.6, 1H), 9.36
(br s, 1H), 10.80 (br s, 1H);

13

CNMR (100 MHz, CD3OD) δ (ppm): 27.16, 50.29,

69.45, 111.20, 111.86, 115.53, 116.78, 118.78, 120.28, 121.39, 123.21, 123.88,
124.37, 125.99, 126.46, 127.78, 128.01, 128.64, 129.24, 129.73, 131.62, 134.98,
136.64, 139.90, 140.80, 141.62, 160.25, 164.40, 166.79; HRMS (ESI-TOF, m/z):
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calculated for [M+H]+ C39H34N4O3H+, 607.2709, found 607.2736. HPLC analytical
purity analysis 94.9%.

Synthesis of (S)-N-(4-amino-[1,1'-biphenyl]-3-yl)-4-(2-benzamido-3-(1Hindol-3-yl) propoxybenzamide (Bnz-3): Compound 44b (630 mg, 1.47 mmol) was
dissolved in MeOH (25 mL), followed by the addition of NaOH (588 mg, 14.7 mmol)
in H2O (5 mL). The reaction was left to stir at room temperature for 18 hours. Then
the reaction was concentrated under vacuum. HCl (10 N) was added drop wise until
the pH was 6. The reaction was diluted with water (10 mL) and extracted with EtOAc
(3X30 mL), dried over MgSO4, and evaporated to give 45b.
Crude product 45b was dissolved in dry DMF (5 mL), followed by the addition
on triethyl amine (0.22 mL, 1.57 mmol). PyBOP (446 mg, 1.57 mmol) was dissolved
in dry DCM (5 mL) and added to the reaction, followed by the biaryl amine 49 (817
mg, 1.57 mmol) in dry DCM (5 mL). The reaction was left to stir for 21 hours. The
reaction was then concentrated under reduced pressure, diluted with water (10 mL),
and extracted with ethyl acetate (3x30mL). The reaction was purified by flash silicagel chromatography (EtOAc:Hexanes 1:2-1:1) to afford 50b, which was used in the
next reaction with no characterization.
Compound 50b was dissolved in dry DCM (4mL), then TFA (4 mL) was
added. The reaction was left to stir at room temperature for 4 hours. The reaction
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was then concentrated under vacuum and a saturated solution of NaHCO3 was
added till no effervescence was observed. The product was extracted with EtOAc
(3x20mL), purified by flash silica-gel chromatography (EtOAc:Hexanes 1:1.5-1:1)
and afforded Bnz-3 (18% over three steps). 1HNMR (400 MHz, DMSO-d6) δ (ppm):
3.11 (d, J = 6.0 Hz, 2H), 4.12 (m, 1H), 4.23 (m, 1H), 4.61 (m, 1H), 5.06 (br s, 2H),
6.84 (d, J = 8.8, 1H), 6.97 (t, J = 7.2, 1H), 7.05 (m, 3H), 7.20 (m, 2H), 7.29-7.39
(overlapped t and t, J = 8, 4H), 7.44-7.53 (m, 6H), 7.63 (d, J = 8, 1H), 7.84 (d, J =
7.2, 2H), 7.95 (d, J = 8.4 , 2H), 8.53 (d, J = 8.4, 1H), 9.61 (br s, 1H), 10.82 (br s, 1H);
13

CNMR (100 MHz, CD3OD) δ (ppm): 27.17, 50.24, 69.52, 111.18, 111.87, 114.54,

116.98, 118.79, 121.40, 123.90, 125.24, 125.95, 126.45, 127.24, 127.79, 127.86,
128.58, 128.66, 129.25, 130.17, 131.65, 134.96, 136.62, 140.66, 143.25, 161.54,
166.79; HRMS (ESI-TOF, m/z): calculated for [M+H]+ C37H32N4O3H+, 581.2553,
found 581.2573. HPLC analytical purity analysis 94.9%.

Synthesis
oxopropyl)phenoxy)

of

(S)-N-(1-(4-(3-((4-amino-[1,1'-biphenyl]-3-yl)amino)-3-3-(1H-indol-3-yl)propan-2-yl)benzamide

(Bnz-2):

Compound 45a (600 mg, 1.36 mmol) was dissolved in MeOH (15 mL), followed by
the addition of Pd/C (60 mg, 10% w/w). Air was replaced with argon (3X), then
hydrogen gas (3X). The reaction was left to stir overnight under hydrogen at room
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temperature. The reaction was then filtered, evaporated and the crude product was
used in the next reaction.
The crude product 30 was dissolved in dry DMF (10 mL), followed by the
addition of triethyl amine (0.244 mL, 1.75 mmol). PyBOP (911 mg, 1.75 mmol) was
dissolved in dry DCM (5 mL) and added to the reaction, followed by amine 49 (451
mg, 1.59 mmol) in dry DCM (5 mL). The reaction was left to stir overnight at room
temperature. The reaction was then concentrated under reduced pressure, diluted
with water (15 mL), and extracted with ethyl acetate (3x20mL). The reaction was
purified by flash silica-gel chromatography (EtOAc:Hexanes 1:2-1:1) and the product
was used in the next reaction with no characterization.
The crude product from previous reaction was dissolved in dry DCM (4 mL),
then TFA (4 mL, 52 mmol) was added. The reaction was left to stir at room
temperature for 2 hours. The reaction was then concentrated under vacuum and a
saturated solution of NaHCO3 was added until no effervescence was observed. The
product was extracted with ethyl acetate (3x15mL), purified by flash silica-gel
chromatography (EtOAc:Hexanes 2:1-3:1), and afforded Bnz-2 (11% over three
steps). 1HNMR (400 MHz, DMSO-d6) δ (ppm): 2.59 (t, J = 8.0 Hz, 2H), 2.84 (t, J =
7.2 Hz, 2H), 3.08 (d, J = 4.8 Hz, 2H), 3.95 (m, 1H), 4.10 (m, 1H), 4.56 (m, 1H), 4.95
(br s, 2H), 6.76 (d, J = 8.0, 1H), 6.86 (d, J = 8.4, 1H), 6.94 (t, J = 7.2, 1H), 7.03 (t, J =
7.2, 1H), 7.14-7.23 (m, 5H), 7.29-7.48 (m, 9H), 7.61 (d, J = 7.6, 1H), 7.82 (d, J = 7.2,
2H), 8.47 (d, J = 7.6, 1H), 9.18 (br s, 1H), 10.79 (br s, 1H);

13

CNMR (100 MHz,

CD3OD) δ (ppm): 27.20, 30.73. 38.21, 50.34, 69.36, 111.30, 111.83, 114.91, 116.54,
118.80, 121.37, 123.82, 123.92, 124.07, 124.46, 125.92, 126.41, 127.78, 127.87,
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128.42, 128.63, 129.23, 129.73, 131.59, 133.76, 135.00, 136.62, 142.03, 157.29,
166.74, 171.06; HRMS (ESI-TOF, m/z): calculated for [M+H]+ C39H36N4O3H+,
609.2866, found 607.2854. HPLC analytical purity analysis 94.3%.
6.5.4. Procedures for biological screenings
6.4.3.1. Inhibitor testing with HDAC isoforms
To measure HDAC isoforms inhibition, individual baclovirus-expressed
HDAC isoform (50 ng for HDAC1 (Enzo Life), 3 ng HDAC1 (BPS Bioscience), 0.5
ng for HDAC2 (BPS Bioscience), 6 ng for HDAC3 (Enzo Life), and 65 ng for
HDAC6 (Enzo Life)) was mixed with HDAC-Glo™ buffer (Promega) in polystyrene
96-well half area white plate (Corning). Inhibitor in DMSO (1 µL) was then added
to a final volume of 25 µL, and pre-incubation for 2 hours at room temperature
without rocking. An uninhibited control reaction was also included that contained
DMSO (1 µL) with each HDAC enzyme in HDAC-Glo™ buffer (24 µL).
Deacetylase activity was measured using the HDAC-Glo™ assay kit as per the
manufacturer’s protocol (Promega). Specifically, the HDAC-Glo™ substrate (1
mL) and developer (1 µL) were first premixed to form the HDAC-Glo™ reagent.
Then, to monitor deacetylase activity, HDAC-Glo™ reagent (5 µL) diluted in
HDAC-Glo™ buffer (20 µL) was added to each well (50 µL total volume) and
incubated for 30-45 minutes at room temperature without rocking. The
deacetylase activity was measured as luminescent signal using a GeniosPlus
Fluorimeter (Tecan) at optimal gain. The concentrations of inhibitors reported in
the dose-dependent studies are final concentrations after addition of HDAC-Glo™
reagent and HDAC-Glo™ buffer. Percent deacetylase activity was calculated by
dividing the signal for each reaction by the signal of the uninhibited control, and

155
then multiplying by 100. IC50 values were calculated by fitting the percent
deacetylase activity remaining as a function of inhibitor concentration to a
sigmoidal dose-response curve (y = 100/(1+(x/IC50)z), where y = percent
deacetylase activity and x = inhibitor concentration) using non-linear regression
with KaleidaGraph 4.1.3 software. Results are reported in Figures 6.3, D.24 and
D.25, and Tables 6.1, D.2 and D.3.
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CHAPTER 7 - CONCLUSION
In this thesis, several HDAC inhibitors have been designed, synthesized, and
screened for biological activity. Several SAHA (Vorinostat) analogs were modified at
different positions in the linker region of SAHA. C2-modififed SAHA analogs were
generated by Dr. Anton Bieliauskas. Herein, isoforms selectivity assessment, and in
cellulo testing of the C2-SAHA analogs were performed. Several of the C2-modified
SAHA analogs displayed selectivity for HDAC6 and HDAC8 over HDAC1, 2, and 3.
C2-n-hexyl SAHA analog 1i, showed the highest selectivity with 49- to 300-fold
selectivity for HDAC6 and 8 over HDAC1, 2, and 3. Enantioselective syntheses of
both the (R) and (S) enantiomers of C2-n-hexyl SAHA were performed, and both
enantiomers exhibited similar potency and selectivity to the racemic C2-n-hexyl
SAHA 1i.
In addition, several other SAHA derivatives substituted at the C4 and C5
positions of the linker region were synthesized and screened. The C4-SAHA analogs
showed up to 1300-fold dual selectivity for HDAC6 and HDAC8 over HDAC1,
HDAC2, and HDAC3. C4-benzyl SAHA 19f, was the best analogs, which showed
the highest fold selectivity with 210- to 740-fold selectivity for HDAC6 and 8
compared to HDAC1, 2, and 3, and 140 and 57 nM IC 50 with HDAC6 and HDAC8. In
cellulo testing of the C4-benzyl SAHA analog showed consistent isoform selectivity
with the in vitro screening. Both enantiomers of the C4-benzyl SAHA were
synthesized via enantioselective syntheses. In vitro screening of the pure
enantiomers revealed that (R)-C4-benzyl SAHA is more potent and selective than
the (S) enantiomer, with 48 and 27 nM IC50 with HDAC6 and HDAC8, and 520- to
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1300-fold selectivity for HDAC6 and 8 over HDAC1, 2, and 3. In addition, C5modified SAHA analogs also displayed dual HDAC6/8 selectivity. The best analog,
C5-benzyl SAHA, showed much lower selectivity (8- to 21-fold selectivity) compared
to the C4-benzyl SAHA. The potency (IC50 values of 270 and 380 nM with HDAC6
and 8, respectively) was also lower compared to the C4-benzyl SAHA.
In terms of structure activity relationship (SAR), the position of the
modification is critical and can greatly affect both potency and selectivity of the
inhibitors. In the C2-modified SAHA analogs, high fold selectivities were observed
(up to 300-fold) to HDAC6 and 8, but with micromolar to submicromolar IC 50 values
(0.6 to 2 µM). Modifications at the C4 position of the linker gave analogs with higher
fold selectivity (up to 1300-fold) to HDAC6 and 8, and the potency was enhanced as
well (48 and 27 nM IC50 values with HDAC6 and 8, respectively) compared to the
C2-modified SAHA analogs. On the other hand, moving the same modification
farther to the C5- position of the linker (C5-benzyl SAHA) resulted in reduction in
both selectivity (8- to 12-fold only), and potency (270 and 380 nM IC50 values with
HDAC6 and 8) compared to the C4-benzyl SAHA.
Docking studies were done for the (R)- and (S)-C2-n-hexyl SAHA, and (R)and (S)-C4-benzyl SAHA, and showed that the presence of the hexyl or benzyl
groups at the C2 or C4 positions in the linker region led to the dual HDAC6/HDAC8
selectivity over HDAC1, 2, and 3 due to steric clash between the substituents and
the active site entrances of HDAC1, 2, and 3.
In another project, several biaryl indolyl benzamide derivatives were
designed, synthesized, and screened as possible HDAC1-selective inhibitors. Bnz-3
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showed the highest potency compared to Bnz-1 and Bnz-2. Bnz-3 displayed about
10-fold higher potency than Bnz-2, and about 100-fold higher potency than Bnz-1.
Bnz-3 exhibited a modest inhibitory potency with HDAC1 (548 nM), but only 7.3-fold
selectivity for HDAC1 over HDAC2.
This thesis, along with previous reports103-105, indicate that modifying SAHA in
the linker region can alter the selectivity of HDAC inhibitors, and suggest that
modifying current drugs can significantly improve their properties. The dual
HDAC6/8 selective inhibitors reported in this work can be used as biological tools to
study both HDAC6 and HDAC8-related cancer biology, and as leads for
development of more effective anti-cancer agents targeting both HDAC6 and
HDAC8.
The first future direction in this work is to test the (R)-C4-benzyl SAHA analog (R)19f in mouse studies in a collaboration work with Dr. Ge at Karmanos Cancer
institute. A second future direction is based on the unique dual HDAC6/8 selectivity
that was observed upon substituting the C4 in the linker of SAHA, in which HDAC
substrate bearing the benzyl group in its linker region will be synthesized and tested
for isoform selectivity. Isoform selective HDAC substrate can be used for PET
imaging, to monitor levels of HDAC isoforms in different types of tumors (like brain
tumors) in order to monitor treatment effectiveness and disease progression in a
collaboration with Dr. Gelovani at college of engineering, Wayne State University.
Finally, to develop highly selective HDAC1 selective inhibitors, several analogs of
Cpd-60 and other HDAC1/2 selective inhibitors will be designed and synthesized
based on computer aided design. The design will be done by modifying chemical
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structures of the HDAC1/2 selective inhibitors and then docking of the modified
structures in the crystal structures of HDAC1 and HDAC2 using LeadIt program. The
best hits that show selectivity to HDAC1 over HDAC2 will be synthesized and
screened in vitro for isoform selectivity.
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APPENDIX A
A.1. Compound characterization data of (R) and (S)-C2-n-hexyl SAHA (1i)

Figure A.1. 1H NMR spectrum of (S)-9.

Figure A.2. 13C NMR spectrum of (S)-9.
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`
Figure A.3. Low resolution mass spectrum of (S)-9.

Figure A.4. 1H NMR spectrum of (R)-9.
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Figure A.5. 13C NMR spectrum of (R)-9.

Figure A.6. Low resolution mass spectrum of (R)-9.
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Figure A.7. 1H NMR spectrum of (S)-10.

Figure A.8. 13C NMR spectrum of (S)-10.
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`
Figure A.9. Low resolution mass spectrum of (S)-10.

Figure A.10. 1H NMR spectrum of (R)-10.
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Figure A.11. 13C NMR spectrum of (R)-10.

Figure A.12. Low resolution mass spectrum of (R)-10.
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Figure A.13. 1H NMR spectrum of (R)-11.

Figure A.14. 13C NMR spectrum of (R)-11.
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Figure A.15. Low resolution mass spectrum of (R)-11.

Figure A.16. Low resolution mass spectrum of (R)-11.
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Figure A.17. 1H NMR spectrum of (S)-11.

Figure A.18. 13C NMR spectrum of (S)-11.
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Figure A.19. Low resolution mass spectrum of (S)-11.

Figure A.20. 1H NMR spectrum of R-C2-n-hexyl SAHA (R)-1i.
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Figure A.21. 13C NMR spectrum of R-C2-n-hexyl SAHA (R)-1i.

Figure A.22. High resolution mass spectrum of (R)-C2-n-hexyl SAHA (R)-1i.
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Figure A.23. 1H NMR spectrum of (S)-C2-n-hexyl SAHA (S)-1i.

Figure A.24. 13C NMR spectrum of (S)-C2-n-hexyl SAHA (S)-1i.
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Figure A.25. High resolution mass spectrum of (S)-C2-n-hexyl SAHA (S)-1i.

Figure A.26. Chiral HPLC spectrum taken at 254 nm of the C2-n-hexyl SAHA (1i) as
a racemic mixture. The spectrum shows peaks for both the R and the S
enantiomers. The calculated area and height under each peak, along with % area, is
shown in the table below the spectrum.
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Figure A.27. Chiral HPLC spectrum taken at 254 nm of the (R)-C2-n-hexyl SAHA
(R)-1i. The major peak (at 36.5 min) represents the R enantiomer, while the minor
peak (at 30.2 min) represents the S enantiomer. The calculated area and height
under each peak, along with % area, is shown in the table below the spectrum.

Figure A.28. Chiral HPLC spectrum taken at 254 nm of the (S)-C2-n-hexyl SAHA
(S-1i). The major peak (at 29.3 min) represents the S enantiomer, while the minor
peak (at 38.6 min) represents the R enantiomer. The calculated area and height
under each peak, along with % area, is shown in the table below the spectrum.
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A.2. In vitro HDAC activity screening data
Table A.1. Percent remaining deacetylase activity after incubation of a single
concentration of SAHA and each C2-modified SAHA analog with HDAC1, HDAC2,
HDAC3, and HDAC6 using the ELISA-based activity assay.a
Deacetylase activity (%)
compound

HDAC1

HDAC2

HDAC3

HDAC6

SAHA93

8.9±0.1

8.3±0.2

14±3

7.9±1.6

1a (methyl)

62±8

78±3

96±4

55±6

1b (ethyl)

76±5

65±6

88±5

52±6

1c (propyl)

75±4

69±1

86±7

49±5

1d (butyl)

69±8

82±4

78±6

39±4

1e (allyl)

83±6

78±3

90±3

52±7

1f (propargyl)

90±7

91±2

99±3

62±7

1g (benzyl)

92±4

99±1

92±8

30±6

1h (pentyl)

89±1

99±2

95±4

21±5

1i (hexyl)
91±4
98±1
100±3
26±2
The means and standard errors for a minimum of three independent trials are
shown. All analogs were used at 5M final concentration, except SAHA and C2-butyl
(1d) which were tested at 1µM and 10µM respectively. This data is associated with
Figure 2.3.
a
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Figure A.29. Dose dependent curve of SAHA with HDAC8 isoform with error bars
depicting the standard error of at three independent trials. In some cases, the error
bars are smaller than the size of the filled circle. IC50 values associated with Table
2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3
(Synergy Software) (Table A.2).

Table A.2. Percentage remaining deacetylase activity after incubation of SAHA with
HDAC8.a
Concentration (M)
-6

3.2 x 10
1.6 x 10-6
8.0 x 10-7
4.0 x 10-7
2.0 x 10-7
1.0 x 10-7
a

Deacetylase activity (%)
111
231
382
603
742
863

Means and standard errors of at three independent trials with the SAHA
concentrations shown. Data is associated with Figure A.29 and Table 2.2.
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Figure A.30. Dose dependent curve of tubastatin with HDAC8 isoform with error
bars depicting the standard error of at three independent trials. In some cases, the
error bars are smaller than the size of the filled circle. IC 50 values associated with
Table 2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table A.3).

Table A.3. Percentage remaining deacetylase activity after incubation of tubastatin
with HDAC8.a

a

Concentration (M)

Deacetylase activity (%)

2.0 x 10-6
1.0 x 10-6
5.0 x 10-7
2.5 x 10-7
1.25 x 10-7
6.25 x 10-8

152
252
402
581
733
824

Means and standard errors of at three independent trials with the tubastatin
concentrations shown. Data is associated with Figure A.30 and Table 2.2.
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Figure A.31. Dose dependent curves of C2-benzyl SAHA analog (1g) with HDAC1,
HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting the
standard error of at least two independent trials. IC50 values associated with Table
2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3
(Synergy Software) (Table A.4).
Table A.4. Percentage remaining deacetylase activity after incubation of C2-benzyl
SAHA (1g) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Deacetylase activity (%)
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
-4
4.0 x 10
131
171
112
-4
2.0 x 10
312
302
273
1.0 x 10-4
416
551
502
5.0 x 10-5
661
741
682
-5
2.5 x 10
813
843
827
-6
4.0 x 10
252
217
-6
2.0 x 10
373
503
-6
1.0 x 10
544
646
-7
5.0 x 10
696
731
-7
2.5 x 10
845
809
a
Means and standard errors of at least two independent trials with the C2-benzyl
SAHA (1g) concentrations shown. Data is associated with Figure A.31 and Table
2.2.
Concentration
(M)
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Figure A.32. Dose dependent curves of C2-n-pentyl SAHA analog (1h) with
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting
the standard error of at least two independent trials. IC50 values associated with
Table 2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table A.5).
Table A.5. Percentage remaining deacetylase activity after incubation of C2-n-pentyl
SAHA (1h) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Concentration
(M)
-4

HDAC1
211
381
564
711
833

Deacetylase Activity (%)
HDAC2
HDAC3
HDAC6
261
193
441
362
593
503
741
714
841
836

HDAC8

1.6 x 10
8.0 x 10-5
4.0 x 10-5
2.0 x 10-5
1.0 x 10-5
8.0 x 10-6
172
-6
4.0 x 10
185
261
2.0 x 10-6
314
413
1.0 x 10-6
424
552
-7
5.0 x 10
646
711
-7
2.5 x 10
781
a
Means and standard errors of at least two independent trials with the C2-n-pentyl
SAHA (1h) concentrations shown. Data is associated with Figure A.32 and Table
2.2.
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Figure A.33. Dose dependent curves of C2-n-hexyl SAHA derivative (1i) with
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting
the standard error of at least two independent trials. IC50 values associated with
Table 2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table A.6).
Table A.6. Percentage of remaining HDAC deacetylase activity after incubation of
C2-n-hexyl SAHA derivative (1i) HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Concentration
(M)
-4

Deacetylase Activity (%)
HDAC1

HDAC2

6.4 x 10
322
353
-4
3.2 x 10
398
431
1.6 x 10-4
523
555
-5
8.0 x 10
603
612
-5
4.0 x 10
774
617
-6
8.0 x 10
4.0 x 10-6
2.0 x 10-6
1.0 x 10-6
5.0 x 10-7
2.5 x 10-7
a
Means and standard errors of at least two
associated with Figure A.33 and Table 2.2.

HDAC3

HDAC6

HDAC8

285
383
435
505
632
181
302
511
704
844

153
283
441
502
676
independent trials are shown. Data is
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Figure A.34. Dose dependent curves of (S)-C2-n-hexyl SAHA ((S)-1i) with HDAC1,
HDAC2, HDAC3, and HDAC8 isoforms with error bars depicting the standard error
of at least two independent trials. IC50 values associated with Table 2.2 were
determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3 (Synergy
Software) (Table A.7).
Table A.7. Percentage of remaining HDAC deacetylase activity after incubation of
(S)-C2-n-hexyl SAHA ((S)-1i) HDAC1, HDAC2, HDAC3, and HDAC8.a
Concentration
(M)

Deacetylase Activity (%)
HDAC1

HDAC2

HDAC3

HDAC8

1.28 x 10-3
205
241
304
-4
6.4 x 10
321
492
385
-4
3.2 x 10
561
683
684
1.6 x 10-4
675
862
822
8.0 x 10-5
752
911
9010
1.6 x 10-5
8.0 x 10-6
4.0 x 10-6
2.0 x 10-6
1.0 x 10-6
a
Means and standard errors of at least two independent trials
associated with Figure A.34 and Table 2.2.

154
262
434
602
786
are shown. Data is
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Figure A.35. Dose dependent curves of (R)-C2-n-hexyl SAHA derivative ((S)-1i)
with HDAC8 isoform with error bars depicting the standard error of at least two
independent trials. IC50 values associated with Table 2.2 were determined by fitting
data to a sigmoidal curve using KaleidaGraph 4.1.3 (Synergy Software) (Table A.8).
Table A.8. Percentage of remaining HDAC deacetylase activity after incubation of
(R)-C2-n-hexyl SAHA and HDAC8.a
Concentration
(M)
-6

Deacetylase Activity (%)
HDAC8

8.0 x 10
3.73.5
4.0 x 10-6
114
-6
2.0 x 10
241
-6
1.0 x 10
506
-7
5.0 x 10
635
2.5 x 10-7
728
1.25 x 10-7
7612
a
Means and standard errors of at least two independent trials are shown. Data is
associated with Figure A.35 and Table 2.2.
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A.3. In cellulo selectivity data
A

B
SAHA Tuba DMSO
2
2

1g
(Bn)
30

1h
1i
(Pen) (Hex)
30
30 µM

Tuba DMSO
5

C2-benzyl SAHA
30
50
60

C2-pentyl SAHA
30
50
60 µM

AcH3

AcH3

AcTub

AcTub

GAPDH

GAPDH

C
Tuba DMSO
2

C2-benzyl SAHA
30
50
60

C2-pentyl SAHA
30
50
60 µM

AcH3

AcTub
GAPDH

Figure A.36. Representative cell-based selectivity trials with SAHA, tubastatin and
SAHA analogs. U937 cells were treated with DMSO (1%), SAHA, C2-benzyl SAHA
(1g), C2-n-pentyl SAHA (1h), C2-n-hexyl SAHA (1i). After lysis and SDS-PAGE
separation of the proteins in the lysates, western blots analysis of acetyl-histone H3
(AcH3) and acetyl-α-tubulin (AcTub) was performed. GAPDH was used as a loading
control. DMSO was used as the no inhibitor control. These three trials (parts A-C)
are associated with the fourth trial shown in Figure 2.4a.
Table A.9. Fold increase in acetyl-histone H3 and acetyl-tubulin at 30 µM of SAHA
analogs 1g, 1i, and 1h, compared to DMSO treated cells for the western blots
images in figures 2.4a and A.36.a

Compound
1g (benzyl)
1i (pentyl)

Acetyl-histone H3
Mean fold
Standard
increase
error
0.99
0.32
1.6

0.84

Acetyl-tubulin
Mean fold
Standard
increase
error
5.0
0.80
7.5

3.2

1h (hexyl)
1.3
0.44
3.9
0.53
Means and standard errors of four independent trials are shown. Data is
associated with Figures 2.4a, A.36 and A.37.
a
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AcTub
GAPDH

A
DMSO

5

10

1i (Hex)
20
30

B
c
40

DMSO 10

50 µM

20

1i (Hex)
30
40 50

60 µM
AcH3

AcH3

1

2

3

4

5

6

7

AcTub

AcTub

GAPDH

GAPDH
1

2

3

4

5

6

AcH3 Fold increa

AcH3

AcTub Fold increase

DMSO SAHA Tuba (Bn) (Pen) (Hex)

7

Figure A.37. Repetitive cell-based selectivity trials with C2-n-hexyl SAHA analog
(1i). U937 cells were treated with increasing concentrations of C2-n-hexyl SAHA
analog (1i, 10-60 µM or 5-50 µM). After lysis and SDS-PAGE separation of the
proteins in the lysates, western blot analysis of acetyl-histone H3 (AcH3) and acetylα-tubulin (AcTub) was performed. GAPDH was used as a loading control. DMSO
was used as the no inhibitor control. These two trials (parts a and b) are associated
with the third trial shown in Figure 2.4b.
A.4. Cell growth inhibition data
Table A.10. Percentage of viable cells after treatment of Jurkat cell line with of C2benzyl SAHA 1g, C2-pentyl SAHA 1h, C2-hexyl SAHA 1i, and SAHA.a
Viable cells (%)
Compound

1 µM

10 µM

1g (benzyl)

100 ± 8

83 ± 2

1h (pentyl)

80 ± 13

92 ± 8

1i (hexyl)

88 ± 11

47 ± 9

SAHA
49 ± 6
5±3
Means and standard errors for a minimum of three independent trials are shown.
All analogs were tested at 1 and 10M final concentrations. Data is associated with
Figure 2.5.
a

10
8
6
4
2
0
12
10
8
6
4
2
0
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Figure A.38. Dose dependent cell viability of SAHA with Jurkat, AML MOLM-13, and
U937 cell lines, with error bars depicting the standard error of at least three
independent trials. EC50 values associated with Table 2.3 were determined by fitting
data to a sigmoidal curve using KaleidaGraph 4.1.3 (Synergy Software) (Table
A.11).
Table A.11. Percentage of viable cells after treatment of different cell lines with
SAHA at the specified concentrations.a

Concentration (M)
-6

4.0 x 10
2.0 x 10-6
1.0 x 10-6
5.0 x 10-7
2.5 x 10-7
1.25 x 10-7
a

Jurkat
12  1
18  4
53  5
59  9
70  11

Viable cells (%)
AML-MOL13
91
24  2
60  6
88  3
103  10

U937
22  3
24  6
43  23
75  11
76  4
83  11

Standard errors of at least three independent trials are shown. Data is associated
with Figure A.38 and Table 2.3.
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Figure A.39. Dose dependent cell viability of C2-n-hexyl SAHA (1i) with Jurkat, AML
MOLM-13, and U937 cell lines, with error bars depicting the standard error of more
than three independent trials. EC50 values associated with Table 2.3 were
determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3 (Synergy
Software) (Table A.12).
Table A.12. Percentage of viable cells after treatment of different cell lines with of
C2-n-hexyl SAHA (1i) at the specified concentrations.a

Concentration (M)

Viable cells (%)
Jurkat

AML-MOL13

U937
14  3

6.4 x 10-5
3.2 x 10-5

30  2

11  1

19  3

1.6 x 10-5

41  2

54  3

30  1

8.0 x 10-6

52  6

64  5

98  10

4.0 x 10-6

83  10

64  4

94  20

2.0 x 10-6

83  5

84  3

98  10

1.0 x 10
108  5
80  11
Means and standard errors of at least three independent trials are shown. Data is
associated with Figure A.39 and Table 2.3.
-6

a
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APPENDIX B
B.1. Compound characterization of the C4-modified SAHA analogs

Figure B.1. 1HNMR spectrum of 16b in CD3OD.

Figure B.2. 13CNMR spectrum of 16b in CD3OD.

187

Figure B.3. IR spectrum of 16b using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.4. Low resolution mass spectrum of 16b.
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Figure B.5. 1HNMR spectrum of 16c in CD3OD.

Figure B.6. 13CNMR spectrum of 16c in CD3OD.
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Figure B.7. IR spectrum of 16c using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.8. Low resolution mass spectrum of 16c.
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Figure B.9. 1HNMR spectrum of 16e in CDCl3.

Figure B.10. 13CNMR spectrum of 16e in CDCl3.
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Figure B.11. IR spectrum of 16e using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.12. Low resolution mass spectrum of 16e.
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Figure B.13. 1HNMR spectrum of 17b in CDCl3.

Figure B.14. 13CNMR spectrum of 17b in CDCl3.
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Figure B.15. IR spectrum of 17b using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.16. Low resolution mass spectrum of 17b.
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Figure B.17. 1HNMR spectrum of 17e in CD3OD.

Figure B.18. 13CNMR spectrum of 17e in CDCl3.
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Figure B.19. IR spectrum of 17e using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.20. Low resolution mass spectrum of 17e.
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Figure B.21. 1HNMR spectrum of 18a in CD3OD.

Figure B.22. 13CNMR spectrum of 18a.
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Figure B.23. IR spectrum of 18a using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.24. Low resolution mass spectrum of 18a.
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Figure B.25. 1HNMR spectrum of 18b in CD3OD.

Figure B.26 13CNMR spectrum of 18b in CD3OD.
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Figure B.27. IR spectrum of 18b using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.28. Low resolution mass spectrum of 18b.
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Figure B.29. 1HNMR spectrum of 18c in CD3OD.

Figure B.30. 13CNMR spectrum of 18c in CD3OD.
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Figure B.31. IR spectrum of 18c using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.32. Low resolution mass spectrum of 18c.
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Figure B.33. 1HNMR spectrum of 18d in CD3OD.

Figure B.34. 13CNMR spectrum of 18d in CD3OD.
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348.26

Figure B.35. Low resolution mass spectrum of 18d.

Figure B.36. 1HNMR spectrum of 18e in CD3OD.
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Figure B.37. 13CNMR spectrum of 18e in CD3OD.

Figure B.38. IR spectrum of 18e using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure B.39. Low resolution mass spectrum of 18e.

Figure B.40. 1HNMR spectrum of 18f in CD3OD.
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Figure B.41. 13CNMR spectrum of 18f in CD3OD.

Figure B.42. IR spectrum of 18f using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure B.43. Low resolution mass spectrum of 18f.

Figure B.44. 1HNMR spectrum of 19a in CD3OD.
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Figure B.45. 13CNMR spectrum of 19a in CD3OD.

Figure B.46. IR spectrum of 19a using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure B.47. High resolution mass spectrum of 19a.

Figure B.48. HPLC spectrum taken at 254 nm of C4-methyl SAHA (19a). The peak
at 13.676 is C4-methyl SAHA. The calculated area and height under each peak,
along with % area, is shown in the table below the spectrum.
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Figure B.49. 1HNMR spectrum of 19b in CD3OD.

Figure B.50. 13CNMR spectrum of 19b in CD3OD.
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Figure B.51. IR spectrum of 19b using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.52. High resolution mass spectrum of 19b.
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Figure B.53. HPLC spectrum taken at 254 nm of C4-ethyl SAHA (19b). The peak at
16.388 is C4-ethyl SAHA. The calculated area and height under each peak, along
with % area, is shown in the table below the spectrum.

Figure B.54. 1HNMR spectrum of 19c in CD3OD.
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Figure B.55. 13CNMR spectrum of 19c in CD3OD.

Figure B.56. IR spectrum of 19c using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure B.57. High resolution mass spectrum of 19c.

Figure B.58. HPLC spectrum taken at 254 nm of C4-n-butyl SAHA (19c). The peak
at 20.128 is C4-n-butyl SAHA. The calculated area and height under each peak,
along with % area, is shown in the table below the spectrum.
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Figure B.59. 1HNMR spectrum of 19d in CD3OD.

Figure B.60. 13CNMR spectrum of 19d in CD3OD.
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Figure B.61. IR spectrum of 19d using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.62. High resolution mass spectrum of 19d.
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Figure B.63. HPLC spectrum taken at 254 nm of C4-n-hexyl SAHA (19d). The peak
at 22.624 is C4-n-hexyl SAHA. The calculated area and height under each peak,
along with % area, is shown in the table below the spectrum.

Figure B.64. 1HNMR spectrum of 19e in CD3OD.
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Figure B.65. 13CNMR spectrum of 19e in CD3OD.

Figure B.66. IR spectrum of 19e using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure B.67. High resolution mass spectrum of 19e.

Figure B.68. HPLC spectrum taken at 254 nm of C4-phenyl SAHA (19e). The peak
at 19.398 is C4-phenyl SAHA. The calculated area and height under each peak,
along with % area, is shown in the table below the spectrum.
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Figure B.69. 1HNMR spectrum of 19f in CD3OD.

Figure B.70. 13CNMR spectrum of 19f in CD3OD.
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Figure B.71. IR spectrum of 19f using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure B.72. High resolution mass spectrum of 19f.
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Figure B.73. HPLC spectrum taken at 254 nm of C4-benzyl SAHA (19f). The peak
at 18.119 is C4-benzyl SAHA. The calculated area and height under each peak,
along with % area, is shown in the table below the spectrum.

Figure B.74. 1HNMR spectrum of (R)-20 in CDCl3.
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Figure B.75. 13CNMR spectrum of (R)-20 in CDCl3.

Figure B.76. Low resolution mass spectrum of (R)-20.
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Figure B.77. 1HNMR spectrum of (RS)-21 in CDCl3.

Figure B.78. Enlarged 1HNMR spectrum of (RS)-21 showing a peak of the major
diastereomer at 4.05 (overlapping with another peak) and a peak of the minor
diastereomer (RR)-21 at 3.82. Integration of these two peaks (2.00 and 0.02) was
used to calculate the diastereomeric ratio (dr) discussed in the text (99:1 dr).

225

Figure B.79. 13CNMR spectrum of (RS)-21 in CDCl3.

Figure B.80. Low resolution mass spectrum of (RS)-21.
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Figure B.81. 1HNMR spectrum of (R)-23 in CDCl3.

Figure B.82. 13CNMR spectrum of (R)-23 in CDCl3.
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Figure B.83. Low resolution mass spectrum of (R)-23.

Figure B.84. 1HNMR spectrum of (RR)-21 in CDCl3.
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Figure B.85. Enlarged 1HNMR spectrum of (RR)-21 showing a peak of the major
diastereomer at 4.45 and a peak of the minor diastereomer (RS)-21 at 4.63.
Integration of these two peaks (0.99 and 0.03) was used to calculate the
diastereomeric ratio (dr) discussed in the text (97:3 dr).

Figure B.86. 13CNMR spectrum of (RR)-21 in CDCl3.

229

Figure B.87. Low resolution mass spectrum of (RR)-21.

Figure B.88. 1HNMR spectrum of (S)-22 in CDCl3.
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Figure B.89. 13CNMR spectrum of (S)-22 in CDCl3.

Figure B.90. 1HNMR spectrum of (R)-22 in CDCl3.
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Figure B.91. 13CNMR spectrum of (R)-22 in CDCl3.
B.2. Synthesis scheme for Mosher's esters
Scheme B.1: Synthesis of Mosher's esters (S)-22-(R)-MTPA and (R)-22-(R)-MTPA
discussed in Chapter 3
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Figure B.92. 1HNMR spectrum of (S)-22-(R)-MTPA in CDCl3.

Figure B.93. Enlarged 1HNMR spectrum of (S)-22-(R)-MTPA showing a singlet peak
of the major diastereomer at 3.491, and another singlet peak of the minor
diastereomer (R)-22-(R)-MTPA at 3.481. Integration of these two peaks (100.00 and
1.42) was used to calculate the diastereomeric ratio (dr) discussed in the text (99:1
dr).
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Figure B.94. Enlarged 1HNMR spectrum of (S)-22-(R)-MTPA showing a doublet
peak of the major diastereomer at 6.961 and 6.973, and another doublet peak of the
minor diastereomer (R)-22-(R)-MTPA at 7.003 and 7.015. Integration of these two
peaks (100.00 and 1.14) was used to calculate the diastereomeric ratio (dr)
discussed in the text (99:1 dr).

Figure B.95. 13CNMR spectrum of (S)-22-(R)-MTPA in CDCl3.
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Figure B.96. 19FNMR spectrum of (S)-22-(R)-MTPA in CDCl3.

Figure B.97. Low resolution mass spectrum of (S)-22-(R)-MTPA.
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Figure B.98. 1HNMR spectrum of (R)-22-(R)-MTPA in CDCl3.

Figure B.99. Enlarged 1HNMR spectrum of (R)-22-(R)-MTPA showing a doublet
doublet peaks of the major diastereomer at 4.004-4.029 and another doublet doublet
peak of the minor diastereomer (S)-22-(R)-MTPA at 4.107-4.133. Integration of
these two peaks (100.06 and 2.07) was used to calculate the diastereomeric ratio
(dr) discussed in the text (98:2 dr).
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Figure B.100. Enlarged 1HNMR spectrum of (R)-22-(R)-MTPA showing a doublet
peak of the major diastereomer at 7.004 and 7.016, and another doublet peak of the
minor diastereomer (S)-22-(R)-MTPA at 6.962 and 6.974. Integration of these two
peaks (100.00 and 2.53) was used to calculate the diastereomeric ratio (dr)
discussed in the text (98:2 dr).

Figure B.101. 13CNMR spectrum of (R)-22-(R)-MTPA in CDCl3.
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Figure B.102. 19FNMR spectrum of (R)-22-(R)-MTPA in CDCl3.

Figure B.103. Low resolution mass spectrum of (R)-22-(R)-MTPA.
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Figure B.104. 1HNMR spectrum of (R)-24 in CDCl3.

Figure B.105. 13CNMR spectrum of (R)-24 in CDCl3.
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Figure B.106. IR spectrum of (R)-24.

Figure B.107. Low resolution mass spectrum of (R)-24.
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Figure B.108. 1HNMR spectrum of (S)-24 in CDCl3.

Figure B.109. 13CNMR spectrum of (S)-24 in CDCl3.
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Figure B.110. IR spectrum of (S)-24.

Figure B.111. Low resolution mass spectrum of (S)-24.
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Figure B.112. 1HNMR spectrum of (S)-25 in CDCl3.

Figure B.113. 13CNMR spectrum of (S)-25 in CDCl3.
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Figure B.114. IR spectrum of (S)-25.

Figure B.115. Low resolution mass spectrum of (S)-25.
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Figure B.116. 1HNMR spectrum of (R)-25 in CDCl3.

Figure B.117. 13CNMR spectrum of (R)-25 in CDCl3.
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Figure B.118. IR spectrum of (R)-25.

Figure B.119. Low resolution mass spectrum of (R)-25.
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Figure B.120. 1HNMR spectrum of 26 in CDCl3.

Figure B.121. 13CNMR spectrum of 26 in CDCl3.
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Figure B.122. 1HNMR spectrum of (S)-27 in CDCl3.

Figure B.123. 13CNMR spectrum of (S)-27 in CDCl3.
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Figure B.124. IR spectrum of (S)-27.

Figure B.125. Low resolution mass spectrum of (S)-27.
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Figure B.126. 1HNMR spectrum of (R)-27 in CDCl3.

Figure B.127. 13CNMR spectrum of (R)-27 in CDCl3.
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Figure B.128. IR spectrum of (R)-27.

Figure B.129. Low resolution mass spectrum of (R)-27.
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Figure B.130. 1HNMR spectrum of (R)-19f in CD3OD.

Figure B.131. 13CNMR spectrum of (R)-19f in CD3OD.
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Figure B.132. IR spectrum of (R)-1f.

Figure B.133. High resolution mass spectrum of (R)-19f.
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Figure B.134. HPLC spectrum taken at 254 nm of R-C4-benzyl SAHA ((R)-19f). The
peak at 18.465 is R-C4-benzyl SAHA. The calculated area and height under each
peak, along with % area, is shown in the table below the spectrum.

Figure B.135. 1HNMR spectrum of (S)-19f in CD3OD.
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Figure B.136. 13CNMR spectrum of (S)-19f in CD3OD.

Figure B.137. IR spectrum of (S)-1f.
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Figure B.138. High resolution mass spectrum of (S)-19f.

Figure B.139. HPLC spectrum taken at 254 nm of R-C4-benzyl SAHA ((S)-19f). The
peak at 18.240 is R-C4-benzyl SAHA. The calculated area and height under each
peak, along with % area, is shown in the table below the spectrum.
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B.3. In vitro screening with HDAC isoforms tables and figures

Figure B.140. Dose response curve of SAHA and C4-SAHA analogs 19a-f tested
using the HDAC activity in HeLa cells lysates from three independent trials with error
bars indicating standard error (see Table S1). In some cases, the error bar is smaller
than the marker size. Data were fit to the sigmoidal curve using KaleidaGraph 4.1.3
(Synergy Software) to determine the IC50. The data are reported in Table 3.1.
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Table B.1. Percent remaining HDAC activity after incubation of SAHA or C4-SAHA
analogs 19a-f with HeLa Lysates
Deacetylase activity (%)
Concentration
SAHA
19a
19b
19c
19d
19e
19f
(M)
2.0 x 10-4
21±3
15±1
19±2
-4
1.0 x 10
35±3
32±1
35±5
-4
1.2 x 10
24±1
-5
6.0 x 10
44±4
-5
5.0 x 10
56±2
57±2
58±4
-5
12±1
4.8 x 10
-5
3.0 x 10
69±2
-5
2.5 x 10
73±2
88±1
74±5
-5
31±2
2.4 x 10
-5
1.5 x 10
88±1
-5
1.25 x 10
87±1
104±1
88±4
-5
53±3
1.2 x 10
-5
1.0 x 10
17±2
-6
7.5 x 10
97±2
-6
6.0 x 10
82±7
-6
5.0 x 10
38±4
-6
3.0 x 10
92±1
-6
2.5 x 10
60±3
-6
1.25 x 10
79±3
-6
6.25 x 10
91±2
-7
2.0 x 10
49±1
-7
1.0 x 10
78±4
-8
5.0 x 10
86±4
-8
2.5 x 10
97±1
a
Mean percentage deacetylase activity and standard error of three trials are shown.
This data is associated with Figure B.131 and Table 3.1.
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Table B.2. Percent remaining deacetylase activity after incubation of a single
concentration of each C4-modified SAHA analog with HDAC1, HDAC2, HDAC3, and
HDAC6 using the ELISA-based activity assay.a
Deacetylase activity (%)

a

Compound

HDAC1

HDAC2

HDAC3

HDAC6

SAHA93 1 µM

8.9±0.1

8.3±0.2

14±3

7.9±1.6

19a (methyl) 0.75 µM

75±2

90±7

78±4

26±5

19b (ethyl) 0.75 µM

91±2

87±1

71±10

18±6

19c (butyl) 2.5 µM

88±2

87±1

85±2

5±3

19d (hexyl) 1.25 µM

97±3

101±2

100±6

21±2

19e (phenyl) 2.5 µM

86±1

85±3

85±5

17±7

19f (benzyl) 5 µM

87±4

92±4

90±3

2.9±0.5

The means and standard errors for a minimum of two independent trials are
shown. This data is associated with Figure 3.2.

259

Figure B.141. Dose dependent curves of C4-ethyl SAHA analog (19b) with HDAC1,
HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting the
standard error of at least three independent trials. IC50 values associated with Table
3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3
(Synergy Software) (Table B.3).
Table B.3. Percentage remaining deacetylase activity after incubation of C4-ethyl
SAHA analog (19b) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Deacetylase activity (%)
Concentration
(M)
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
-5
1.6 x 10
191
232
178
-6
8.0 x 10
324
347
526
-6
4.0 x 10
581
592
642
-6
2.0 x 10
685
691
714
-6
1.0 x 10
813
862
837
-7
4.0 x 10
333
251
-7
2.0 x 10
435
391
1.0 x 10-7
616
552
5.0 x 10-8
747
732
-8
2.5 x 10
808
832
a
Means and standard errors of at least three independent trials with the C4-ethyl
SAHA (19b) concentrations shown. Data is associated with Figure B.132 and Table
3.2.
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Figure B.142. Dose dependent curves of C4-butyl SAHA analog (19c) with HDAC1,
HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting the
standard error of at least three independent trials. IC50 values associated with Table
3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3
(Synergy Software) (Table B.4).
Table B.4. Percentage remaining deacetylase activity after incubation of C4-butyl
SAHA analog (19c) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Deacetylase activity (%)
Concentration (M)
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
-5
5.6 x 10
191
1810
255
-5
2.8 x 10
351
432
485
-5
1.4 x 10
533
571
642
-6
7.0 x 10
672
712
793
-6
3.5 x 10
811
815
793
-7
4.0 x 10
233
-7
2.0 x 10
395
284
-7
1.0 x 10
469
415
-8
5.0 x 10
616
617
2.5 x 10-8
706
743
1.25 x 10-8
841
a
Means and standard errors of at least three independent trials with the C4-butyl
SAHA (19c) concentrations shown. Data is associated with Figure B.133 and Table
3.2.

261

Figure B.143. Dose dependent curves of C4-n-hexyl SAHA analog (19d) HDAC1,
HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting the
standard error of at least three independent trials. IC50 values associated with Table
3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3
(Synergy Software) (Table B.5).
Table B.5. Percentage remaining deacetylase activity after incubation of C4-n-hexyl
SAHA analog (19d) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Deacetylase activity (%)
Concentration (M)
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
-4
1.6 x 10
131
161
53
-5
8.0 x 10
262
312
251
-5
4.0 x 10
461
466
425
-5
2.0 x 10
674
732
564
-5
1.0 x 10
834
796
882
-7
4.0 x 10
272
-7
2.0 x 10
424
272
-7
1.0 x 10
564
424
5.0 x 10-8
756
634
2.5 x 10-8
779
786
-8
1.25 x 10
921
a
Means and standard errors of at least three independent trials with the C4-n-hexyl
SAHA (19d) concentrations shown. Data is associated with Figure B.134 and Table
3.2.
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Figure B.144. Dose dependent curves of C4-phenyl SAHA analog (19e) with
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting
the standard error of at least three independent trials. IC 50 values associated with
Table 3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table B.6).
Table B.6. Percentage remaining deacetylase activity after incubation of C4-phenyl
SAHA analog (19e) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Deacetylase activity (%)
Concentration (M)
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
-5
4.8 x 10
191
222
302
-5
2.4 x 10
341
336
533
-5
1.2 x 10
532
531
643
6.0 x 10-6
635
682
745
3.0 x 10-6
742
723
884
-7
8.0 x 10
291
-7
4.0 x 10
327
487
-7
2.0 x 10
402
572
-7
1.0 x 10
525
693
-8
5.0 x 10
647
802
-8
2.5 x 10
713
a
Means and standard errors of at least three independent trials with the C4-phenyl
SAHA (19e) concentrations shown. Data is associated with Figure B.135 and Table
3.2.
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Figure B.145. Dose dependent curves of C4-benzyl SAHA analog (19f) with
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting
the standard error of at least three independent trials. IC50 values associated with
Table 3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table B.7).
Table B.7. Percentage remaining deacetylase activity after incubation of C4-benzyl
SAHA analog (19f) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Deacetylase activity (%)
Concentration (M)
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
-4
1.6 x 10
161
201
192
-5
8.0 x 10
272
275
332
-5
4.0 x 10
442
471
553
2.0 x 10-5
585
601
635
1.0 x 10-5
755
744
874
-7
4.0 x 10
184
-7
2.0 x 10
455
211
-7
1.0 x 10
604
342
-8
5.0 x 10
765
511
-8
2.5 x 10
907
732
-8
1.25 x 10
874
a

Means and standard errors of at least three independent trials with the C4-beznyl
SAHA (19f) concentrations shown. Data is associated with Figure B.136 and Table
3.2.
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Figure B.146. Dose dependent curves of (R)-C4-benzyl SAHA analog ((R)-19f) with
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting
the standard error of at least three independent trials. IC 50 values associated with
Table 3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table B.8).
Table B.8. Percentage remaining deacetylase activity after incubation of C4-benzyl
SAHA analog ((R)-19f) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Deacetylase activity (%)
Concentration (M)
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
-5
8.0 x 10
242
291
252
4.0 x 10-5
383
435
392
-5
2.0 x 10
536
714
544
-5
1.0 x 10
723
835
772
-6
5.0 x 10
884
961
892
-7
2.0 x 10
264
161
-7
1.0 x 10
376
221
-8
5.0 x 10
575
373
-8
2.5 x 10
598
564
-8
1.25 x 10
674
642
a

Means and standard errors of at least three independent trials with the (S)-C4beznyl SAHA ((R)-19f) concentrations shown. Data is associated with Figure B.137
and Table 3.2.
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Figure B.147. Dose dependent curves of (S)-C4-benzyl SAHA analog ((S)-19f) with
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting
the standard error of at least three independent trials. IC 50 values associated with
Table 3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table B.9).
Table B.9. Percentage remaining deacetylase activity after incubation of C4-benzyl
SAHA analog ((S)-19f) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a
Concentration (M)
-4

1.6 x 10
8.0 x 10-5
4.0 x 10-5
2.0 x 10-5
1.0 x 10-5
8.0 x 10-7
4.0 x 10-7
2.0 x 10-7
1.0 x 10-7
5.0 x 10-8
a

HDAC1
171
322
503
683
847

Deacetylase activity (%)
HDAC2
HDAC3
HDAC6
222
152
376
334
563
482
743
674
875
765
166
176
377
487
644

HDAC8

191
281
422
613
756

Means and standard errors of at least three independent trials with the (S)-C4beznyl SAHA ((S)-19f) concentrations shown. Data is associated with Figure B.138
and Table 3.2.
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Table B.10. Fold selectivity of SAHA, tubastatin, and C4-SAHA analogs 19b-19f for
HDAC6 and HDAC8 over HDAC1, 2, and 3.a
HDAC6 fold selectivity
HDAC8 fold selectivity
Compound
HDAC1 HDAC2 HDAC3 HDAC1 HDAC2 HDAC3
SAHA

1

3

0.6 b

0.06 c

0.2 c

0.04 c

Tubastatin

87

130

94

8.2

12

8.8

C4-ethyl SAHA 19b

28

31

38

34

38

46

C4-butyl SAHA 19c

170

200

260

200

240

310

C4-hexyl SAHA 19d

250

270

210

440

480

380

C4-phenyl SAHA 19e

100

350

210

38

130

79

C4-benzyl SAHA 19f

210

270

300

510

670

740

(S)-C4-benzyl SAHA
520
750
560
930
1300
1000
(S)-19f
(R)-C4-benzyl SAHA
420
540
390
260
330
240
(R)-19f
a
Fold selectivities were calculated from the IC50 values in tables 2 and 3. b SAHA
displayed 1.65-fold preference for HDAC3 versus HDAC6. c SAHA displayed 16-fold,
6-fold, and 27-fold preference for HDAC1, 2, and 3, respectively, over HDAC8
B.4. In cellulo selectivity testing figure
A)

B)

DMSO

C4-Benzyl SAHA
20

40

DMSO SAHA

60 µM

5

C4-Benzyl SAHA
10

20

30

40

50

60 µM

AcH3

1

2

3

4

AcH3

AcTub

AcTub

GAPDH

GAPDH
1

2

3

4

5

6

7

8

Figure B.148. Repetitive cell-based selectivity trials of the western blots analysis of
acetyl-α-tubulin (AcTub) after treatment with SAHA or the SAHA analogs. U937 cells
were treated with SAHA (5 µM), DMSO (1%), C4-benzyl SAHA (19f) analog before
lysis, SDS-PAGE separation, transfer to a PVDF membrane, and western blotted
with AcTub antibody. GAPDH levels in the samples were also probed as a gel load
control. A DMSO control sample was included for comparison to inhibitor treated
samples. These three trials are associated with the fourth trial shown in Figure 3.3.
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B.5. In vitro cancer cell growth inhibition tables and figures

Figure B.149. Dose dependent cell viability of C4-n-butyl SAHA (19c) with U937 cell
line, with error bars depicting the standard error of more than three independent
trials. EC50 values associated with Table 3.2 were determined by fitting data to a
sigmoidal curve using KaleidaGraph 4.1.3 (Synergy Software) (Table B.11).

C4-n-hexyl SAHA (M)

Figure B.150. Dose dependent cell viability of C4-n-hexyl SAHA (19d) with U937
cell line, with error bars depicting the standard error of six independent trials. EC 50
values associated with Table 3.2 were determined by fitting data to a sigmoidal
curve using KaleidaGraph 4.1.3 (Synergy Software) (Table B.11).
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Figure B.151. Dose dependent cell viability of C4-benzyl SAHA (19f) with U937 cell
line, with error bars depicting the standard error of more than three independent
trials. EC50 values associated with Table 3.2 were determined by fitting data to a
sigmoidal curve using KaleidaGraph 4.1.3 (Synergy Software) (Table B.11).
Table B.11. Percentage of viable cells after treatment of U937 cell line with C4-butyl
SAHA (19c), C4-hexyl SAHA (19d) and C4-benzyl SAHA (19f) at the specified
concentrations.a

Viable cells (%)

Concentration (M)

a

19c (butyl)

19d (hexyl)

19f (benzyl)

6.4 x 10-5

24  1

24  4

26  2

3.2 x 10

-5

54  2

28  6

49  3

1.6 x 10

-5

80  4

37  7

69  8

8.0 x 10

-6

87  6

102  7

80  2

4.0 x 10-6

100  9

108  9

74  4

2.0 x 10-6

100  7

106  10

80  7

Means and standard errors of at least three independent trials are shown. Data is
associated with Figures B.140-B.142 and Table 3.3.
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Figure B.152. Cytotoxicity screening of SAHA, and C4-SAHA analogs 19c, 19d, and
19f, at 1 and 10 µM concentrations using an MTT assay with Jurkat cell line. Mean
percent cell viability from a minimum of three independent trials with standard errors
were plotted (Table B.12).
Table B.12. Percentage of viable cells after treatment of Jurkat cell line with of C4butyl SAHA 19c, C4-hexyl SAHA 19d, C4-benzyl SAHA 19f, and SAHA.a
Viable cells (%)
Compound

1 µM

10 µM

19c (butyl)

98  6

62  16

19d (hexyl)

69  4

39  6

19f (benzyl)

89  20

97  4

SAHA
49  6
53
Means and standard errors for a minimum of four independent trials are shown. All
analogs were tested at 1 and 10M final concentrations. Data is associated with
Figure B.143.
a
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APPENDIX C
C.1. Compound characterization of the C5-modified SAHA analogs

Figure C.1. 1HNMR spectrum of 29.

Figure C.2 13CNMR spectrum of 29.
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Figure C.3. 1HNMR spectrum of 30.

Figure C.4. 13CNMR spectrum of 30.
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Figure C.5. Low resolution mass spectrum of 30 using a Waters ZQ LC-SQMS
instrument.

Figure C.6. IR spectrum of 30 using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure C.7. 1HNMR spectrum of 33a.

Figure C.8. 13CNMR spectrum of 33a.
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Figure C.9. Low resolution mass spectrum of 33a using a Waters ZQ LC-SQMS
instrument.

Figure C.10. IR spectrum of 33a using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure C.11. 1HNMR spectrum of 33b.

Figure C.12. 13CNMR spectrum of 33b.
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Figure C.13. Low resolution mass spectrum of 33b using a Waters ZQ LC-SQMS
instrument.

Figure C.14. IR spectrum of 33b using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure C.15. 1HNMR spectrum of 33c.

Figure C.16. 13CNMR spectrum of 33c.
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Figure C.17. Low resolution mass spectrum of 33c using a Waters ZQ LC-SQMS
instrument.

Figure C.18. IR spectrum of 33c using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure C.19. 1HNMR spectrum of 33d.

Figure C.20. 13CNMR spectrum of 33d.
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Figure C.21. Low resolution mass spectrum of 33d using a Waters ZQ LC-SQMS
instrument.

Figure C.22. IR spectrum of 33d using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure C.23. 1HNMR spectrum of 33e.

Figure C.24. 13CNMR spectrum of 33e.
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Figure C.25. Low resolution mass spectrum of 33e using a Waters ZQ LC-SQMS
instrument.

Figure C.26. IR spectrum of 33e using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure C.27. 1HNMR spectrum of 34a in CD3OD in the presence of trace amounts of
acetone (2.15 ppm).124

Figure C.28. 13CNMR spectrum of 34a in presence of trace amount of acetone
(29.25 ppm).124
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Figure C.29. High resolution mass spectrum of 34a using a Waters LCT-MS premier
TOF instrument.

Figure C.30. IR spectrum of 34a using a Perkin Elmer Spectrum Two ATR-FTIR.

285

Figure C.31. HPLC spectrum taken at 254 nm of C5-methyl SAHA (34a). The peak
at 13.760 is C5-methyl SAHA. The calculated area and height under each peak,
along with % area, is shown in the table below the spectrum.

Figure C.32. 1HNMR spectrum of 34b.
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Figure C.33. 13CNMR spectrum of 34b.

Figure C.34. High resolution mass spectrum of 34b using a Waters LCT-MS premier
TOF instrument.
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Figure C.35. IR spectrum of 34b using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure C.36. HPLC spectrum taken at 254 nm of C5-butyl SAHA (34b). The peak at
20.969 is C5-butyl SAHA. The calculated area and height under each peak, along
with % area, is shown in the table below the spectrum.
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Figure C.37. 1HNMR spectrum of 34c.

Figure C.38. 13CNMR spectrum of 34c.
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Figure C.39. High resolution mass spectrum of 34c using a Waters LCT-MS premier
TOF instrument.

Figure C.40. IR spectrum of 34c using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure C.41. HPLC spectrum taken at 254 nm of C5-hexyl SAHA (34c). The peak at
22.847 is C5-hexyl SAHA. The calculated area and height under each peak, along
with % area, is shown in the table below the spectrum.

Figure C.42. 1HNMR spectrum of 34d.
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Figure C.43. 13CNMR spectrum of 34d.

Figure C.44. High resolution mass spectrum of 34d using a Waters LCT-MS premier
TOF instrument.
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Figure C.45. IR spectrum of 34d using a Perkin Elmer Spectrum Two ATR-FTIR.

Figure C.46. HPLC spectrum taken at 254 nm of C5-phenyl SAHA (34d). The peak
at 17.693 is C5-phenyl SAHA. The calculated area and height under each peak,
along with % area, is shown in the table below the spectrum.
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Figure C.47. 1HNMR spectrum of 34e.

Figure C.48. 13CNMR spectrum of 34e.
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Figure C.49. High resolution mass spectrum of 34e using a Waters LCT-MS premier
TOF instrument.

Figure C.50. IR spectrum of 34e using a Perkin Elmer Spectrum Two ATR-FTIR.
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Figure C.51. HPLC spectrum taken at 254 nm of C5-benzyl SAHA (34e). The peak
at 18.748 is C5-benzyl SAHA. The calculated area and height under each peak,
along with % area, is shown in the table below the spectrum.
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C.2. In vitro screening with HeLa cell lysates and HDAC isoforms

Figure C.52. Dose response curve of C5-modified SAHA analogs 34a-e tested
using the HDAC activity in HeLa cells lysates from three independent trials with error
bars indicating standard error (see Table C.1). In some cases, the error bar is
smaller than the marker size. Data were fit to the sigmoidal curve using
KaleidaGraph 4.1.3 (Synergy Software) to determine the IC50. The data are reported
in Table 4.1.
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Table C.1. Percent remaining HDAC activity after incubation of SAHA or C5modified SAHA analogs 34a-e with HeLa Lysates.a
Deacetylase activity (%)
Concentration
(M)

SAHA

34a
(methyl)

34b
(butyl)

2.0 x 10-5
1.2 x 10-5

34c93
(hexyl)
15±2

17±1

35±2

33±3

8.0 x 10-6

15±2

6.0 x 10-6

42±3

5.0 x 10-6

58±2

4.0 x 10-6
66±6

2.5 x 10-6

83±1

2.0 x 10-6
88±4

1.0 x 10-6

74±3

1.25 x 10-6

92±2

7.5 x 10-7
14±1

2.5 x 10-7

15±2

94±3

49±1

1.25 x 10-7

44±2
78±4

6.25 x 10-8

68±4
86±4

3.13 x 10-8
a

93±4

101±4

5.0 x 10-7

2.5 x 10-8

78±3
53±3

1.5 x 10-6

5.0 x 10-8

56±4
31±4

3.0 x 10-6

1.0 x 10-7

34e
(benzyl)

23±3

1.0 x 10-5

2.0 x 10-7

34d
(phenyl)

85±2
97±1

Mean percentage deacetylase activity and standard error of three trials are shown.
This data is associated with Figure C.52 and Table 4.1.
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Table C.2. Percent remaining deacetylase activity after incubation of a single
concentration of each C5-modified SAHA analog with HDAC1, HDAC2, HDAC3, and
HDAC6 using the ELISA-based activity assay.a
Deacetylase activity (%)
Compound

a

HDAC1

HDAC2

HDAC3

HDAC6

SAHAb 1 µM

8.9±0.1

8.3±0.2

14±3

7.9±1.6

34a (C5-methyl) 0.025 µM

67±6

81±3

80±2

63±3

34b (butyl) 0.25 µM

84±3

83±3

74±3

35±6

34c (hexyl) 1.25 µM

64±5

72±1

71±2

28±1

34d (phenyl) 0.125 µM

83±1

85±1

86±2

63±4

34e (benzyl) 1.25 µM

69±1

74±1

74±1

17±2

The means and standard errors for a minimum of two independent trials are
shown. This data is associated with Figure 4.2. b Previously reported values using
the same assay procedure.93
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Figure C.53. Dose dependent curves of the C5-butyl SAHA analog (34b) with
HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 isoforms, with error bars depicting
the standard error of at least three independent trials. IC50 values associated with
Table 4.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table C.3).
Table C.3. Percentage remaining deacetylase activity after incubation of C5-butyl
SAHA analog (34b) with HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8.a
Concentration (M)

Deacetylase activity (%)
HDAC2
HDAC3
HDAC6
253
273
381
443

HDAC1
HDAC8
4.0 x 10-6
182
2.0 x 10-6
373
-6
1.6 x 10
222
-6
1.0 x 10
526
604
575
-7
8.0 x 10
286
352
5.0 x 10-7
684
731
837
4.0 x 10-7
482
503
-7
2.5 x 10
814
831
923
-7
2.0 x 10
607
694
-7
1.0 x 10
7011
836
5.0 x 10-8
9011
a
Means and standard errors of at least three independent trials with the C5-butyl
SAHA (34b) concentrations shown. Data is associated with Figure C.53 and Table
4.2.
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Figure C.54. Dose dependent curves of the C5-n-hexyl SAHA analog (34c) with
HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 isoforms, with error bars depicting
the standard error of at least three independent trials. IC 50 values associated with
Table 4.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table C.4).
Table C.4. Percentage remaining deacetylase activity after incubation of C5-n-hexyl
SAHA analog (34c) with HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8.a
Concentration (M)
-5

HDAC1

Deacetylase activity (%)
HDAC2
HDAC3
HDAC6
142
123
211
274
416
394
575
679

HDAC8

1.6 x 10
8.0 x 10-6
223
-6
4.0 x 10
374
-6
2.0 x 10
548
-6
1.6 x 10
212
-6
1.0 x 10
665
705
711
8.0 x 10-7
354
344
-7
5.0 x 10
772
-7
4.0 x 10
515
543
-7
2.0 x 10
705
664
-7
1.0 x 10
788
697
-8
5.0 x 10
824
a
Means and standard errors of at least three independent trials with the C5-n-hexyl
SAHA (34c) concentrations shown. Data is associated with Figure C.54 and Table
4.2.
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Figure C.55. Dose dependent curves of the C5-benzyl SAHA analog (34e) with
HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 isoforms, with error bars depicting
the standard error of at least three independent trials. IC 50 values associated with
Table 4.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph
4.1.3 (Synergy Software) (Table C.5).
Table C.5. Percentage remaining deacetylase activity after incubation of C5-benzyl
SAHA analog (34e) with HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8.a
Concentration
(M)
-5

HDAC1

Deacetylase activity (%)
HDAC2
HDAC3
HDAC6
191
234
301
437
493
533
625
8512

HDAC8

1.6 x 10
8.0 x 10-6
272
-6
4.0 x 10
452
-6
2.0 x 10
548
1.6 x 10-6
191
1.0 x 10-6
775
773
856
8.0 x 10-7
332
263
-7
5.0 x 10
844
-7
4.0 x 10
472
432
-7
2.0 x 10
654
543
-7
1.0 x 10
825
763
-8
5.0 x 10
833
a
Means and standard errors of at least three independent trials with the C5-beznyl
SAHA (34e) concentrations shown. Data is associated with Figure C.55 and Table
4.2.
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Table C.6. Fold selectivity of SAHA and C5-SAHA analogs 34b, 34c, and 34e for
HDAC6 or HDAC8 over HDAC1, 2, and 3.a
HDAC6 fold selectivity

HDAC8 fold selectivity

Compound
HDAC1

HDAC2

HDAC3

HDAC1

HDAC2

HDAC3

SAHA

1

3

0.6 b

0.06 c

0.2 c

0.04 c

C5-butyl SAHA
34b

3

4

5

3

3

4

C5-hexyl SAHA
34c

5

6

7

5

6

7

C5-benzyl SAHA
34e

11

13

21

8

9

15

a

Fold selectivities were calculated from the IC50 values in Table 4.2. b SAHA
displayed 1.65-fold preference for HDAC3 versus HDAC6. c SAHA displayed 16fold, 6-fold, and 27-fold preference for HDAC1, 2, and 3, respectively, over HDAC8.
C.3. In cellulo selectivity testing
A)

B)

SAHA DMSO
5

1

1e (Benzyl)
10

2

3

20

4

DMSO

40

5

1e (Benzyl)
20

40

60

80 µM

AcH3

AcH3

AcTub

AcTub

GAPDH

GAPDH
1

2

3

4

5

Figure C.56. Western blots analysis of acetyl-histone H3 (Lys9) (AcH3) and acetylα-tubulin (Lys40) (AcTub) after treatment with SAHA or the C5-benzyl SAHA analog
34e. U937 cells were treated with SAHA (5 µM), DMSO (1%) or C5-benzyl SAHA
analog 34e at the specified concentrations, before lysis, SDS-PAGE separation,
transfer to a PVDF membrane, and western blotted with AcH3 or AcTub antibodies.
GAPDH levels in the samples were also probed as a gel load control. A DMSO
control sample was included for comparison to inhibitor treated samples. These
three trials (parts A-B) are associated with the third trial shown in Figure 4.3.

303
C.4. In vitro cancer cell growth inhibition
Table C.7. Percentage of viable cells after treatment of Jurkat cell line with of C5butyl SAHA 34b, C5-hexyl SAHA 34c, C5-benzyl SAHA 34e, and SAHA.a
Viable cells (%)

a

Compound

1 µM

10 µM

34b (butyl)

67  6

39  2

34c (hexyl)

101  6

24  2

34e (benzyl)

71  9

50  5

SAHA

49  6

53

Means and standard errors for a minimum of four independent trials are shown. All
analogs were tested at 1 and 10M final concentrations. Data is associated with
Figure 4.4.
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APPENDIX D
D.1. Compound characterization of the biaryl indolyl benzamide inhibitors

Figure D.1. 1HNMR spectrum of 40.

Figure D.2. 1HNMR spectrum of 42a.
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Figure D.3. 1HNMR spectrum of 42b.

Figure D.4. 1HNMR spectrum of 44a.
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Figure D.5. 1HNMR spectrum of 44b.

Figure D.6. 1HNMR spectrum of 47.
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Figure D.7. 1HNMR spectrum of 48.

Figure D.8. 1HNMR spectrum of 49.
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Figure D.9. 1HNMR spectrum of Bnz-1.

Figure D.10. 1HNMR spectrum of Bnz-1 enlarged in the aromatic protons region.
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Figure D.11. 13CNMR spectrum of Bnz-1.

Figure D.12. High resolution mass spectrum of Bnz-1 using a Waters LCT-MS
premier TOF instrument.
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Figure D.13. HPLC spectrum taken at 254 nm of Bnz-1. The peak at 23.579 is Bnz1. The calculated area and height under each peak, along with % area, is shown in
the table below the spectrum.

Figure D.14. 1HNMR spectrum of Bnz-3.
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Figure D.15. 1HNMR spectrum of Bnz-3 enlarged in the aromatic protons region.

Figure D.16. 13CNMR spectrum of Bnz-3.
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Figure D.17. High resolution mass spectrum of Bnz-3 using a Waters LCT-MS
premier TOF instrument.

Figure D.18. HPLC spectrum taken at 254 nm of Bnz-3. The peak at 22.773 is Bnz3. The calculated area and height under each peak, along with % area, is shown in
the table below the spectrum.
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Figure D.19. 1HNMR spectrum of Bnz-2.

Figure D.20. 1HNMR spectrum of Bnz-2 enlarged in the aromatic protons region.
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Figure D.21. 13CNMR spectrum of Bnz-2.

Figure D.22. High resolution mass spectrum of Bnz-2 using a Waters LCT-MS
premier TOF instrument.
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Figure D.23. HPLC spectrum taken at 254 nm of Bnz-2. The peak at 23.057 is Bnz2. The calculated area and height under each peak, along with % area, is shown in
the table below the spectrum.
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D.2. In vitro screening with HDAC isoforms
Table D.1. Percent remaining deacetylase activity after incubation of a single
concentration of each compound with HDAC1, HDAC2, HDAC3, and HDAC6.a
Deacetylase activity (%)

a

Compound

HDAC1

HDAC2

HDAC3

HDAC6

SAHA (20 nM)

61±3

55±2

67±1

65±1

Cpd-60 (28 nM)

19±5

59±6

90±2

101±3

Bnz-1 (200 µM)

15±2

27±1

-

-

Bnz-1 (20 µM)

54±3

77±2

-

-

Bnz-2 (20 µM)

21±1

44±3

-

-

Bnz-2 (2 µM)

48±1

71±2

-

-

Bnz-3 (2 µM)

19±2

63±1

91±1

103±6

Bnz-3 (200 nM)

64±6

83±3

93±2

108±9

The means and standard errors for a minimum of two independent trials are
shown. "-" not determined. This data is associated with Figure 6.3.
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Figure D.24. Dose dependent curves of Cpd-60 with HDAC1 and HDAC2 isoforms,
with error bars depicting the standard error of at least three independent trials. IC 50
values associated with Table 6.1 were determined by fitting data to a sigmoidal
curve using KaleidaGraph 4.1.3 (Synergy Software) (Table D.2)
Table D.2. Percentage remaining deacetylase activity after incubation of Cpd-60
with HDAC1 and HDAC2.a
Concentration (M)

a

Deacetylase activity (%)
HDAC1

HDAC2

1.6 x 10-7

31  1

8.0 x 10-8

52  5

4.0 x 10

-8

14  1

67  3

2.0 x 10

-8

33  3

74  1

1.0 x 10

-8

53  4

82  5

5.0 x 10-9

71  4

2.5 x 10-9

80  2

Means and standard errors of at least three independent trials with the Cpd-60
concentrations shown. Data is associated with Figure D.24 and Table 6.1.
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Figure D.25. Dose dependent curves of Bnz-3 with HDAC1 and HDAC2 isoforms,
with error bars depicting the standard error of at least three independent trials. IC 50
values associated with Table 6.1 were determined by fitting data to a sigmoidal
curve using KaleidaGraph 4.1.3 (Synergy Software) (Table D.3)
Table D.3. Percentage remaining deacetylase activity after incubation of Bnz-3 with
HDAC1 and HDAC2.a
Concentration (M)
2.0 x 10-6
1.0 x 10-6
5.0 x 10-7
2.0 x 10-7
1.0 x 10-7
5.0 x 10-8
3.2 x 10-5
1.6 x 10-5
8 x 10-6
4 x 10-6
2 x 10-6
1 x 10-6
a

Deacetylase activity (%)
HDAC1
HDAC2
28  4
38  7
54  5
70  4
77  4
80  4
21  3
35  2
44  6
59  5
66  6
76  2

Means and standard errors of at least three independent trials with the Bnz-3
concentrations shown. Data is associated with Figure D.25 and Table 6.1.
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Copyrights permission (Open access article "which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
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Reprint authorization for Figure 1.3.

322
Reprint authorization for Figure 1.4.

323
Reprint authorization for Figure 1.5.

324
Reprint authorization for the C2-SAHA analogs publication: "Reprinted
(adapted) with permission from (Structural Requirements of HDAC Inhibitors: SAHA
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Chemistry Letters 2017, 8 (3), 281-286). Copyright (2017) American Chemical
Society."
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ABSTRACT
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF
HISTONE DEACETYLASE (HDAC) INHIBITORS: SAHA
(VORINOSTAT) ANALOGS AND BIARYL INDOLYL BENZAMIDE
INHIBITORS DISPLAY ISOFORM SELECTIVITY
by
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August 2017
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Major: Chemistry (Organic)
Degree: Doctor of Philosophy
HDAC proteins have emerged as interesting targets for anti-cancer drugs due
to their involvement in cancers, as well as several other diseases. Several HDAC
inhibitors have been approved by the FDA as anti-cancer drugs, including SAHA
(suberoylanilide hydroxamic acid, Vorinostat). Unfortunately, SAHA inhibits most
HDAC isoforms, which limit its use as a pharmacological tool and may lead to side
effects in the clinic. In this work we were interested in developing isoform selective
HDAC inhibitors, which may decrease or eliminate the side effects associated with
non-selective inhibitors treatment. In addition, isoform selective HDAC inhibitors can
be used as biological tools to help understand the HDAC-related cancer biology. Our
strategy was based on synthesis and screening of several derivatives of the nonselective FDA approved drug SAHA substituted at different positions of the linker
region. Several SAHA analogs modified at the C4 and C5 positions of the linker
were synthesized. The new C4- and C5-modified SAHA libraries, along with the
previously synthesized C2-modified SAHA analogs were screened in vitro and in

351
cellulo for HDAC isoform selectivity. Interestingly, several analogs exhibited dual
HDAC6/HDAC8 selectivity. Enantioselective syntheses of the pure enantiomers of
some of the interesting analogs were performed and the enantiomers were screened
in vitro. Among the most interesting analogs, (R)-C4-benzyl SAHA displayed 520- to
1300-fold selectivity for HDAC6 and HDAC8 over HDAC1, 2, and 3, with IC 50 values
of 48 and 27 nM with HDAC6 and 8, respectively. Docking studies were performed
to provide structural rationale for the observed selectivity of the new analogs. In
addition, rational design, synthesis, and screening of several other biaryl indolyl
benzamide HDAC inhibitors is discussed, and some showed modest HDAC1
selectivity. The new biaryl indolyl benzamides can be useful to further develop
HDAC1 selective inhibitors. The dual HDAC6/8 selective inhibitors can be used as
lead compounds and as a chemical tool to study HDAC related cancer biology. The
observed enhancement of selectivity upon modifying the linker region of the nonselective inhibitor SAHA shows that modifying current drugs, like SAHA, could lead
to substantial improvement in its pharmacodynamic properties.
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